User Image Cart Icon 0 Search Image

HSP90

Hsp90ย (heat shock protein 90) is aย chaperone proteinย that assists other proteins toย foldย properly, stabilizes proteins againstย heat stress, and aids inย protein degradation. It also stabilizes a number of proteins required for tumor growth, which is whyย Hsp90 inhibitorsย are investigated as anti-cancer drugs.

Heat shock proteins, as a class, are among the most highly expressedย cellularย proteins across all species.[3]ย As their name implies, heat shock proteins protect cells when stressed by elevated temperatures. They account for 1โ€“2% of total protein in unstressed cells. However, when cells are heated, the fraction of heat shock proteins increases to 4โ€“6% of cellular proteins.[4]

Heat shock protein 90 (Hsp90) is one of the most common of the heat-related proteins. The โ€œ90โ€ comes from the fact that it weighs roughly 90ย kiloDaltons. A 90ย kDa protein is considered fairly large for a non-fibrous protein. Hsp90 is found inย bacteriaย and all branches ofย eukarya, but it is apparently absent inย archaea.[5]ย Whereas cytoplasmic Hsp90 is essential for viability under all conditions inย eukaryotes, the bacterial homologueย HtpGย is dispensable under non-heat stress conditions.[6]

This protein was first isolated by extracting proteins from cells stressed by heating, dehydrating or by other means, all of which caused the cellโ€™s proteins to begin toย denature.[7]ย However it was later discovered that Hsp90 also has essential functions in unstressed cells. -wiki

Identification of HSP90 inhibitors as a novel class of senolytics

 

Aging is the main risk factor for many chronic degenerative diseases and cancer. Increased senescent cell burden in various tissues is a major contributor to aging and age-related diseases. Recently, a new class of drugs termed senolytics were demonstrated to extending healthspan, reducing frailty and improving stem cell function in multiple murine models of aging. To identify novel and more optimal senotherapeutic drugs and combinations, we established a senescence associated ฮฒ-galactosidase assay as a screening platform to rapidly identify drugs that specifically affect senescent cells. We used primary Ercc1 โˆ’/โˆ’ murine embryonic fibroblasts with reduced DNA repair capacity, which senesce rapidly if grown at atmospheric oxygen. This platform was used to screen a small library of compounds that regulate autophagy, identifying two inhibitors of the HSP90 chaperone family as having significant senolytic activity in mouse and human cells. Treatment of Ercc1 โˆ’/โˆ† mice, a mouse model of a human progeroid syndrome, with the HSP90 inhibitor 17-DMAG extended healthspan, delayed the onset of several age-related symptoms and reduced p16INK4a expression. These results demonstrate the utility of our screening platform to identify senotherapeutic agents as well as identified HSP90 inhibitors as a promising new class of senolytic drugs.

SCIENTIFIC STUDIES

  1. Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone
  2. Inhibiting the Hsp90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression
  3. Inhibiting Hsp90 to treat cancer: a strategy in evolution
  4. Molecular simulation of HER2/neu degradation by inhibiting HSP90
  5. Inhibiting the Hsp90 chaperone slows cyst growth in a mouse model of autosomal dominant polycystic kidney disease
  6. Black tea polyphenols induce human leukemic cell cycle arrest by inhibiting Akt signaling: Possible involvement of Hsp90, Wnt/ฮฒโ€catenin signaling and FOXO1
  7. Microparticles from patients with the acute coronary syndrome impair vasodilatation by inhibiting the Akt/eNOS-Hsp90 signaling pathway
  8. Cks1 proteasomal degradation is induced by inhibiting Hsp90-mediated chaperoning in cancer cells
  9. Inhibiting the molecular evolution of cancer through HSP90
  10. A chemical compound inhibiting the Aha1โ€“Hsp90 chaperone complex
  11. Hsp90 is a novel target molecule of CDDO-Me in inhibiting proliferation of ovarian cancer cells
  12. Inhibiting heat shock protein 90 (Hsp90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice
  13. Inhibiting Hsp90 prevents the induction of myeloid-derived suppressor cells by melanoma cells
  14. 3-O-(Z)-coumaroyloleanolic acid overcomes Cks1b-induced chemoresistance in lung cancer by inhibiting Hsp90 and MEK pathways
  15. Uncaria rhynchophylla Ameliorates Parkinsonโ€™s Disease by Inhibiting Hsp90 Expression: Insights from Quantitative Proteomics
  16. Targeting Hsp90-Cdc37: a promising therapeutic strategy by inhibiting Hsp90 chaperone function
  17. Combination Immunotherapy of Melanoma by inhibiting Hsp90 and targeting its client proteins.(TUM7P. 934)
  18. Influence of co-inhibiting mTORC2 and Hsp90 on proliferation apoptosis of multiple myeloma cells
  19. Hsp90 inhibiting anti-cancer therapeutics enhance bone loss by increasing osteoclast formation: Mechanism of action.
  20. Abstract# 1854: Superoxide-dependent hepatotoxicity of the Hsp90 inhibiting anticancer drugs geldanamycin and its two derivatives
  21. Development of Small Molecules Blocking Glucose Transporter Or Inhibiting Hsp90 for the Therapy of Cancer
  22. Gambogic acid attenuates liver fibrosis by inhibiting the PI3K/AKT and MAPK signaling pathways via inhibiting HSP90
  23. Ritonavir inhibits breast cancer cell proliferation, in part, by inhibiting Hsp90 function and Akt phosphorylation
  24. The effect of curcumin on bortezomib by inhibiting Hsp90 of myeloma MM1. R
  25. Diosgenin suppressed LPS-induced inflammation through inhibiting Hsp90 induced phosphorylation of NF-ฮบb p65
  26. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer
  27. Inhibiting protein-protein interactions in Hsp90 dimerization as a novel approach for targeting cancer
  28. Characterization of celastrol to inhibit Hsp90 and cdc37 interaction
  29. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase
  30. Synthesis and evaluation of coumermycin A1 analogues that inhibit the Hsp90 protein folding machinery
  31. Disruption of the EF-2 kinase/Hsp90 protein complex: a possible mechanism to inhibit glioblastoma by geldanamycin
  32. Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells
  33. Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin
  34. Hsp90 blockers inhibit adipocyte differentiation and fat mass accumulation
  35. Cyclic lipopeptide antibiotics bind to the N-terminal domain of the prokaryotic Hsp90 to inhibit the chaperone activity
  36. New, Nonโ€quinone Fluorogeldanamycin Derivatives Strongly Inhibit Hsp90
  37. Ca2+/S100 proteins inhibit the interaction of FKBP38 with Bcl-2 and Hsp90
  38. 2D-QSAR of purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells
  39. Discovery of 18ฮฒ-glycyrrhetinic acid conjugated aminobenzothiazole derivatives as Hsp90-Cdc37 interaction disruptors that inhibit cell migration and reverse drug โ€ฆ
  40. Single-walled carbon nanotubes (SWCNTs) inhibit heat shock protein 90 (Hsp90) signaling in human lung fibroblasts and keratinocytes
  41. Sarqaquinoic acid and related synthetic naphthoquinones inhibit the function of Hsp90
  42. Deguelin analogues, L80 and SH-1242, inhibit Hsp90 activity and exert potent anticancer efficacy with limited toxicities in non-small cell lung cancer (NSCLC)
  43. Abstract B80: Hsp90 inhibitor SNXโ€2112 and prodrug SNXโ€5422 (PFโ€04929113) inhibit key signal pathways Akt, Src and STAT3 and reactivate tumor suppressor โ€ฆhttp://mct.aacrjournals.org/content/8/12_Supplement/B80.short
  44. Hsp90 inhibition decreases mitochondrial protein turnover
  45. Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress
  46. Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition
  47. Inhibition of Hsp90: a multitarget approach to radiosensitization
  48. Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of IฮบB kinase (IKK)
  49. Hsp90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer โ€ฆ
  50. Hsp90 inhibition: two-pronged exploitation of cancer dependencies
  51. 17 AAG for Hsp90 inhibition in cancer-from bench to bedside
  52. Hsp90 inhibition transiently activates Src kinase and promotes Src-dependent Akt and Erk activation
  53. Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses
  54. Quantitative proteomics reveals that Hsp90 inhibition preferentially targets kinases and the DNA damage response
  55. Hsp90 modulates actin dynamics: inhibition of Hsp90 leads to decreased cell motility and impairs invasion
  56. โ€ฆ reticulum vacuolization and valosin-containing protein relocalization result from simultaneous Hsp90 inhibition by geldanamycin and proteasome inhibition by โ€ฆ
  57. To fold or not to fold: modulation and consequences of Hsp90 inhibition
  58. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives
  59. ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition
  60. Inhibition of Hsp90 in Trypanosoma cruzi induces a stress response but no stage differentiation
  61. Hsp90 Inhibition with Resorcylic Acid Lactones (RALs)
  62. 3-Arylcoumarin derivatives manifest anti-proliferative activity through Hsp90 inhibition
  63. Targeting HSF1 sensitizes cancer cells to Hsp90 inhibition
  64. Combined EGFR/MET or EGFR/Hsp90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET
  65. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-ฮฒ signalling to prevent fibrosis
  66. Hsp90 inhibition protects against inherited retinal degeneration
  67. FGFR3 translocations in bladder cancer: differential sensitivity to Hsp90 inhibition based on drug metabolism
  68. Hsp90 inhibition by 17-DMAG attenuates oxidative stress in experimental atherosclerosis
  69. Targeting multiple signal transduction pathways through inhibition of Hsp90
  70. Inhibition of Hsp90 molecular chaperones: moving into the clinic
  71. Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation
  72. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo
  73. Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat-shock protein 90 (Hsp90) inhibition
  74. Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic โ€ฆ
  75. Heat-induced Oligomerization of the Molecular Chaperone Hsp90 INHIBITION BY ATP AND GELDANAMYCIN AND ACTIVATION BY TRANSITION METAL โ€ฆ
  76. Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin
  77. Phase Iโ€“II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in โ€ฆ
  78. Inhibition of Hsp90: a new strategy for inhibiting protein kinases
  79. Synthetic lethality of combined glutaminase and Hsp90 inhibition in mTORC1-driven tumor cells
  80. Hsp90 inhibition by PU-H71 induces apoptosis through endoplasmic reticulum stress and mitochondrial pathway in cancer cells and overcomes the โ€ฆ
  81. Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibition
  82. Hsp90 inhibition: Elimination of shock and stress
  83. Inhibition of MDM2 by Hsp90 contributes to mutant p53 stabilization
  84. Inhibition of N-terminal ATPase on Hsp90 attenuates colitis through enhanced Treg function
  85. Inhibition of Hsp90 compromises the DNA damage response to radiation
  86. Hsp90 inhibition enhances cancer immunotherapy by upregulating interferon response genes
  87. Mineralocorticoid receptor degradation is promoted by Hsp90 inhibition and the ubiquitin-protein ligase CHIP
  88. Inhibition of ALK, PI3K/MEK, and Hsp90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene
  89. Protein kinase CK2 protects multiple myeloma cells from ER stressโ€“induced apoptosis and from the cytotoxic effect of Hsp90 inhibition through regulation of the โ€ฆ
  90. Hsp90 inhibition increases p53 expression and destabilizes MYCN and MYC in neuroblastoma
  91. Hsp90 inhibition differentially destabilises MAP kinase and TGF-beta signalling components in cancer cells revealed by kinase-targeted chemoproteomics
  92. Hsp90 inhibition enhances PI-3 kinase inhibition and radiosensitivity in glioblastoma
  93. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells
  94. Inhibition of heat shock protein Hsp90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic โ€ฆ
  95. Hsp90 inhibition by 17-DMAG reduces inflammation in J774 macrophages through suppression of Akt and nuclear factor-ฮบB pathways
  96. Identification of a new scaffold for Hsp90 C-terminal inhibition
  97. Hsp90 inhibition protects against biomechanically induced osteoarthritis in rats
  98. Therapeutic potential of Hsp90 inhibition for neurofibromatosis type 2
  99. Hsp90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5FU-based chemotherapy
  100. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis
  101. Induction of premature senescence by Hsp90 inhibition in small cell lung cancer
  102. Inhibition of Hsp90 attenuates inflammation in endotoxin-induced uveitis
  103. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel
  104. Radiosensitization of human vascular endothelial cells through Hsp90 inhibition with 17-N-allilamino-17-demethoxygeldanamycin
  105. Efficient synthesis of a novel resorcyclide as anticancer agent based on Hsp90 inhibition
  106. Inhibition of heat shock protein 90 (Hsp90) as a therapeutic strategy for the treatment of myeloma and other cancers
  107. UBR1 promotes protein kinase quality control and sensitizes cells to Hsp90 inhibition
  108. S-nitrosylation of Hsp90 promotes the inhibition of its ATPase and endothelial nitric oxide synthase regulatory activities
  109. Blocking NF-ฮบB and Akt by Hsp90 inhibition sensitizes Smac mimetic compound 3-induced extrinsic apoptosis pathway and results in synergistic cancer cell death
  110. Hsp90 inhibition as a means of radiosensitizing resistant, aggressive soft tissue sarcomas
  111. Inhibition of Hsp90 function by ansamycins causes retinoblastoma gene product-dependent G1 arrest
  112. Hsp90 inhibition and the expression of phenotypic variability in the rainforest species Drosophila birchii
  113. Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis in cancer cells
  114. Additive viability-loss following hsp70/hsc70 double interference and Hsp90 inhibition in two breast cancer cell lines
  115. Inhibition of Hsp90 activates osteoclast c-Src signaling and promotes growth of prostate carcinoma cells in bone
  116. Intrinsic inhibition of the Hsp90 ATPase activity
  117. Resistance to Hsp90 inhibition involving loss of MCL1 addiction
  118. Hsp90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia
  119. PI3K-independent mTOR activation promotes lapatinib resistance and IAP expression that can be effectively reversed by mTOR and Hsp90 inhibition
  120. Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition
  121. Molecular mechanism of inhibition of the human protein complex Hsp90โ€“Cdc37, a kinome chaperoneโ€“cochaperone, by triterpene celastrol
  122. Inhibition of Hsp90 function delays and impairs recovery from heat shock
  123. Hsp90 inhibition induces cytotoxicity via down-regulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells
  124. SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis
  125. Inhibition of Hsp90 as a special way to inhibit protein kinases
  126. Disruption of zebrafish somite development by pharmacologic inhibition of Hsp90
  127. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex
  128. 18ฮฒ-Glycyrrhetinic acid potentiates Hsp90 inhibition-induced apoptosis in human epithelial ovarian carcinoma cells via activation of death receptor and mitochondrial
  129. Effect of heat-shock protein-90 (Hsp90) inhibition on human hepatocytes and on liver regeneration in experimental models
  130. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by Hsp90 inhibition
  131. Hsp90 inhibition by NVP-AUY922 and NVP-BEP800 decreases migration and invasion of irradiated normoxic and hypoxic tumor cell lines
  132. Inhibition of Hsp90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer
  133. 5-Episinuleptolide acetate, a norcembranoidal diterpene from the formosan soft coral Sinularia sp., induces leukemia cell apoptosis through Hsp90 inhibition
  134. Heat shock protein 90 (Hsp90) is overexpressed in p16-negative oropharyngeal squamous cell carcinoma, and its inhibition in vitro potentiates the effects of โ€ฆ
  135. Influence of Hsp90 and HDAC inhibition and tubulin acetylation on perinuclear protein aggregation in human retinal pigment epithelial cells
  136. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation
  137. Inhibition of Hsp90 with synthetic macrolactones: synthesis and structural and biological evaluation of ring and conformational analogs of radicicol
  138. Destabilization of PDK1 by Hsp90 inactivation suppresses hepatitis C virus replication through inhibition of PRK2-mediated viral RNA polymerase phosphorylation
  139. Pharmacologic and genetic inhibition of Hsp90-dependent trafficking reduces aggregation and promotes degradation of the expanded glutamine androgen receptor โ€ฆ
  140. Inhibition of Hsp90 with Pochoximes: SAR and Structureโ€Based Insights
  141. Hsp90 inhibition suppresses lipopolysaccharide-induced lung inflammation in vivo
  142. Inhibition of GRโ€mediated transcription by p23 requires interaction with Hsp90
  143. Inhibition of heat shock protein 90 (Hsp90) in proliferating endothelial cells uncouples endothelial nitric oxide synthase activity
  144. Radioresistant human lung adenocarcinoma cells that survived multiple fractions of ionizing radiation are sensitive to Hsp90 inhibition
  145. Induction of nitric oxide synthase-dependent telomere shortening after functional inhibition of Hsp90 in human tumor cells
  146. Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition
  147. Inhibition of Hsp90 function by ansamycins causes downregulation of cdc2 and cdc25c and G2/M arrest in glioblastoma cell lines
  148. The Hsp70 inhibiting peptide aptamer A17 potentiates radiosensitization of tumor cells by Hsp90 inhibition
  149. Enhancement of radiation sensitivity in lung cancer cells by celastrol is mediated by inhibition of Hsp90
  150. Inhibition of Hsp90 by AUY922 preferentially kills mutant KRAS colon cancer cells by activating Bim through ER stress
  151. Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in human malignant pleural mesothelioma
  152. Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
  153. Molecular imaging of EGFR and CD44v6 for prediction and response monitoring of Hsp90 inhibition in an in vivo squamous cell carcinoma model
  154. Blocking the survival of the nastiest by Hsp90 inhibition
  155. Dynamic cycling with Hsp90 stabilizes neuronal nitric oxide synthase through calmodulin-dependent inhibition of ubiquitination
  156. Hsp90 inhibition induces both protein-specific and global changes in the ubiquitinome
  157. Inhibition of Hsp90 via 17-DMAG induces apoptosis in a p53-dependent manner to prevent medulloblastoma
  158. Oxidative inhibition of Hsp90 disrupts the superโ€chaperone complex and attenuates pancreatic adenocarcinoma in vitro and in vivo
  159. Induction of heat shock protein HSPA6 (HSP70Bโ€ฒ) upon Hsp90 inhibition in cancer cell lines
  160. Blocking the heat shock response and depleting HSF-1 levels through heat shock protein 90 (Hsp90) inhibition: a significant advance on current Hsp90 โ€ฆ
  161. Hsp90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo
  162. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
  163. Inhibition of Hsp90 could be possible mechanism for anti-cancer property of amniotic membrane
  164. Dicoumarol down-regulates human PTTG1/Securin mRNA expression through inhibition of Hsp90
  165. Calpain genetic disruption and Hsp90 inhibition combine to attenuate mammary tumorigenesis
  166. Hsp90 inhibition enhances antimitotic drug-induced mitotic arrest and cell death in preclinical models of non-small cell lung cancer
  167. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma
  168. Inhibition of Hsp90 suppresses PI3K/AKT/mTOR signaling and has antitumor activity in Burkitt lymphoma
  169. Inhibition of Hsp90 acts synergistically with topoisomerase II poisons to increase the apoptotic killing of cells due to an increase in topoisomerase II mediated DNA โ€ฆ
  170. Combined inhibition of Hsp90 and the proteasome affects NSCLC proteostasis and attenuates cell migration
  171. The interplay between inhibition of JAK2 and HSP90
  172. Structural basis for topoisomerase VI inhibition by the anti-Hsp90 drug radicicol
  173. Inhibition of cell death by a novel 16.2 kD heat shock protein predominantly via Hsp90 mediated lipid rafts stabilization and Akt activation pathway
  174. Hsp90 binds directly to fibronectin (FN) and inhibition reduces the extracellular fibronectin matrix in breast cancer cells
  175. Targeted inhibition of mitochondrial Hsp90 suppresses localised and metastatic prostate cancer growth in a genetic mouse model of disease
  176. Hsp90 inhibition results in apoptosis of Philadelphia acute lymphoblastic leukaemia cells: an attractive prospect of new targeted agents
  177. Down-regulation of MSH2 expression by Hsp90 inhibition enhances cytotoxicity affected by tamoxifen in human lung cancer cells
  178. Synthesis of flavokawain analogues and their anti-neoplastic effects on drug-resistant cancer cells through Hsp90 inhibition
  179. Inhibition of Hsp90 and 70 sensitizes melanoma cells to hyperthermia using ferromagnetic particles with a low Curie temperature
  180. Inhibition of Hsp90 with resorcylic acid macrolactones: synthesis and binding studies
  181. Combined BRAF and Hsp90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma
  182. Down-regulation of cellular FLICE-inhibitory protein (Long Form) contributes to apoptosis induced by Hsp90 inhibition in human lung cancer cells
  183. Migration pattern, actin cytoskeleton organization and response to PI3K-, mTOR-, and Hsp90-inhibition of glioblastoma cells with different invasive capacities
  184. Inhibition of HSP90โ€dependent telomerase activity in amyloid ฮฒโ€induced apoptosis of cerebral endothelial cells
  185. Hsp90 inhibition in HER2-positive breast cancer cells
  186. Synthesis of butein analogues and their anti-proliferative activity against gefitinib-resistant non-small cell lung cancer (NSCLC) through Hsp90 inhibition
  187. Regulating the cytoprotective response in cancer cells using simultaneous inhibition of Hsp90 and Hsp70
  188. Inhibition of heat shock protein 70 and 90 (Hsp70 and Hsp90) in target spesific cancer treatment
  189. Dynamic impacts of the inhibition of the molecular chaperone Hsp90 on the T-cell proteome have implications for anti-cancer therapy
  190. Combined inhibition of extracellular signal-regulated kinases and Hsp90 sensitizes human colon carcinoma cells to ionizing radiation
  191. Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR
  192. Identification of mixed lineage leukemia 1 (MLL1) protein as a coactivator of heat shock factor 1 (HSF1) protein in response to heat shock protein 90 (Hsp90) inhibition
  193. Antiproliferative and proapoptotic activity of GUT-70 mediated through potent inhibition of Hsp90 in mantle cell lymphoma
  194. Hsp90 inhibition increases SOCS3 transcript and regulates migration and cell death in chronic lymphocytic leukemia
  195. Hsp90 inhibition suppresses NF-ฮบB transcriptional activation via Sirt-2 in human lung microvascular endothelial cells
  196. Concomitant inhibition of HSP90, its mitochondrial localized homologue TRAP1 and HSP27 by green tea in pancreatic cancer HPAFโ€II cells
  197. Prospective identification of resistance mechanisms to Hsp90 inhibition in KRAS mutant cancer cells
  198. Hsp90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal โ€ฆ
  199. Co-inhibition of HSP70/Hsp90 synergistically sensitizes nasopharyngeal carcinoma cells to thermotherapy
  200. EGFR Exon 20 insertion mutations display sensitivity to Hsp90 inhibition in preclinical models and lung adenocarcinomas
  201. Boosting the effects of hyperthermia-based anticancer treatments by Hsp90 inhibition
  202. Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma
  203. Evaluation of prostate-specific antigen as a novel biomarker of Hsp90 inhibition
  204. AIDing cancer treatment: reducing AID activity via Hsp90 inhibition
  205. Pharmacological inhibition of Hsp90 and ras activity as a new strategy in the treatment of HNSCC
  206. Anti-Candida-biofilm activity of micafungin is attenuated by voriconazole but restored by pharmacological inhibition of Hsp90-related stress responses
  207. Effects of Hsp90 inhibition in neuroblastoma: analysis of drug sensitivity, target modulation and the influence of bone marrow microenvironment.
  208. Pharmacological inhibition of Hsp90 activity negatively modulates myogenic differentiation and cell survival in C2C12 cells
  209. Hsp90 inhibition results in glucocorticoid receptor degradation in association with increased sensitivity to paclitaxel in triple-negative breast cancer
  210. โ€ฆ ฮฒ peptide-induced inhibition of endothelial nitric oxide production involves oxidative stress-mediated constitutive eNOS/Hsp90 interaction and disruption of โ€ฆ
  211. Hsp90 inhibition renders iNOS aggregation and the clearance of iNOS aggregates by proteasomes requires SPSB2
  212. Hsp90 inhibition without heat shock response
  213. Hsp90-mediated inhibition of FKBP38 regulates apoptosis in neuroblastoma cells
  214. Reactive oxygen species-dependent Hsp90 protein cleavage participates in arsenical As+ 3-and MMA+ 3-induced apoptosis through inhibition of telomerase activity โ€ฆ
  215. Sulphoxythiocarbamates modify cysteine residues in Hsp90 causing degradation of client proteins and inhibition of cancer cell proliferation
  216. Inhibition of Hsp90 attenuates porcine reproductive and respiratory syndrome virus production in vitro
  217. Magnetic nanoparticle-mediated hyperthermia therapy induces tumour growth inhibition by apoptosis and Hsp90/AKT modulation
  218. Changes in heat-shock protein synthesis and thermotolerance of Arabodopsis thaliana seedlings resulting from Hsp90 inhibition by geldanamycin
  219. Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib โ€ฆ
  220. Combined inhibition of Hsp90 and heme oxygenase-1 induces apoptosis and endoplasmic reticulum stress in melanoma
  221. Inhibition of Plasmodium falciparum Hsp90 Contributes to the Antimalarial Activities of Aminoalcohol-carbazoles
  222. Dysregulated fibronectin trafficking by Hsp90 inhibition restricts prostate cancer cell invasion
  223. Hsp90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome
  224. Strong antitumor synergy between DNA crosslinking and Hsp90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells
  225. Inhibition and flare patterns of metabolic response to the heat shock protein 90 (Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced โ€ฆ
  226. Inhibition of Hsp90 attenuates pro-inflammatory cytokines and prevents LPS induced liver injury
  227. Little effect of Hsp90 inhibition on the quantitative wing traits variation in Drosophila melanogaster
  228. Inhibition of HIV-1 reactivation by a telomerase-derived peptide in a Hsp90-dependent manner
  229. Tomato plant cell death induced by inhibition of Hsp90 is alleviated by Tomato yellow leaf curl virus infection
  230. Pharmacologic inhibition of Hsp90 to prevent GLT-1 degradation as an effective therapy for epilepsy
  231. Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro
  232. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer
  233. Expression of focal adhesion kinase in uveal melanoma and the effects of Hsp90 inhibition by 17-AAG
  234. Efficacy of Hsp90 inhibition for the induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo
  235. In silico investigations on Hsp90 and its inhibition for the therapeutic prevention of breast cancer
  236. โ€ฆ not HSP90, confers neuroprotection against fatal endotoxemia via augmentation of nitric-oxide synthase I (NOS I)/protein kinase G signaling pathway and inhibition of โ€ฆ
  237. Hsp90 inhibition suppresses PGE2 production via modulating COX-2 and 15-PGDH expression in HT-29 colorectal cancer cells
  238. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells
  239. Targeting the MYC oncogene in Burkitt lymphoma through Hsp90 inhibition
  240. Hsp90 inhibition induces destabilization of actin cytoskeleton in tumor cells: functional significance of Hsp90 interaction with Fโ€“actin
  241. Ascorbic acid inhibition of Candida albicans Hsp90-mediated morphogenesis occurs via the transcriptional regulator Upc2
  242. The targeted inhibition of mitochondrial Hsp90 overcomes the apoptosis resistance conferred by Bcl-2 in Hep3B cells via necroptosis
  243. Bioactive metabolites from Chaetomium aureum: Structure elucidation and inhibition of the Hsp90 machine chaperoning activity
  244. Heat shock protein 90 (Hsp90) inhibition in acute myeloid leukemiaโ€”Targeting of disease heterogeneity through direct and indirect antileukemic effects
  245. HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging
  246. Selective Inhibition of HDAC6 regulates preferential cytotoxicity in cancer cells by modulating p53 and Hsp90 stability
  247. 2-Aroylquinoline-5, 8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (Hsp90) inhibition
  248. Epigenetic effects of inhibition of heat shock protein 90 (Hsp90) in human pancreatic and colon cancer
  249. Quantitative proteomics reveals molecular mechanism of gamabufotalin and its potential inhibition on Hsp90 in lung cancer
  250. Hsp90 inhibition affects cell metabolism by disrupting mitochondrial protein insertion
  251. Drug-induced Hsp90 inhibition alleviates pain in monoarthritic rats and alters the expression of new putative pain players at the DRG
  252. Hsp90 inhibition in adrenocortical carcinoma: Limited drug synergism with mitotane
  253. Hsp90 inhibition by AT13387 modulates growth factor and cytokine stimulated cell signalling in multiple cell lines.
  254. Hyponatremia and V2 vasopressin receptor upregulation: a result of Hsp90 inhibition
  255. Inhibition of hepatitis C virus using siRNA targeted to the virus and Hsp90
  256. โ€ฆ inhibition of Heat Shock Protein 90 (Hsp90) chaperone function in patienets with metastatic GIST: results of a Phase I Trial of IPI-504, a water-soluble Hsp90 โ€ฆ
  257. Hsp90 inhibition as a means to inhibit activation of the NLRP3 inflammasome
  258. Hsp90 inhibition drives degradation of FGFR2 fusion proteins: Implications for treatment of cholangiocarcinoma
  259. Targeting the Hsp90 C-terminal domain to induce allosteric inhibition and selective client downregulation
  260. Inhibition of Heat Shock proteins Hsp90 and HSP70 induce oxidative stress, suppressing cotton fiber development
  261. Hsp90 inhibition targets autophagy and induces a CASP9-dependent resistance mechanism in NSCLC
  262. MicroPET/CT imaging of AXL downregulation by Hsp90 inhibition in triple-negative breast cancer
  263. Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms
  264. Radicicol binding to Swo1/Hsp90 and inhibition of growth of specific temperature-sensitive cell cycle mutants of fission yeast
  265. Hsp90 inhibition results in a significant delay in tumor progression in a model of emerging EGFR TKI resistance in non-small cell lung cancer
  266. Inhibition of Hsp90 promotes neural stem cell survival from oxidative stress through attenuating NF-ฮบB/p65 activation
  267. โ€ฆ docking analysis of the molecular chaperone-kinase interactions: Towards allosteric inhibition of protein kinases by targeting the Hsp90-Cdc37 chaperone machinery
  268. Phenotypic variability of Arabidopsis thaliana seedlings as a result of inhibition of Hsp90 chaperones
  269. Antiangiogenic effects associated with the inhibition of Hsp90 in colorectal cancer
  270. Hsp90 inhibition is a potential therapeutic strategy in treatment of adenocarcinoma of the esophagus
  271. Hsp90 inhibition as an anticancer strategy: Novel approaches and future directions
  272. 17-DMAG-loaded nanofibrous scaffold for effective growth inhibition of lung cancer cells through targeting Hsp90 gene expression
  273. Geldanamycin derivatives as promising anticancer drugs: therapy via Hsp90 inhibition
  274. Effect of Hsp90 inhibition on Rac activation, cell migration, tumor growth and liver metastasis of human pancreatic carcinoma
  275. Targeted inhibition of mitochondrial Hsp90 induces mitochondrial elongation in Hep3B hepatocellular carcinoma cells undergoing apoptosis by increasing โ€ฆ
  276. Traditional and novel mechanisms of heat shock protein 90 (Hsp90) inhibition in cancer chemotherapy including Hsp90 cleavage
  277. Simultaneous inhibition of Hsp90 and mTOR synergistically reduces tumor growth and angiogenesis of hepatocellular cancer in an experimental model
  278. โ€ฆ sesterterpenoid-type metabolite, induces apoptosis in prostate LNcap cells via oxidative and ER stress combined with the inhibition of topoisomerase II and Hsp90
  279. AMH and AMHR2 regulate survival signaling, epithelial-mesenchymal transition (EMT) and resistance to Hsp90 inhibition in non-small cell lung cancer (NSCLC)
  280. Hsp90 Inhibition Reduces TLR5 Surface Expression and NF-ฮบB Activation in Human Myeloid Leukemia THP-1 Cells
  281. Overcoming acquired resistance to Hsp90 inhibition by targeting JAK-STAT signalling in triple-negative breast cancer
  282. Evaluating dual Hsp90 and Hsp70 inhibition as a cancer therapy
  283. Intrinsic proteotoxic stress levels vary and act as a predictive marker for sensitivity of cancer cells to Hsp90 inhibition
  284. Correction: Strong antitumor synergy between DNA crosslinking and Hsp90 inhibition causes massive premitotic DNA fragmentation in ovarian cancer cells
  285. Changes in heat shock protein synthesis and thermotolerance of Arabidopsis thaliana seedlings as a result of inhibition of Hsp90 by geldanamycin
  286. Novel and less explored chemotypes of natural origin for the inhibition of Hsp90
  287. Hsp90 inhibition attenuates LPS-mediated NF-ฮบB-dependent gene activation by preventing the de-acetylation and maintaining the DNA binding of acetyl-histone H3 โ€ฆ
  288. Hsp90-mediated inactivation of NF {kappa} B switches autophagy to apoptosis through becn1 transcriptional inhibition in selenite-induced NB4 cells
  289. โ€ฆ yeast into whether the rapamycin inhibition of heat shock transcription factor (Hsf1) can prevent the Hsf1 activation that results from treatment with an Hsp90 โ€ฆ
  290. Celastrol Mediated Hsp90 Protein Inhibition in Cancer
  291. Downregulation of androgen receptors by NaAsO2 via inhibition of AKTโ€NFโ€ฮบB and Hsp90 in castration resistant prostate cancer
  292. Transcriptomics-based screening identifies pharmacological inhibition of Hsp90 as a means to defer aging
  293. Enhanced HIF1ฮฑ inhibition through dual inhibition of CDK and HSP90
  294. Hsp90 N-and C-terminal double inhibition synergistically suppresses Bcr-Abl-positive human leukemia cells
  295. Inhibition of Hsp90 by triptolide (TPL) augments Bortezomib-induced U266 cells apoptosis
  296. Hsp90 inhibition promotes proteasome function in vascular endothelial cells
  297. Inhibition of elemene on Hsp90/Raf-1 molecular complex in C6 glioblastoma cells [J]
  298. Targeted Inhibition Of Mitochondrial Hsp90 Improves Pulmonary Arterial Hypertension
  299. The targeted inhibition of Hsp90 by a synthetic small molecule, DPide offers an effective treatment strategy against TNBCs
  300. Epilepsy: Hsp90 inhibition suppresses seizures
  301. A scaffold merging approach to Hsp90 C-terminal inhibition: synthesis and evaluation of a chimeric library
  302. Hsp90 Inhibition Reverts IL13-and IL17-Induced Goblet Cell Metaplasia in Human Airway Epithelia
  303. INVESTIGATION OF THE CELLULAR EFFECTS OF Hsp90 INHIBITION ON HEPATOCELLULAR CARCINOMA CELLS
  304. RNAi knockdown or chemical inhibition of anaphase-promoting complex components is synthetic lethal with Hsp90 inhibition
  305. Inhibition Of Hsp90 Repairs The LPS-Induced Ali In Mice
  306. A comprehensive study to analyze tumor sensitivity to Hsp90 inhibition therapy.
  307. Trypanosoma cruzi Inhibition of Hsp90 in
  308. Acquired resistance to Hsp90 inhibition in triple-negative breast cancer
  309. Inhibition of Hsp90 in Streptomyces coelicolor
  310. Hsp90 inhibition affects MHC class II presentation of glutamic acid decarboxylase
  311. Role of PRKD2 in Hsp90 inhibition-mediated suppression of cancer growth
  312. MRS detection of altered choline metabolism following Hsp90 inhibition
  313. Hsp90 inhibition radiosensitize head and neck carcinoma via EGFR degradation
  314. Impact of Hsp90 Inhibition on Viability and Cell Cycle in Relation to p53 Status
  315. Preclinical efficacy of Hsp90 inhibition by using PF-04942847 in osteosarcoma
  316. CLU inhibition using OGX-011 is a new adjuvant therapeutic strategy for Hsp90 inhibition in prostate cancer
  317. Dual inhibition of CDK1 and Hsp90 destabilizes HIF1ฮฑ and synergistically induces cancer cell death
  318. Functional inhibition of Hsp90 potentiates the effects of ionizing radiation in colorectal cancer
  319. Combining Hsp90 Inhibition with Standard Therapies for HER2 Positive Breast Cancer.
  320. The new molecular target therapy of Hsp90 inhibition in esophageal squamous cell carcinoma
  321. Hsp90 inhibition decreases ovarian cancer cell proliferation and potentiates platinum sensitivity
  322. Hsp90 inhibition down regulates EGFR and its effector signaling proteins in pancreatic cancer cell lines
  323. Synthetic lethal screen identifies candidates that modulate cancer cell sensitivity in response to Hsp90 inhibition.
  324. CLU inhibition using OGX-011 as an adjuvant therapeutic strategy for Hsp90 inhibition in prostate cancer.
  325. Inhibition of Hsp90 suppresses BmNPV replication in Bombyx mori
  326. โ€ฆ : Modulation of the Hsp90 cochaperone carboxyโ€terminus HSC70โ€interacting protein (CHIP) increases cellular sensitivity to heat shock protein 90 (Hsp90) inhibition
  327. Heat shock protein 90 (Hsp90) inhibition reduces glomerular filtration rate (GFR) and sodium excretion.
  328. Changes in choline metabolism as potential biomarkers of Hsp90 inhibition in NEU/HER2-driven mammary carcinoma Oncomouseยฎ cells
  329. Hsp90 acetylation following histone deacetylase inhibition: A role for the histone acetyltransferases p300 and PCAF
  330. A67 BREAKDOWN: THE CELLULAR CONTRIBUTION TO PULMONARY HYPERTENSION: Targeted Inhibition Of Mitochondrial Hsp90 Improves Pulmonary Arterial โ€ฆ
  331. HDAC and Hsp90 inhibition as therapeutic strategy for translocation renal cell carcinoma
  332. Hsp90 inhibition leads to a differential proteomics profile in non small cell lung cancer cell lines
  333. THU0057 Inhibition of Heat Shock Protein 90 (Hsp90) Prevents Fibrosis by Targeting Canonical TGF-B Signaling
  334. Immunostimulatory effects of Hsp90 inhibition: Insights from combinational immunotherapies targeting EphA2
  335. Proteomic analysis of ubiquitination identifies the interplay between Hsp90 inhibition and CUL5 in the control of autophagy
  336. TREATMENT OF AVIAN TIBIAL DYSCHONDROPLASIA USING TRADITIONAL CHINESE MEDICINES BY Hsp90 INHIBITION
  337. Supplementary Materials: Targeting the MYC Oncogene in Burkitt Lymphoma through Hsp90 Inhibition
  338. Abstract B16: Phenotypic plasticity in the EML cell culture system as a result of Hsp90 inhibition
  339. Visualizing dual downregulation of IGF-1R and VEGF by Hsp90 inhibition effect in triple negative breast cancer
  340. Hsp90 Inhibition Leads to the Degradation of O-Linked N-Acetylglucosamine Transferase and to the Reduction of O-GlcNAcylation
  341. Effect of Hsp90 inhibition in tumor cells Apoptosis and cell migration
  342. HER2-overexpressing lines are sensitive to Hsp90 inhibition irrespective of p53 status
  343. Analysis of cell cycle-related gene expressions in MDM2-transfected LNCaP-MST cells after inhibition of HSP90
  344. Inhibition of Hsp90 overcomes resistance to chemotherapy and radiotherapy in pancreatic cancer
  345. Cellular and molecular effects of Hsp90 inhibition by 17-AAG in sporadic and hereditary breast cancer
  346. Hsp90 Inhibition and Cellular Stress Elicits Phenotypic Plasticity in Hematopoietic Differentiation
  347. Therapeutic inhibition of Hsp90 in a mouse model of diabetic atherosclerosis and nephropathy
  348. Slow, tight binding inhibition of Hsp90 isoforms correlates with potent anti-proliferative activity in cancer cell lines
  349. Empirical Modeling the Effect of Hsp90 Inhibition on Cytokines Associated With Impaired Biotransport of Apoptotic Debris
  350. Effect of Hsp90 inhibition on the gene expression profile of MDM2 transfected LNCaP-MST prostate cancer cells
  351. Evaluation of biomarkers for imaging and radio-immunotherapy in combination with Hsp90 inhibition in squamous cell carcinomas
  352. 177Lu-octreotate therapy for neuroendocrine tumours is enhanced by Hsp90 inhibition
  353. Novobiocinโ€“ferrocene conjugates possessing anticancer and antiplasmodial activity independent of Hsp90 inhibition
  354. A62 LUNG FIBROSIS: FIBROBLAST BIOLOGY: Hsp90 Inhibition Prevents Lung Fibroblast Activation And Epithelial-Mesenchymal Transition
  355. Abstract P4-16-05: Hsp90 inhibition potentiates chemotherapy effectiveness in triple negative breast cancer: Role of glucocorticoid receptor signaling
  356. Discovery of novel NO-releasing celastrol derivatives with Hsp90 inhibition and cytotoxic activities
  357. Hsp90 inhibition rescues behavioral deficits and reduces tau phosphorylation in ps19 mice model for Alzheimerโ€™s disease (AD)
  358. Inhibition of heat shock protein 90 (Hsp90) and degradation of client proteins associated with oncogenesis using analogs of Novobiocin
  359. Hsp90 Inhibition Has Potent Activity Against T-Cell Acute Lymphoblastic Leukemia (T-ALL) Through Degradation Of TYK2 Kinase
  360. Hsp90 inhibition ameliorates CD4+ T cellโ€mediated acute Graft versus Host disease in mice
  361. Hsp90 inhibition depletes DNA repair proteins to sensitize acute myelogenous leukemia to nucleoside analog chemotherapeutics
  362. Computational modeling of Hsp90 inhibition illustrates a potential therapy to inhibit immune-mediated inflammation in systemic lupus erythematosus.(87.8)
  363. Hsp90 inhibition suppresses LPS-mediated NFkB target gene expression without affecting NFkB nuclear translocation in human lung microvascular endothelial cells
  364. Hsp90 inhibition induced cytotoxicity via downregulation of Rad51 expression and DNA repair capacity in non-small cell lung cancer cells
  365. Hsp90 inhibition abolishes LPS-mediated NF-ฮบB transcriptional activation independent of IKKฮฒ in human lung microvascular endothelial cells (HLMVEC)(847.7)
  366. Hsp90 inhibition prevents bacterial lipopolysaccharide-induced and RhoA-mediated signaling leading to paracellular hyper-permeability in human lung microvascular โ€ฆ
  367. USP22-dependent HSP90AB1 expression promotes resistance to Hsp90 inhibition in mammary and colorectal cancer
  368. Role for NQO1 and MnSOD in 17AAG-Induced Hsp90 inhibition in Pancreatic Cancer Cells
  369. Hsp90 inhibition results in GR, AR and JAK protein degradation, decreased triple-negative breast cancer proliferation and increased paclitaxel sensitivity
  370. Hsp90 inhibition prevents monocrotaline-induced pulmonary hypertension in rats, as revealed by high resolution echocardiography
  371. Correction: 2-Aroylquinoline-5, 8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (Hsp90) inhibition
  372. Compromising the constitutive p16INK4a expression sensitizes human neuroblastoma cells to Hsp90 inhibition and promotes premature senescence
  373. Hsp90 Inhibition Enhances the Anti-Tumor Efficacy of Combination Chemo Immunotherapy Targeting DNA Repair Proteins
  374. Casting a wide net: Hsp90 inhibition to circumvent resistance to TKIs in EGFR-mutated and ALK-rearranged NSCLC
  375. Hsp90 inhibition attenuates the LPS-mediated phosphorylation of CREB and STAT3 in human lung microvascular endothelial cells
  376. Ligand-independent activation of the P2X7 receptor by Hsp90 inhibition stimulates motor neuron apoptosis
  377. Abstract# 2835: Inhibition of heat shock protein 90 (Hsp90) modulates macrophage stimulating-1 receptor (MSR1) expression and signaling, and reduces pancreatic โ€ฆ
  378. Pharmacological Inhibition of Hsp90 as a Novel Antitumor Strategy to Target Cytoarchitecture Through Extracellular Matrix Signaling
  379. Metabolic profiling of drug response in prostate cancer cells following PI3K, MAPK and Hsp90 inhibition using magnetic resonance spectroscopy
  380. 17-AAG Hsp90 Inhibition as an Effective Therapy for Lymphoma Stem Cells.
  381. Chemical inhibition of Hsp90 inhibits TNFโ€ฮฑ mediated proliferation and induces apoptosis in human rheumatoid arthritis fibroblastโ€like synoviocytes
  382. Integration of Hsp90 inhibition in combinational immunotherapies targeting receptor tyrosine kinase EphA2
  383. 17-AAG Mediated Hsp90 Inhibition as an Effective Therapy for Lymphoma Stem Cells
  384. A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to Hsp90 Inhibition
  385. Visualizing dual downregulation of IGF-1 R and VEGF-A by Hsp90 inhibition effect in triple negative breast cancer
  386. Abstract A226: ImmunoPET with 89Zrโ€DFOโ€trastuzumab: Monitoring the pharmacodynamic effects on HER2/neu expression by Hsp90 inhibition in vivo
  387. Effects of Hsp90 inhibition and/or PKC activation on ErbB2 in MDA-MB-453 cells
  388. Abstract B103: Hsp90 inhibition targets the dysregulated signal and transcription factor network and malignant phenotype of head and neck squamous cell carcinoma โ€ฆ
  389. Abstract P1-03-07: Differential Effect of Specific p53 Mutations on Breast Cancer Growth and Response to Hsp90 Inhibition In Vivo
  390. โ€ฆ # 4975: Activating transcription factor-3 (ATF3) functions as a tumor suppressor in colon cancer and is up-regulated upon heat shock protein 90 (Hsp90) inhibition
  391. Effect of heat stress and Hsp90 inhibition on T-type calcium currents and voltage-dependent potassium currents in leydig cells
  392. This is a repository copy of FGFR3 translocations in bladder cancer: differential sensitivity to Hsp90 inhibition based on drug metabolism..
  393. B28 BARRIER DYNAMICS IN THE PULMONARY CIRCULATION: Hsp90 Inhibition Suppresses Bacterial Endotoxin-Mediated Nf-[kappa] b Transcriptional Activation โ€ฆ
  394. Abstract B140: Positron emission tomography imaging of HER2 expression and pharmacodynamic response to Hsp90 inhibition with the next-generation ZHER2 โ€ฆ
  395. Inhibition of heat-shock protein 90 (Hsp90) disrupts mutliple pro-angiogenic signaling pathways in gastric cancers cells in vitro and reduces tumor growth and โ€ฆ
  396. Hsp90 Inhibition Abrogates the Topoisomerase I Poison-induced G2/M Checkpoint in p53-null Tumor cells by Depleting Chk1 and Wee1
  397. Heat Shock Protein 90 (Hsp90) Inhibition as a Potential Novel Approach to the Treatment of Patients with ALK Mutated Non-small Cell Lung Cancer (NSCLC)
  398. MP64-14 TARGETING HEAT SHOCK FACTOR 1 SENSITIZES CASTRATION-RESISTANT PROSTATE CANCER CELLS TO Hsp90 INHIBITION IN PART BY โ€ฆ
  399. โ€ฆ mutation of PI3K p110alpha subunit in HER2-overexpressing mammary epithelial cells confers aโ€โ€ stem-likeโ€โ€ phenotype and acute sensitivity to Hsp90 inhibition
  400. Heat shock protein 90 (Hsp90) inhibition in squamous cell carcinoma of the head and neck (SCCHN): An in vitro analysis with a focus on p16 status.
  401. Inhibition of Hsp90 by AT13387 Delays the Emergence of
  402. Acetylation of Hsp90 reverses dexamethasone-mediated inhibition of insulin secretion
  403. Local Inhibition of Hsp90 to Prevent Intimal Hyperplasia after Balloon Injury
  404. Combination of Hsp90 and mTOR inhibition promotes pancreatic cancer growth inhibition
  405. Hsp90 characterization and inhibition: a multi-methodological study
  406. Immune Expression and Inhibition of Hsp90 in Retinoblastoma
  407. Immune Expression and Inhibition of Hsp90 in Metastatic Uveal Melanoma
  408. Therapeutic advantages of inhibition of Hsp90 and proteasomal inhibition in prostate cancer cells
  409. Immune expression and inhibition of Hsp90 in uveal melanoma
  410. Synthesis of Novel Hsp90 Inhibotor and Its Inhibition
  411. Immune Expression and Inhibition of Hsp90 in Human Uveal Melanoma
  412. Reduction of cardiac TGFฮฒ-mediated profibrotic events by inhibition of Hsp90 with engineered protein
  413. Inhibition of Hsp90 induces BRCA1 degradation and hypersensitivity to ionizing radiation
  414. Cancer drug resistance: rationale for drug delivery systems and targeted inhibition of Hsp90 family proteins
  415. Therapeutic Inhibition Of Hsp90 Attenuates Fibroblast Activation Involved In Severe Fibrotic Lung Disease
  416. Inhibition of curcumin derivative C1209 on proliferation of CML cells by disrupting Hsp90 chaperon function
  417. Low-level inhibition of Hsp90 forces cells to tip their (antigenic) hand
  418. Induction of enhanced tumor-specific immunity by Hsp90 targeted photodynamic therapy (Hsp90-PDT) combined with immune checkpoint inhibition
  419. Inhibition of Hsp90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells
  420. Combinatorial inhibition of mTORC2 and Hsp90 leads to a distinctly effective therapeutic strategy in malignant pheochromocytom.
  421. Abstract B99: Targeting TPR cochaperones of the Hsp90 molecular chaperone complex for specific inhibition.
  422. The stress protein response transiently inhibits STAT1 signaling via inhibition of Hsp90 binding
  423. Inhibition of Hsp90 sensitizes pancreatic cancer in vitro and in vivo to chemo-radiotherapy
  424. Targeted blockade of Hsp90 impairs DNA-damage response proteins and increases the sensitivity of ovarian carcinoma cells to PARP inhibition
  425. HSP70/Hsp90 Expression in CA9-22 after thermotherapy and the effect of inhibition of HSP70/Hsp90 expression on the efficacy of thermotherapy
  426. INHIBITION OF Hsp90 IN TRYPANOSOMA BRUCEI AND PHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIPS OF ANTITRYPANOSOMALS
  427. Inhibition of Hsp90 chaperone and 26S proteasomal activities by efrapeptins in breast cancer cells
  428. Functional inhibition of Hsp90 induces G0/G1 arrest and downregulates thymidylate synthase in colorectal cancer
  429. Inhibition of heat shock protein 90 (Hsp90) by diterpenoids from roots of Zhumeria majdae
  430. C76 HEAT SHOCK PROTEIN: Therapeutic Inhibition Of Hsp90 Attenuates Fibroblast Activation Involved In Severe Fibrotic Lung Disease
  431. Inhibition of novobiocin on proliferation of HL-60/Bcr-Abl cells involves disruption of Hsp90 chaperon function
  432. 292 INHIBITION OF Hsp90 AGGRAVATES THE EFFECTS OF HEAT SHOCK ON DEVELOPMENTAL COMPETENCE OF BOVINE OOCYTES
  433. V599E B-Raf as the next Hsp90 client protein: A novel strategy for selective inhibition of mutated B-Raf
  434. Inhibition of Hsp90 enhances T cell-mediated antitumor immune responses through expression of interferon-alpha response Genes
  435. Hsp90 protects LPS induced pancreatic inflammation of AR42J cells by inhibition of p38MAPK/NF-ฮบB pathways
  436. Inhibition of Hsp90 with NVP-AUY922 induces a synergistic effect in HER2-amplified, trastuzumab-resistant breast and gastric cancer
  437. Inhibition of histone deacetylases 1 and 2 increases p21CIP1/WAF1 expression independent of p53 and Hsp90 in colon cancer cells
  438. Inhibition of Hsp90 and its Client Kinase FAK has Therapeutic Potential in Squamous Cell Carcinomas of the Uterine Cervix and Oral Cavity
  439. In vitro and in vivo inhibition of the Hsp90 molecular chaperone by novel, synthetic, potent pyrazole/isoxazole resorcinol 5-amide analogs
  440. Combined Pharmacological Inhibition of Cyclophilins, FK506-Binding Proteins, Hsp90, and Hsp70 Protects Cells From Clostridium botulinum C2 Toxin
  441. Inhibition of Hepatitis C Replication by Targeting the Molecular Chaperone Hsp90: Synthesis and Biological Evaluation of 4,5,6,7โ€Tetrahydrobenzo[1,2โ€d]thiazole โ€ฆ
  442. Benzo [a] pyrene Inhibition of Follicular Development and Survival Is Associated with Dysregulation of Hsp90, Bax, CYP1A1, and CYP1B1 Expression.
  443. Inhibition of heat stress-related apoptosis of chicken myocardial cells through inducing Hsp90 expression by aspirin administration in vivo
  444. Abstract NT-094: TARGETED INHIBITION OF Hsp90 IMPAIRS DNA-DAMAGE RESPONSE PROTEINS AND INCREASES THE SENSITIVITY OF OVARIAN โ€ฆ
  445. Targeted inhibition of histone deacetylase leads to suppression of Ewing sarcoma tumor growth through an unappreciated EWS-FLI1/HDAC3/Hsp90 signaling axis
  446. Inhibition of heat shock protein 90 (Hsp90) sensitizes HER2-negative breast cancer derived MDA-MD-231 cell line to the cytotoxic effect of troglitazone (TRO)
  447. Effects of Hsp90 inhibition on galectin3 expression in human monocytic cell line THP1
  448. Radiosensitization of human tumor cells by Hsp90 inhibition
  449. Hsp90 inhibition as a way to treat cancer
  450. Hsp90 inhibition causes heterochronies in the skull ossification sequences of Pleurodeles waltl (Urodela). Evolutionary implications.
  451. Hsp90 Inhibition verbessert die antitumor Effektivitรคt von Rapamycin durch Blockade von Akt und NF-ฮบB
  452. Inhibition von Hsp90 in Gemcitabine-und 5-Fluorouracil-resistenten Pankreaskarzinomen
  453. Inhibition of Hsp90 with pochoximes: structure-activity relationship and structure-based insights
  454. Inhibition von Heat-shock Protein 90 ( Hsp90 ) mittels EC154, einem neuen synthetischen Hsp90 Antagonist, reduziert das Wachstum von humanen Magen-undโ€ฆ
  455. VII. Molekulare Onkologie: Therapie Inhibition von Heat-shock Protein 90 ( Hsp90 ) mittels EC154, einem neuen synthetischen Hsp90 Antagonist, reduziert dasโ€ฆ
  456. Design and synthesis of a library of cyclopeptides and Shepherdine analogues for the inhibition of the Hsp90 -Survivine interaction
  457. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitorshttps://www.nature.com/articles/nature01913
  458. Hsp90 inhibitors as novel cancer chemotherapeutic agents
  459. Hsp90 molecular chaperone inhibitors: are we there yet?
  460. Development and application of Hsp90 inhibitors
  461. Targeting Hsp90: small-molecule inhibitors and their clinical development
  462. Inhibitors of the Hsp90 molecular chaperone: current status
  463. Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function
  464. Update on Hsp90 inhibitors in clinical trial
  465. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors
  466. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket
  467. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors
  468. Hsp90 inhibitors in the clinic
  469. Discovery and development of pyrazole-scaffold Hsp90 inhibitors
  470. Hsp90 inhibitors identified from a library of novobiocin analogues
  471. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers
  472. The stress response: implications for the clinical development of Hsp90 inhibitors
  473. Natural product origins of Hsp90 inhibitors
  474. Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive
  475. Discovery and development of Hsp90 inhibitors: a promising pathway for cancer therapy
  476. Hsp90 inhibitors: small molecules that transform the Hsp90 protein folding machinery into a catalyst for protein degradation
  477. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design
  478. Development of purine-scaffold small molecule inhibitors of Hsp90
  479. Hsp90 inhibitors reduce influenza virus replication in cell culture
  480. Hsp90 inhibitors: current development and potential in cancer therapy
  481. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3, 4-diarylpyrazole class of Hsp90 inhibitors
  482. Targeting heat shock response to sensitize cancer cells to proteasome and Hsp90 inhibitors
  483. Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice
  484. Genetic resistance to JAK2 enzymatic inhibitors is overcome by Hsp90 inhibition
  485. Recent advances in Hsp90 inhibitors as antitumor agents
  486. New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential
  487. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors
  488. Structure-based discovery of a new class of Hsp90 inhibitors
  489. Effectiveness of Hsp90 inhibitors as anti-cancer drugs
  490. Maximizing the therapeutic potential of Hsp90 inhibitors
  491. Purine-scaffold Hsp90 inhibitors
  492. Hsp90 inhibition accelerates cell lysis anti-Hsp90 ribozyme reveals a complex mechanism of Hsp90 inhibitors involving both superoxide-and Hsp90-dependent โ€ฆ
  493. Emerging Hsp90 inhibitors: from discovery to clinic.
  494. Discovery and design of novel Hsp90 inhibitors using multiple fragmentโ€based design strategies
  495. A fluorescence polarization assay for inhibitors of Hsp90
  496. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2
  497. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification
  498. Auditing the Pharmacological Accounts for Hsp90 Molecular Chaperone Inhibitors: Unfolding the Relationship between Pharmacokinetics and Pharmacodynamics1
  499. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs
  500. Discovery and development of purine-scaffold Hsp90 inhibitors
  501. Brain-permeable small-molecule inhibitors of Hsp90 prevent ฮฑ-synuclein oligomer formation and rescue ฮฑ-synuclein-induced toxicity
  502. Design, synthesis, and biological evaluation of Hsp90 inhibitors based on conformational analysis of radicicol and its analogues
  503. Identification of Hsp90 inhibitors as a novel class of senolytics
  504. Inhibitors of Hsp90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth
  505. Using natural product inhibitors to validate Hsp90 as a molecular target in cancer
  506. Antileukemic activity of shepherdin and molecular diversity of Hsp90 inhibitors
  507. Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to Hsp90 inhibitors
  508. Fragmentโ€based identification of Hsp90 inhibitors
  509. 3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential Hsp90 inhibitors
  510. Optimizing natural products by biosynthetic engineering: discovery of nonquinone Hsp90 inhibitors
  511. 3-(5-Chloro-2, 4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone
  512. Inhibitors of Hsp90 and other chaperones for the treatment of cancer
  513. Geldanamycin, radicicol, and chimeric inhibitors of the Hsp90 Nterminal ATP binding site
  514. High-throughput assay for the identification of Hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase
  515. Insights into designing the dual-targeted HER2/Hsp90 inhibitors
  516. Hsp90 inhibitors as promising agents for radiotherapy
  517. p23/Sba1p protects against Hsp90 inhibitors independently of its intrinsic chaperone activity
  518. A biochemical rationale for the anticancer effects of Hsp90 inhibitors: slow, tight binding inhibition by geldanamycin and its analogues
  519. Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors
  520. Inhibitors of the Hsp90 molecular chaperone: attacking the master regulator in cancer
  521. Adenine derived inhibitors of the molecular chaperone HSP90โ€”SAR explained through multiple X-ray structures
  522. Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors
  523. Identification of new biomarkers for clinical trials of Hsp90 inhibitors
  524. Hsp90 inhibitors for cancer therapy and overcoming drug resistance
  525. BRAF and NRAS mutations in melanoma: potential relationships to clinical response to Hsp90 inhibitors
  526. Hsp90 inhibitors disrupt mitochondrial homeostasis in cancer cells
  527. Hsp90 inhibitors as anti-cancer agents, from basic discoveries to clinical development
  528. Evidence for efficacy of new Hsp90 inhibitors revealed by ex vivo culture of human prostate tumors
  529. Neuroprotective activity and evaluation of Hsp90 inhibitors in an immortalized neuronal cell line
  530. A novel class of Hsp90 inhibitors isolated by structure-based virtual screening
  531. Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90
  532. Progress in the discovery and development of heat shock protein 90 (Hsp90) inhibitors: Miniperspective
  533. Hsp90 inhibitors in breast cancer: a systematic review
  534. Hsp90 inhibitors deplete key antiโ€apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin
  535. Natural product inhibitors of Hsp90: potential leads for drug discovery
  536. Purine-scaffold Hsp90 inhibitors.
  537. Medicinal chemistry of Hsp90 inhibitors
  538. Hsp90 inhibitors: multi-targeted antitumor effects and novel combinatorial therapeutic approaches in cancer therapy
  539. Synthesis and evaluation of Hsp90 inhibitors that contain the 1, 4-naphthoquinone scaffold
  540. Search for Hsp90 inhibitors with potential anticancer activity: isolation and SAR studies of radicicol and monocillin I from two plant-associated fungi of the Sonoran โ€ฆ
  541. Geldanamycin and its derivatives as Hsp90 inhibitors
  542. High-throughput screening for Hsp90 ATPase inhibitors
  543. Preclinical characterization of mitochondria-targeted small molecule Hsp90 inhibitors, gamitrinibs, in advanced prostate cancer
  544. Hsp90 inhibitors, GA and 17AAG, lead to ER stress-induced apoptosis in rat histiocytoma
  545. Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone
  546. Development of a high throughput drug screening assay for the detection of changes in tau levels-proof of concept with Hsp90 inhibitors
  547. Targeting the Hsp90 chaperone: synthesis of novel resorcylic acid macrolactone inhibitors of Hsp90
  548. Dihydroxyphenylisoindoline amides as orally bioavailable inhibitors of the heat shock protein 90 (Hsp90) molecular chaperone
  549. Structureโ€based and in silico design of Hsp90 inhibitors
  550. Hsp90 and its inhibitors
  551. Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors
  552. Novel Hsp90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair โ€ฆ
  553. Natural Product Inspired Nโ€Terminal Hsp90 Inhibitors: From Bench to Bedside?
  554. Hsp90 inhibitors cause G2/M arrest associated with the reduction of Cdc25C and Cdc2 in lung cancer cell lines
  555. Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancerโ€initiating cells
  556. Genes and proteins governing the cellular sensitivity to Hsp90 inhibitors: a mechanistic perspective
  557. Hsp90 inhibitors: clinical development and future opportunities in oncology therapy.
  558. Design and synthesis of Hsp90 inhibitors: exploring the SAR of Sansalvamide A derivatives
  559. Targeting of KRAS mutant tumors by Hsp90 inhibitors involves degradation of STK33
  560. An investigation into the potential use of serum Hsp70 as a novel tumour biomarker for Hsp90 inhibitors
  561. Hsp90 inhibitors block outgrowth of EBV-infected malignant cells in vitro and in vivo through an EBNA1-dependent mechanism
  562. Constitutively-active androgen receptor variants function independently of the Hsp90 chaperone but do not confer resistance to Hsp90 inhibitors
  563. An AlphaScreenTM-Based High-Throughput Screen to Identify Inhibitors of Hsp90-Cochaperone Interaction
  564. Assays for Hsp90 and inhibitors
  565. N-Aryl-benzimidazolones as novel small molecule Hsp90 inhibitors
  566. Molecular basis for the actions of Hsp90 inhibitors and cancer therapy
  567. Hsp90 inhibitors exhibit resistance-free antiviral activity against respiratory syncytial virus
  568. Synthesis of pochoxime prodrugs as potent Hsp90 inhibitors
  569. Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells
  570. Inside the Hsp90 inhibitors binding mode through induced fit docking
  571. โ€ฆ 90 (Hsp90)-targetting drugs with heterologous expression of the human Hsp90ฮฒ, a property that can be exploited in screens for new Hsp90 chaperone inhibitors
  572. Learning from nature: advances in geldanamycin-and radicicol-based inhibitors of Hsp90
  573. Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (Hsp90) inhibitors targeting proliferation and angiogenesis
  574. Hsp90 inhibitors and drugs from fragment and virtual screening
  575. Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression
  576. Hsp90 inhibitors promote p53-dependent apoptosis through PUMA and Bax
  577. โ€ฆ of Hsp90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors
  578. Human leukemias with mutated FLT3 kinase are synergistically sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5 signal transduction pathway
  579. Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series
  580. A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors
  581. Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors
  582. Anticancer inhibitors of Hsp90 function: beyond the usual suspects
  583. Enhancement of complement-induced cell lysis: a novel mechanism for the anticancer effects of Hsp90 inhibitors
  584. Hsp90 inhibitors enhance differentiation and MITF (microphthalmia transcription factor) activity in osteoclast progenitors
  585. Inhibition of Hsp90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma โ€ฆ
  586. Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 โ€ฆ
  587. Tricyclic Series of Heat Shock Protein 90 (Hsp90) Inhibitors Part I: Discovery of Tricyclic Imidazo[4,5-c]pyridines as Potent Inhibitors of the Hsp90 Molecular โ€ฆ
  588. Natural and semisynthetic azaphilones as a new scaffold for Hsp90 inhibitors
  589. A Chemicalโ€“Biological Study Reveals C9-type Iridoids as Novel Heat Shock Protein 90 (Hsp90) Inhibitors
  590. Exploring the binding site of C-terminal Hsp90 inhibitors
  591. 5-Aryl-4-(5-substituted-2, 4-dihydroxyphenyl)-1, 2, 3-thiadiazoles as inhibitors of Hsp90 chaperone
  592. Organelle-specific Hsp90 inhibitors
  593. Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells
  594. Hsp90 inhibitors as therapy for multiple myeloma
  595. Isoxazolo (aza) naphthoquinones: A new class of cytotoxic Hsp90 inhibitors
  596. Combining trail with PI3 kinase or Hsp90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling
  597. Hsp90 inhibitors as new leads to target parasitic diarrheal diseases
  598. Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone
  599. Impact of posttranslational modifications on the anticancer activity of Hsp90 inhibitors
  600. Mps1 mediated phosphorylation of Hsp90 confers renal cell carcinoma sensitivity and selectivity to Hsp90 inhibitors
  601. Synthesis and evaluation of new Hsp90 inhibitors based on a 1, 4, 5-trisubstituted 1, 2, 3-triazole scaffold
  602. Bioinformatics, chemoinformatics, and pharmainformatics analysis of HER2/Hsp90 dual-targeted inhibitors
  603. Hsp90 inhibitors in lung cancer: promise still unfulfilled
  604. Heat shock factor 1 confers resistance to Hsp90 inhibitors through p62/SQSTM1 expression and promotion of autophagic flux
  605. Paralog specific Hsp90 inhibitorsโ€“a brief history and a bright future
  606. Cancer cells harboring MET gene amplification activate alternative signaling pathways to escape MET inhibition but remain sensitive to Hsp90 inhibitors
  607. Will Hsp90 inhibitors prove effective in BRAF-mutant melanomas?
  608. Structural determination of three different series of compounds as Hsp90 inhibitors using 3D-QSAR modeling, molecular docking and molecular dynamics โ€ฆ
  609. Synthesis and evaluation of novologues as C-terminal Hsp90 inhibitors with cytoprotective activity against sensory neuron glucotoxicity
  610. Development of heat shock protein (Hsp90) inhibitors to combat resistance to tyrosine kinase inhibitors through HSP90โ€“kinase interactions
  611. Potent antitumor activity of the novel Hsp90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells
  612. Discovery of potent N-(isoxazol-5-yl) amides as Hsp90 inhibitors
  613. Design, Synthesis, and Biological Evaluation of Conformationally Constrained cis-Amide Hsp90 Inhibitors
  614. IL-6 activated JAK/STAT3 pathway and sensitivity to Hsp90 inhibitors in multiple myeloma
  615. Increased antileukemic effects in human acute myeloid leukemia by combining HSP70 and Hsp90 inhibitors
  616. Design, synthesis, and biological evaluation of ring-constrained novobiocin analogues as Hsp90 C-terminal inhibitors
  617. โ€ฆ Conformational Dynamics between Plasmodium falciparum and Human Hsp90 Orthologues Enable the Structure-Based Discovery of Pathogen-Selective Inhibitors
  618. High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for Hsp90 inhibitors
  619. Principal component analysis on molecular descriptors as an alternative point of view in the search of new Hsp90 inhibitors
  620. Reversing drug resistance of cisplatin by Hsp90 inhibitors in human ovarian cancer cells
  621. Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as โ€ฆ
  622. Pharmacophore-based virtual screening and docking studies on Hsp90 inhibitors
  623. Comparative analysis of novel and conventional Hsp90 inhibitors on HIF activity and angiogenic potential in clear cell renal cell carcinoma: implications for โ€ฆ
  624. FBW7-dependent Mcl-1 degradation mediates the anticancer effect of Hsp90 inhibitors
  625. Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): synthesis, biology, and molecular modeling
  626. Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activity
  627. Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder cancer cells to chemoradiotherapy
  628. Hsp90 inhibitors attenuate effect of dexamethasone on activated NF-ฮบB and AP-1
  629. Possible effects of early treatments of Hsp90 inhibitors on preventing the evolution of drug resistance to other anti-cancer drugs
  630. Synthesis and biological evaluation of novobiocin core analogues as Hsp90 inhibitors
  631. Heat shock protein 90 (Hsp90) inhibitors activate the heat shock factor 1 (HSF1) stress response pathway and improve glucose regulation in diabetic mice
  632. Synthesis and antiproliferative activity of novobiocin analogues as potential Hsp90 inhibitors
  633. High-throughput screen of natural product libraries for Hsp90 inhibitors
  634. Hsp90 inhibitors NVP-AUY922 and NVP-BEP800 may exert a significant radiosensitization on tumor cells along with a cell type-specific cytotoxicity
  635. Chronic treatment with novel small molecule Hsp90 inhibitors rescues striatal dopamine levels but not ฮฑ-synuclein-induced neuronal cell loss
  636. Design and synthesis of novel macrocyclic 2-amino-6-arylpyrimidine Hsp90 inhibitors
  637. Targeting conserved water molecules: design of 4-aryl-5-cyanopyrrolo [2, 3-d] pyrimidine Hsp90 inhibitors using fragment-based screening and structure-based โ€ฆ
  638. Hsp90 C-terminal inhibitors exhibit antimigratory activity by disrupting the Hsp90ฮฑ/Aha1 complex in PC3-MM2 cells
  639. Anti-herpes simplex virus efficacies of 2-aminobenzamide derivatives as novel Hsp90 inhibitors
  640. Assays for identification of Hsp90 inhibitors and biochemical methods for discriminating their mechanism of action
  641. A potential role for Hsp90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry
  642. Development of noviomimetics as C-terminal Hsp90 inhibitors
  643. A large animal model to evaluate the effects of Hsp90 inhibitors for the treatment of lung adenocarcinoma
  644. Solution-phase parallel synthesis of Hsp90 inhibitors
  645. Molecular docking study, synthesis and biological evaluation of Schiff bases as Hsp90 inhibitors
  646. 4, 5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer
  647. Synthesis and biological evaluation of arylated novobiocin analogs as Hsp90 inhibitors
  648. Use of Hsp90 inhibitors to disrupt GDIโ€dependent Rab recycling
  649. โ€ฆ -mediated retinal neovascularization and vascular leakage in diabetic retina is suppressed by HIF-1ฮฑ destabilization by SH-1242 and SH-1280, novel Hsp90 inhibitors
  650. Practical synthesis of novel purine analogues as Hsp90 inhibitors
  651. Hsp90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells
  652. Novel Hsp90 inhibitors effectively target functions of thyroid cancer stem cell preventing migration and invasion
  653. Asymmetric synthesis of pochonin E and F, revision of their proposed structure, and their conversion to potent Hsp90 inhibitors
  654. Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido [4, 3-d] pyrimidines core through shape-based screening
  655. Identification of limonol derivatives as heat shock protein 90 (Hsp90) inhibitors through a multidisciplinary approach
  656. An improved route to 19-substituted geldanamycins as novel Hsp90 inhibitorsโ€“potential therapeutics in cancer and neurodegeneration
  657. RETRACTED: A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cells
  658. Design and synthesis of 2-amino-6-(1H, 3H-benzo [de] isochromen-6-yl)-1, 3, 5-triazines as novel Hsp90 inhibitors
  659. Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors
  660. Breast cancer and Hsp90 inhibitors: is there a role beyond the HER2-positive subtype?
  661. HSP27 knockdown produces synergistic induction of apoptosis by Hsp90 and kinase inhibitors in glioblastoma multiforme
  662. Identification of new Hsp90 inhibitors by structure-based virtual screening
  663. Retinal toxicity induced by small-molecule Hsp90 inhibitors in beagle dogs
  664. Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1, 2, 3-thiadiazole Hsp90 inhibitors
  665. Identification, design and bio-evaluation of novel Hsp90 inhibitors by ligand-based virtual screening
  666. Identification of a new series of potent diphenol Hsp90 inhibitors by fragment merging and structure-based optimization
  667. Fragment-based discovery of hydroxy-indazole-carboxamides as novel small molecule inhibitors of Hsp90
  668. The anticancer drug AUY922 generates a proteomics fingerprint that is highly conserved among structurally diverse Hsp90 inhibitors
  669. Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors
  670. An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma
  671. Hsp90 inhibitors, part 2: combining ligand-based and structure-based approaches for virtual screening application
  672. Client proteins and small molecule inhibitors display distinct binding preferences for constitutive and stress-induced Hsp90 isoforms and their โ€ฆ
  673. Hsp90 inhibitors disrupt a transient Hsp90-HSF1 interaction and identify a noncanonical model of Hsp90-mediated HSF1 regulation
  674. Hsp90 inhibitors, geldanamycin and radicicol, enhance fisetin-induced cytotoxicity via induction of apoptosis in human colonic cancer cells
  675. Design, synthesis, and biological activity of bicyclic radester analogues as Hsp90 inhibitors
  676. Design and synthesis of pyrimidinyl acyl thioureas as novel Hsp90 inhibitors in invasive ductal breast cancer and its bone metastasis
  677. Associating retinal drug exposure and retention with the ocular toxicity profiles of Hsp90 inhibitors.
  678. ER homeostasis and motility of NSCLC cell lines can be therapeutically targeted with combined Hsp90 and HDAC inhibitors
  679. Sensitization of multidrug-resistant human cancer cells to Hsp90 inhibitors by down-regulation of SIRT1
  680. Synthesis and biological evaluation of 3, 5-disubstituted-4-alkynylisoxozales as a novel class of Hsp90 inhibitors
  681. Discovery of hybrid Hsp90 inhibitors and their anti-neoplastic effects against gefitinib-resistant non-small cell lung cancer (NSCLC)
  682. Macrocyclic lactams as potent Hsp90 inhibitors with excellent tumor exposure and extended biomarker activity
  683. Integration-mediated prediction enrichment of quantitative model for Hsp90 inhibitors as anti-cancer agents: 3D-QSAR study
  684. Clinical evaluation and biomarker profiling of Hsp90 inhibitors
  685. ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system
  686. How selective are Hsp90 inhibitors for cancer cells over normal cells?
  687. โ€ฆ II study of Hsp90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase inhibitors โ€ฆ
  688. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90
  689. Redefining the phenotype of heat shock protein 90 (Hsp90) Inhibitors
  690. Multiclass comparative virtual screening to identify novel Hsp90 inhibitors: a therapeutic breast cancer drug target
  691. 2, 4-dihydroxy benzaldehyde derived Schiff bases as small molecule Hsp90 inhibitors: Rational identification of a new anticancer lead
  692. A computational analysis of pyrazole-based inhibitors binding to Hsp90 using molecular dynamics simulation and the MM-GBSA method
  693. Small molecule inhibitors of Hsp90 potently affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis
  694. A novel class of small molecule inhibitors of Hsp90
  695. 4, 5, 6, 7-Tetrahydro-isoxazolo-[4, 5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors
  696. โ€ฆ and SAR study of N-(4-hydroxy-3-(2-hydroxynaphthalene-1-yl) phenyl)-arylsulfonamides: heat shock protein 90 (Hsp90) inhibitors with submicromolar activity in an in โ€ฆ
  697. Hsp90 inhibitors for the treatment of chronic myeloid leukemia
  698. Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins
  699. Virtual screening and biophysical studies lead to Hsp90 inhibitors
  700. Hsp90 inhibitors: a potential treatment for latent EBV infection?
  701. Biological evaluation of 3-acyl-2-arylamino-1, 4-naphthoquinones as inhibitors of Hsp90 chaperoning function
  702. Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3-d]pyrimidine Inhibitors of the Hsp90 Molecular โ€ฆ
  703. HDAC and Hsp90 inhibitors downโ€regulate PTTG1/securin but do not induce aneuploidy
  704. AKT kinase and Hsp90 inhibitors as novel anti-cancer therapeutics
  705. Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
  706. Oncogenic MST1R activity in pancreatic and gastric cancer represents a valid target of Hsp90 inhibitors
  707. A repurposing strategy for Hsp90 inhibitors demonstrates their potency against filarial nematodes
  708. Protection of oligodendrocyte precursor cells by low doses of Hsp90 inhibitors in cell culture
  709. Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (Hsp90)
  710. Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90
  711. Towards the discovery of drug-like epigallocatechin gallate analogs as Hsp90 inhibitors
  712. Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors
  713. Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors
  714. Ansamycin inhibitors of Hsp90: natureโ€™s prototype for anti-chaperone therapy
  715. Design and synthesis of 3โ€ฒ, 5โ€ฒ-ansa-adenosines as potential Hsp90 inhibitors
  716. Reinventing Hsp90 Inhibitors: Blocking Cโ€Terminal Binding Events to Hsp90 by Using Dimerized Inhibitors
  717. New dihydropyrimidin-2 (1 H)-one based Hsp90 C-terminal inhibitors
  718. Hsp90 inhibitors, part 1: definition of 3-D QSAutogrid/R models as a tool for virtual screening
  719. Combined pharmacophore and structure-guided studies to identify diverse Hsp90 inhibitors
  720. High cytotoxic sensitivity of the oligodendrocyte precursor cells to Hsp90 inhibitors in cell cultures
  721. Hsp90 inhibitors in oncology: ready for prime time?
  722. Synthesis and in vitro antiproliferative activity of C5-benzyl substituted 2-amino-pyrrolo [2, 3-d] pyrimidines as potent Hsp90 inhibitors
  723. Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors
  724. โ€ฆ and pharmacological evaluation of 4, 5-diarylisoxazols bearing amino acid residues within the 3-amido motif as potent heat shock protein 90 (Hsp90) inhibitors
  725. The non-Geldanamycin Hsp90 inhibitors enhanced the antifungal activity of fluconazole
  726. Ligand desolvation steers on-rate and impacts drug residence time of heat shock protein 90 (Hsp90) inhibitors
  727. Molecular modelling and docking studies on heat shock protein 90 (Hsp90) inhibitors
  728. Chemoproteomics-driven drug discovery: identification of novel Hsp90 inhibitors
  729. Dimeric and trimeric triazole based molecules as a new class of Hsp90 molecular chaperone inhibitors
  730. Design, synthesis, and structure activity relationships for chimeric inhibitors of Hsp90
  731. The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition
  732. Macrocyclic inhibitors of hsp90
  733. Hsp90 inhibitors decrease AID levels and activity in mice and in human cells
  734. Exploring in vitro and in vivo Hsp90 inhibitors activity against human protozoan parasites
  735. Discovery of Novel 17โ€Phenylethylaminegeldanamycin Derivatives as Potent Hsp90 Inhibitors
  736. Proteolytic degradation of nitric oxide synthase: effect of inhibitors and role of Hsp90-based chaperones
  737. Molecular docking and pharmacophore studies of heterocyclic compounds as Heat shock protein 90 (Hsp90) Inhibitors
  738. A global view of the proteome perturbations by Hsp90 inhibitors
  739. Synthesis and biological evaluation of C-ring truncated deguelin derivatives as heat shock protein 90 (Hsp90) inhibitors
  740. Synthesis and Evaluation of 4-arylmethyl Curcumin Analgues as Potent Hsp90 Inhibitors
  741. 2โ€ฒโ€Oโ€Alkyl Derivatives and 5โ€ฒโ€Analogues of 5โ€Aminoimidazoleโ€4โ€carboxamideโ€1โ€ฮฒโ€Dโ€ribofuranoside (AICAR) as Potential Hsp90 Inhibitors
  742. Effects of Hsp90 inhibitors, geldanamycin and its analog, on ceramide metabolism and cytotoxicity in PC12 cells
  743. Structureโ€“activity relationship of Garcinia xanthones analogues: Potent Hsp90 inhibitors with cytotoxicity and antiangiogenesis activity
  744. Identification of the key structural elements of a dihydropyrimidinone core driving toward more potent Hsp90 C-terminal inhibitors
  745. Design, synthesis, and anticancer activity of C8-substituted-4โ€ฒ-thionucleosides as potential Hsp90 inhibitors
  746. Discovery of novel Hsp90 inhibitors that induced apoptosis and impaired autophagic flux in A549 lung cancer cells
  747. Molecular docking study, synthesis and biological evaluation of Mannich bases as Hsp90 inhibitors
  748. Dynamics-based discovery of allosteric inhibitors: Selection of new ligands for the C-terminal domain of Hsp90
  749. Induction of Hsp70 in tumor cells treated with inhibitors of the Hsp90 activity: A predictive marker and promising target for radiosensitization
  750. Hsp90 inhibitors as senolytic drugs to extend healthy aging
  751. Design and synthesis of N-(5-chloro-2, 4-dihydroxybenzoyl)-(R)-1, 2, 3, 4-tetrahydroisoquinoline-3-carboxamides as novel Hsp90 inhibitors
  752. Comparison of the cellular and biochemical properties of ansamycin and non-ansamycin based Hsp90 inhibitors
  753. An Improved Synthesis of Resorcylic Acid Macrolactone Inhibitors of Hsp90
  754. Modified biphenyl Hsp90 C-terminal inhibitors for the treatment of cancer
  755. Hsp90 inhibitors
  756. Synthesis and evaluation of a novel class Hsp90 inhibitors containing 1-phenylpiperazine scaffold
  757. 1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of Hsp90 and HDAC
  758. Potentiation of Topoisomerase I inhibitors by Hsp90 inhibitors: Mechanistic and Functional studies
  759. Extracellular cleaved HER2 (p95) confers partial resistance to trastuzumab but not Hsp90 inhibitors in models of HER2 amplified breast cancer
  760. Correlation between crystal violet dissolution assay and manual colony counting on the In Vitro effects of Hsp90-inhibitors.
  761. Hsp90 inhibitors and the reduction of anti-cancer drug resistance by non-genetic and genetic mechanisms
  762. Stability of the human Hsp90-p50Cdc37 chaperone complex against nucleotides and Hsp90 inhibitors, and the influence of phosphorylation by casein kinase 2
  763. Design, synthesis and biological evaluation of 7-(aryl)-2, 3-dihydro-[1, 4] dioxino [2, 3-g] quinoline derivatives as potential Hsp90 inhibitors and anticancer agents
  764. Discovery of 5-substituted 2-amino-4-chloro-8-((4-methoxy-3, 5-dimethylpyridin-2-yl) methyl)-7, 8-dihydropteridin-6 (5H)-ones as potent and selective Hsp90 inhibitors
  765. Chalcone-templated Hsp90 inhibitors and their effects on gefitinib resistance in non-small cell lung cancer (NSCLC)
  766. Exploiting conformational dynamics in drug discovery: design of C-terminal inhibitors of Hsp90 with improved activities
  767. Hsp90 inhibitors alter capsaicin-and ATP-induced currents in rat dorsal root ganglion neurons
  768. Sensitization of multidrug-resistant cancer cells to Hsp90 inhibitors by NSAIDs-induced apoptotic and autophagic cell death
  769. Effects of Hsp90 binding inhibitors on sGC-mediated vascular relaxation
  770. Spontaneous assembly of Hsp90 inhibitors at water/octanol interface: A molecular dynamics simulation study
  771. Discovery of potent and selective CDK8 inhibitors from an Hsp90 pharmacophore
  772. Hsp90 inhibitors radicicol and geldanamycin have opposing effects on Leishmania Aha1-dependent proliferation
  773. Design, synthesis and biological evaluation of biphenylamide derivatives as Hsp90 C-terminal inhibitors
  774. A group of novel HIFโ€1ฮฑ inhibitors, glyceollins, blocks HIFโ€1ฮฑ synthesis and decreases its stability via inhibition of the PI3K/AKT/mTOR pathway and Hsp90 binding
  775. Recent advances in macrocyclic Hsp90 inhibitors
  776. Identification of Hsp90 inhibitors with anti-Plasmodium activity
  777. 3D-QSAR, molecular docking, and molecular dynamic simulations for prediction of new Hsp90 inhibitors based on isoxazole scaffold
  778. Computational predictions of corroles as a class of Hsp90 inhibitors
  779. Expression and purification of recombinant NRL-Hsp90ฮฑ and Cdc37-CRL proteins for in vitro Hsp90/Cdc37 inhibitors screening
  780. Comparison of the activity of three different HSP70 inhibitors on apoptosis, cell cycle arrest, autophagy inhibition, and Hsp90 inhibition
  781. New Indications for Hsp90 and HSP70 Inhibitors as Antiviral Drugs
  782. โ€ฆ study of the Hsp90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR tyrosine kinase inhibitors (EGFR โ€ฆ
  783. Crystallization and preliminary X-ray diffraction analysis of Trap1 complexed with Hsp90 inhibitors
  784. Inhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas โ€ฆ
  785. Lead identification: better Hsp90 inhibitors
  786. Development of Phenyl Cyclohexylcarboxamides as a Novel Class of Hsp90 Cโ€terminal Inhibitors
  787. Triazole containing novobiocin and biphenyl amides as Hsp90 C-terminal inhibitors
  788. Recent progress in the study of Hsp90 inhibitors [J]
  789. Met amplification and Hsp90 inhibitors
  790. A novel pharmacodynamic assay to measure Hsp90 target occupancy by the small molecule inhibitors IPI-504 and IPI-493 in tumors
  791. Synthesis and evaluation of 4-(2-hydroxypropyl) piperazin-1-yl) derivatives as Hsp90 inhibitors
  792. Design and synthesis of triple inhibitors of janus kinase (JAK), histone deacetylase (HDAC) and Heat Shock Protein 90 (Hsp90)
  793. Discovery and Bioevaluation of Novel Pyrazolopyrimidine Analogs as Competitive Hsp90 Inhibitors Through Shapeโ€Based Similarity Screening
  794. The Hsp90 Inhibitors, 17-aag and 17-dmag Target Wild-Type B-raf Signaling for the Proliferation of Human Uveal Melanoma Cells
  795. Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2, 4-diaminopyrimidine motifs
  796. Inhibition of the Heat Shock Protein 90 (Hsp90) chaperone with the novel agent IPI-504 to overcome resistance to tyrosine kinase inhibitors (TKIs) in metastatic GIST โ€ฆ
  797. Low-dose Hsp90 inhibitors DPB and AUY-922 repress apoptosis in HUVECs
  798. Hsp90 inhibitors in parasitic nematodes: prospects and challenges
  799. Preface [Hot topic: Hsp90 Molecular Chaperone Inhibitors: Opportunities and Challenges (Guest Editor: Paul Workman)]
  800. Combination therapies with Hsp90 inhibitors against colorectal cancer
  801. Repurposing Hsp90 inhibitors as antibiotics targeting histidine kinases
  802. Design and biological testing of peptidic dimerization inhibitors of human Hsp90 that target the C-terminal domain
  803. Hsp90 inhibitors suppress P53 phosphorylation in LPS-induced endothelial inflammation
  804. Evaluation of miscellaneous heat shock protein (Hsp90) inhibitors using different methodologies
  805. Hsp90 inhibitors in the context of heat shock and the unfolded protein response: effects on a primary canine pulmonary adenocarcinoma cell line
  806. Design, synthesis and biological evaluation of alkylamino biphenylamides as Hsp90 C-terminal inhibitors
  807. Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 Cโ€Terminal Inhibitors
  808. Identification and characterization of the antiplasmodial activity of Hsp90 inhibitors
  809. Synthesis of 5,6โ€dihydroโ€4Hโ€benzo[d]isoxazolโ€7โ€one and 5,6โ€dihydroโ€4Hโ€isoxazolo[5,4โ€c]pyridinโ€7โ€one Derivatives as Potential Hsp90 Inhibitors
  810. A novel class of geldanamycin derivatives as HCV replication inhibitors targeting on Hsp90: synthesis, structureโ€“activity relationships and anti-HCV activity in โ€ฆ
  811. New TRAP1 and Hsp90 chaperone inhibitors with cationic components: Preliminary studies on mitochondrial targeting
  812. Drug Design, Synthesis and In Vitro Evaluation of Substituted Benzofurans as Hsp90 Inhibitors
  813. Hsp90 inhibitors potentiate PGF2ฮฑ-induced IL-6 synthesis via p38 MAP kinase in osteoblasts
  814. Combination of jak2 and Hsp90 inhibitors: An effective therapeutic option in drug-resistant chronic myelogenous leukemia
  815. Abstract# 1710: A novel pharmacodynamic assay to measure Hsp90 target occupancy by the small molecule inhibitors IPI-504 and IPI-493 in tumors
  816. Structural ensemble-based docking simulation and biophysical studies discovered new inhibitors of Hsp90 N-terminal domain
  817. Study on the Hsp90 Inhibitors
  818. Combined in Silico and Experimental Approach for Drug Design: The Binding Mode of Peptidic and Nonโ€Peptidic Inhibitors to Hsp90 Nโ€Terminal Domain
  819. Design, synthesis, and biological evaluation of a series of resorcinol-based N-benzyl benzamide derivatives as potent Hsp90 inhibitors
  820. Hsp90 inhibitors are promising radiosensitizers for radiotherapy
  821. Synthesis and biological evaluation of hybrid acridine-Hsp90 ligand conjugates as telomerase inhibitors
  822. โ€ฆ vitro study comparing the efficacy of the water-soluble Hsp90 inhibitors, 17-AEPGA and 17-DMAG, with that of the nonโ€‘water-soluble Hsp90 inhibitor, 17-AAG โ€ฆ
  823. Inhibitors of the Hsp90 C-terminus
  824. The sensitivity to Hsp90 inhibitors of both normal and oncogenically transformed cells is determined by the equilibrium between cellular quiescence and โ€ฆ
  825. Reduction of benzoquinone ansamycin Hsp90 inhibitors by NQO1 generates hydroquinone ansamycins which are more potent Hsp90 inhibitors
  826. Investigation of B, C-ring truncated deguelin derivatives as heat shock protein 90 (Hsp90) inhibitors for use as anti-breast cancer agents
  827. Identifying inhibitors of the Hsp90-Aha1 protein complex, a potential target to drug cystic fibrosis, by alpha technology
  828. Combining ensemble learning with a fragment-based topological approach to generate new molecular diversity in drug discovery: In silico design of Hsp90 inhibitors
  829. Design, synthesis, and biological activities of vibsanin B derivatives: a new class of Hsp90 C-terminal inhibitors
  830. Progress in the study of small molecule inhibitors of HSP90
  831. Virtual Screening for Dual Hsp90/B-Raf Inhibitors
  832. Prediction of inhibitory activities of Hsp90 inhibitors
  833. New Hsp90 selective inhibitors as therapeutic agents for prostate and bladder cancer.
  834. 145 POSTER Hsp90 inhibitors target addiction to mutant oncoproteins in colorectal cancer
  835. 570 POSTER Overcoming resistance to tyrosine kinase inhibitors (TKls) through inhibition of Heat Shock Protein 90 (Hsp90) chaperone function in patienets โ€ฆ
  836. Towards โ€˜best-in-classโ€™ Hsp90 inhibitors: Design, biosynthesis and pre-clinical profiles
  837. Evaluation of the effect of Hsp90 inhibitors on head and neck squamous cell carcinoma cell lines
  838. Mechanism of action of a novel series of inhibitors of the Hsp90 molecular chaperone
  839. Effects of Inhibitors on Hsp90โ€ฒ s Conformational Dynamics, Cochaperone and Client Interactions
  840. Design and synthesis of imidazopyridine derivatives as novel Hsp90 inhibitors for the treatment of cancer
  841. Therapeutic Uses of Hsp90 Inhibitors in Non-Small Cell Lung Carcinoma (NSCLC)
  842. Development of a FRET-based high-throughput screening system for the discovery of Hsp90 inhibitors
  843. Histone deacetylase inhibitors interrupt HSP90โ€ข RASGRP1 and HSP90โ€ข CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells
  844. Inhibition of mTOR enhances the activity of Hsp90 inhibitors in part through cessation of heat shock protein synthesis.
  845. Hsp90 Flexibility and Development of its Inhibitors for the Treatment of Cancer
  846. Neuroprotective Features Of Hsp90 Inhibitors Exhibiting Anti-Inflammatory Actions: Implications For Multiple Sclerosis
  847. Integration of Hsp90 inhibitors in combinational immunotherapy targeting receptor tyrosine kinases (RTKs) in cancer (131.45)
  848. Tethered Hsp90 inhibitors carrying optical or radioiodinated probes reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells
  849. โ€ฆ the in-silico design of new Hsp90 inhibitors: Molecular docking and 3D-QSAR CoMFA studies of tetrahydropyrido [4, 3-d] pyrimidine derivatives as Hsp90 inhibitors
  850. Hsp90 inhibitors stimulate DNAJB4 protein expression through a mechanism involving N 6-methyladenosine
  851. Hsp90 inhibitors: targeting the cancer chaperone for combinatorial blockade of oncogenic pathways
  852. Structural and energetic insight into the isoform-selective inhibitors of tumour marker Hsp90 against Grp94
  853. In vitro and in vivo Evaluation of 17-phenylpropylamine/phenoxyethylamine-17-demethoxygeldanamycins as Potent Hsp90 Inhibitors
  854. Suppression by Hsp90 inhibitors of BMPโ€‘4โ€‘stimulated osteoprotegerin synthesis in osteoblasts: Attenuation of p70 S6 kinase
  855. Synthesis and evaluation of the tumor cell growth inhibitory potential of new putative Hsp90 inhibitors
  856. Drug metabolism determines resistance of colorectal cancer to resorcinol-based Hsp90 inhibitors
  857. The importance of dose schedule with Hsp90 inhibitors: Results from a Phase II study in dogs with mast cell tumors.
  858. Identification of novel response and predictive biomarkers to Hsp90 inhibitors through proteomic profiling of patient-derived prostate tumor explants
  859. New heat shock protein (Hsp90) inhibitors, designed by pharmacophore modeling and virtual screening: synthesis, biological evaluation and molecular dynamics โ€ฆ
  860. C-Terminal Hsp90 Inhibitors Block the HIF-1 Hypoxic Response by Degrading HIF-1ฮฑ through the Oxygen-Dependent Degradation Pathway
  861. Prediction of new Hsp90 inhibitors based on 3, 4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation
  862. A potential role for NAD (P) H: quinone oxidoreductase 1 (NQO1) in the mechanism of action of the Hsp90 inhibitors geldanamycin and 17AAG
  863. Dorsomorphin induces cancer cell apoptosis and sensitizes cancer cells to Hsp90 and proteasome inhibitors by reducing nuclear heat shock factor 1 levels
  864. Identification of novel response and predictive biomarkers to Hsp90 inhibitors through mass spectrometry-based proteomic profiling of patient-derived prostate tumor โ€ฆ
  865. Correction: Identification of the key structural elements of a dihydropyrimidinone core driving toward more potent Hsp90 C-terminal inhibitors
  866. โ€ฆ and pharmacological evaluation of N-(5-chloro-2, 4-dihydroxybenzoyl)-(R)-N-arylmethyl-1, 2, 3, 4-tetrahydro-3-isoquinolinecarboxamides as potent Hsp90 inhibitors
  867. Molecular insights into the interaction of Hsp90 with allosteric inhibitors targeting the C-terminal domain
  868. Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors
  869. Overcoming Resistance to Small Molecule Kinase Inhibitors (SMKIs) Through Inhibition of Heat Shock Protein 90 (Hsp90) Chaperone Function in Patients with โ€ฆ
  870. Investigation of the Hsp90 C-terminal binding site, novel inhibitors and isoform-dependent client proteins
  871. Hsp90 inhibitors and conjunctival melanoma
  872. Potentials of Hsp90 Inhibitors in Cancer Therapy. pdf
  873. Development of Novel Inhibitors of HSP90
  874. Natural product inspired Hsp90 inhibitors
  875. A New Generation of Isoform Selective Hsp90 Inhibitors: Targeting the Cytosolic Hsp90 Isoforms
  876. Circumventing Hsp90 inhibitors via apoptosis block
  877. A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors
  878. QS288. Potent Blockade of TGF-ฮฒ Signaling by Hsp90 Inhibitors
  879. Hsp90 inhibitors for high-grade glioma treatment
  880. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors.
  881. The role of NQO1 in the metabolism of benzoquinone ansamycin Hsp90 inhibitors and development of novel Hsp90 inhibitors as anticancer agents
  882. Structure-based drug discovery of species-selective inhibitors of Hsp90
  883. Potent non-benzoquinone ansamycin Hsp90 inhibitors from mutasynthesis
  884. Targeting oncogenic Eph receptor proteins with Hsp90 inhibitors
  885. Client depletion assay comparison of paclitaxel to Hsp90 inhibitors
  886. Hsp90 Inhibitors in Sepsis and Sepsis-induced Acute Lung Injury
  887. 19-Substituted benzoquinone ansamycin Hsp90 inhibitors: Effects on Hsp90 co-chaperones and Hsp90-Hsf1 complexes in cellular systems
  888. In Vitro Dual Treatment of Cancer Cells with Hsp90 Inhibitors and Hyperthermia
  889. Recent Advances in the Discovery of Novel Hsp90 Inhibitors: An Update from 2014.
  890. Abstract# 3697: Combination of Hsp90 inhibitors and MEK inhibitors abrogates ERK activation in pancreatic cancer cells
  891. Targeting basal-like breast cancer via purine-scaffold Hsp90 inhibitors
  892. C-terminal Hsp90-inhibitors restore glucocorticoid sensitivity in Cushingโ€™s disease
  893. Development of Hsp90 paralog specific inhibitors with mitochondrial drug delivery system
  894. Use of Hsp90 inhibitors in the combination immunotherapy of melanoma (P4272)
  895. Abstract# 915: Cystine/glutamate transporter SLC7A11 mediates resistance to Hsp90 inhibitors
  896. Proteomic Profiling of Hsp90 Inhibitors
  897. Synthetic Hsp90 inhibitors are active against 17-AAG-resistant tumor lines
  898. Acquired resistance to Hsp90-inhibitors and cancer progression
  899. Profiling Hsp90 inhibitors in cellular extracts on a mass spectrometry chemoproteomics platform
  900. 19-Substituted benzoquinone ansamycins. Hsp90 inhibitors with decreased off-target toxicity
  901. Barrier-protective effects of Hsp90 inhibitors in bovine pulmonary arterial endothelial cells.
  902. Hsp90 Inhibitors in Clinic
  903. Synthesis and exploration of resorcinol derivatives as Plasmodium falciparum Hsp90 inhibitors
  904. Inhibitors of Hsp90 in melanoma
  905. Mitochondrial-targeted Hsp90 C-terminal inhibitors manifest anti-proliferative activity
  906. Verification of a multivariate pharmacodynamic biomarker assay for Hsp90 inhibitors
  907. MP05-16 TSC1 EXPRESSION AS A PREDICTIVE BIOMARKER OF BLADDER CANCER RESPONSE TO Hsp90 INHIBITORS
  908. Computational modeling of the Hsp90 interactions with cochaperones and Small-Molecule inhibitors
  909. Hsp90 inhibitors: Biosynthetic and antitumor evaluation of a non-geldanamycin polyketide
  910. Hsp90 Inhibitors as New Leads To Target
  911. Development of a multivariate pharmacodynamic biomarker assay for Hsp90 inhibitors
  912. Abstract C86: Tethered Hsp90 inhibitors carrying optical or radioiodinated probes reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells.
  913. Correlation between in vitro and in vivo activities of Hsp90 inhibitors
  914. Hsp90 inhibitors target KRAS mutant human tumors through degradation of STK33
  915. Application of Hsp90 inhibitors to treat chronic lymphocytic leukemia by targeting the BCR-NFฮบB pathway
  916. Effect of 19-substituted benzoquinone ansamycin Hsp90 inhibitors on Hsp90/Cdc37/co-chaperone complexes and casein kinase 2 (CK2) activity
  917. Discovery of novel small molecule inhibitors of Hsp90 for oral treatment
  918. Synergistic inhibition of cancer cell viability and suppression of HIF1ฮฑ by CDK4 inhibitors and Hsp90 inhibitors across cancer types
  919. Silencing of the heat shock protein 90 (Hsp90) cochaperone CDC37 by RNA interference sensitises cancer cells to Hsp90 inhibitors
  920. Discovery of Nโ€pyridoylโ€ฮ”2โ€pyrazolines as Hsp90 inhibitors
  921. Hsp90 inhibitors as a future therapeutic strategy in diabetes-driven atherosclerosis.
  922. 555 POSTER Small-molecule inhibitors of Hsp90 in IM-resistant gastrointestinal stromal tumors
  923. Anti-tumor activity of non-benzoquinone ansamycin Hsp90 inhibitors in murine xenograft models
  924. C-terminal Hsp90 inhibitors restore glucocorticoid sensitivity in an experimental model for Cushingโ€™s disease
  925. Abstract B36: Targeting BRCA1 through natural Hsp90 inhibitors to reverse platinum resistance in TNBC
  926. Efficacy of the Hsp90 Inhibitors in Prostate Cancer Therapy
  927. Potent anti-inflammatory activity of a novel of class Hsp90 inhibitors for multiple sclerosis (51.1)
  928. Potential of Hsp90 Inhibitors to Treat Neurofibromatosis-Related Tumors
  929. Screening of miscellaneous Hsp90 inhibitors using virtual co-crystallized pharmacophore
  930. Design, synthesis and biological evaluation of ansamycin prodrugs as water-soluble Hsp90 inhibitors
  931. Role of Hsp90 Inhibitors in the Treatment of Cancer
  932. A high-throughput screen for inhibitors of the Hsp90-chaperone machine
  933. Small-molecule Hsp90 Inhibitors: Applications in Cancer and Neurodegenerative diseases
  934. Anti-cancer effect by combination treatment of CDK and Hsp90 inhibitors through HIF1ฮฑ inhibition
  935. C-terminal Hsp90 Inhibitors Block the HSP90: HIF-1a Interaction and Inhibit the Cellular Hypoxic Response
  936. p23/Sba1p protects against Hsp90 inhibitors
  937. N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-ฮณ induced PD-L1 expression
  938. PHARMACOPHORIC MODEL AND 3D-QSAR OF 5-RESORCINOL-ISOXAZOLE DERIVATIVES AS Hsp90 INHIBITORS
  939. Abstract# 4688: Hsp90 inhibitors downregulate the VEGF excretion in triple negative breast cancer cells
  940. Rational Identification of Hsp90 Inhibitors as Anticancer Lead Molecules by Structure Based Drug Designing Approach.
  941. P2-384: In vivo effects of novel Hsp90 C-terminal inhibitors in Tau mutant mice
  942. In vivo antitumor efficacy of purine-scaffold Hsp90 inhibitors in basal-like breast cancer (BLBC)
  943. 19P Comparative effectiveness analysis of Hsp90 inhibitors in non-small cell lung cancer
  944. Prevention and partial reversal of monocrotaline-induced pulmonary arterial hypertension (PAH) by Hsp90 inhibitors
  945. The Potential Dual-Target Inhibitors for HER2/Hsp90 Proteins from Traditional Chinese Medicine
  946. Development of a cell-based ligand-screening system for identifying Hsp90 inhibitors
  947. Precursor-directed biosynthesis of macbecin analogues: generation of non-quinone containing Hsp90 inhibitors and pre-clinical evaluation
  948. Selective inhibition of Hsp90 by its C-terminal inhibitors is more effective to suppress bladder cancer cell growth
  949. Hsp90 inhibitors prevent LPS-induced endothelial barrier dysfunction by disrupting RhoA signaling.
  950. Hsp90 inhibitors prevent LPS-induced endothelial hyper-permeability by inhibiting pp60src activation and maintaining adherens junction proteins
  951. Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures
  952. Discovery of Hsp90 Inhibitors from Natural Product and Its Analogues
  953. Effects of Hsp90 inhibitors on triple-negative breast cancer: BRCA1 as a therapeutic target for TNBC
  954. AB035. P006. Activity of heat shock protein-90 (Hsp90) inhibitors against pancreatic cancers grown in 3 dimensions
  955. Cover Feature: Synthesis and Biological Evaluation of Stilbene Analogues as Hsp90 Cโ€Terminal Inhibitors (ChemMedChem 24/2017)
  956. Combination use of natural Hsp90 inhibitors to reverse BRCA1-mediated platinum resistance in triple negative breast cancer
  957. Hsp90 inhibitors induce the unfolded protein response in bovine and mice lung cells
  958. A detailed analysis of protein binding and biological activity of methoxy-substituted resorcinylic isoxazole amide Hsp90 inhibitors
  959. Fe3O4 nanoparticles mediated synthesis of novel spirooxindoleโ€dihydropyrimidinone molecules as Hsp90 inhibitors
  960. A genome-wide CRISPR/Cas9 pooled screen identifies EML4-ALK variant-specific synthetic lethal partners of Hsp90 inhibitors
  961. Discovery of Heat Shock Protein 90 (Hsp90) Inhibitors against Cancerous Diseases
  962. Cell cycle control and apoptosis of p53-isogenic cell lines treated with Hsp90 inhibitors
  963. Novel Hsp90 inhibitors exhibiting in vivo xenograft activity discovered using fragment-based drug discovery & structure based drug design.
  964. Targeting Hsp90 with small molecule inhibitors induces the overexpression of the anti-apoptotic molecule, survivin, in human cancer cells
  965. Discovery of Novel Hsp90 Inhibitors and Evaluation of Their Antitumor Activities
  966. Differential sensitivities to heat shock protein 90 (Hsp90) inhibitors in anaplastic lymphoma kinase (ALK)-positive non-small cell ling cancer (NSCLC) cells.
  967. Design, synthesis, and biological evaluation of truncated deguelin derivatives as Hsp90 inhibitors
  968. Design, Synthesis, and Evaluation of Site-Specific Hsp90 Inhibitors
  969. Abstract B102: 19-Substituted benzoquinone ansamycins: Decreasing the toxicity of the benzoquinone ansamycin class of Hsp90 inhibitors.
  970. Real-time imaging of disruption of human heat shock protein 90/co-chaperone p23 interactions by Hsp90 inhibitors in living subjects
  971. Hsp90 Inhibitors Blocking Multiple Oncogenic Signaling Pathways for the Treatment of Cancer
  972. Development of Hsp90 Inhibitors for the Treatment of HER-2 Positive Solid Cancers
  973. Discovery of Hsp90 inhibitors form natural product and its analogues
  974. Rational synthesis and evaluation of IMP dehydrogenase and Hsp90 inhibitors
  975. Abstract# 4677: NVP-BEP795 and NVP-BEP800: Novel, fragment derived orally bioavailable small molecule Hsp90 inhibitors with potent antitumor activity
  976. Ansamycin Class of Natural Product Hsp90 Inhibitors
  977. Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies
  978. โ€ฆ OF Hsp90 SUBPOPULATION CONFORMATIONS TARGETED BY INHIBITORS AND THE EFFECT OF PHOSPHORYLATION ON HSP90โ€™S ASSOCIATION WITH CO โ€ฆ
  979. HSP70 and Hsp90 Inhibitors Repress Expression of TSC1 in T24 Bladder Cancer Cells and UOK139, UOK 140 Kidney Cancer Cells
  980. Identification of the correlation between drug activity and sensitivity of Hsp90 inhibitors in breast cancer cells using a multivariate gene expression assay
  981. Proteomic Analysis of Hct116 Colon Cancer Cells Treated with Inhibitors That Bind to the N-terminal Versus the C-terminal Domain of Hsp90
  982. Differential Sensitivities of Human Multidrug-resistant Cancer Cells to BIIB021 and Modulation of Hsp90 Inhibitors by NSAIDs and Niclosamide
  983. Design of Novel Hsp90 Inhibitors to Trigger Tau Degradation in Alzheimerโ€™s disease: An Insilico Approach
  984. Assessing efficacy of novel Hsp90 inhibitors in breast cancer patients by enumeration of circulating tumor cells and HER-2 degradation
  985. Hsp90 inhibitors diminish PDGF-BB-induced migration of osteoblasts via suppression of p44/p42 MAP kinase
  986. Identification and Structure-Activity Studies of 1, 3-Dibenzyl-2-aryl imidazolidines as Novel Hsp90 Inhibitors
  987. Design, synthesis, and molecular docking studies of novel pyrazolyl 2โ€aminopyrimidine derivatives as Hsp90 inhibitors
  988. 281P Selective depletion of tumour-associated SAMHD1 by Hsp90 inhibitors enhances the anti-AML effect of cytarabine
  989. Insights into the molecular mechanism of Hsp90 binding of methoxy-substituted resorcinylic isoxazole amide inhibitors reveal different isoform selectivity profiles
  990. Hch1p Acts Differently From Its Homologue, Aha1p, in Regulating Sensitivity of Hsp90 to Hsp90 Inhibitors in Yeast
  991. Ddis-12. Cyto-mitoโ„ข-A Novel Class Of Dual-acting Hsp90 Inhibitors For The Treatment Of Glioblastoma
  992. Hsp90 inhibitors: their effects on redox status and on the cytoarchitecture
  993. Trth-03. Cyto-mitoโ„ข-A Novel Class Of Dual-acting Hsp90 Inhibitors For The Treatment Of Glioblastoma
  994. Development of Tethered Hsp90 Inhibitors Carrying Radioiodinated Probes to Specifically Discriminate and Kill Malignant Breast Tumor Cells
  995. Germline JAK2 Mutations In The Kinase Domain Are Responsible For Hereditary Thrombocytosis and Are Resistant To JAK2 and Hsp90 Inhibitors
  996. Abstract PR05: Effects of Hsp90 inhibitors on triple-negative breast cancer: Notch as a therapeutic target for stem cells
  997. Reduction of a series of benzoquinone ansamycin Hsp90 inhibitors by one and two electron reductases, and their interaction with reduced glutathione
  998. Design and synthesis of fungal-selective resorcylate aminopyrazole Hsp90 inhibitors
  999. Abstract B018: A high-throughput screen identifies Hsp90 inhibitors as potent therapeutics across multiple clinically representative organoid models of advanced โ€ฆ
  1000. Hsp90 Inhibitors Suppress Aryl Hydrocarbon Receptor-Mediated Activation of CYP1A1 and CYP1B1 Transcription and DNA Adduct Formation
  1001. Medium-Throughput Detection of Hsp90/Cdc37 Proteinโ€“Protein Interaction Inhibitors Using a Split Renilla Luciferase-Based Assay
  1002. Decoupling the mechanism of action of efrapeptins, dual inhibitors of proteasome and Hsp90 chaperone function: The possible role of endoplasmic reticulum stress
  1003. Structure-based drug design of Hsp90 inhibitors and evaluation of their biological activities
  1004. A New Generation of Hsp90 Inhibitors: Addressing Isoform Selectivity and Heat Shock Induction
  1005. USE OF Hsp90 INHIBITORS TO OVERCOME TRASTUZUMAB RESISITANCE IN THE MINOR VARIANT OF HER2 P95HER2 IN BREAST CANCER
  1006. Abstract# 4676: A novel class of specific Hsp90 small molecular inhibitors demonstrate in vitro and in vivo anti-tumor activity in the human melanoma cells
  1007. A computational study on the role of water and conformational fluctuations in Hsp90 in response to inhibitors
  1008. Hsp90 and Its Inhibitors for Cancer Therapy: Use of Nano-delivery System to Improve Its Clinical Application
  1009. Identification and synthesis of 3, 4-isoxazolediamides as new class of Hsp90 inhibitors.
  1010. Enhanced MHC Class I and II expression induced following staggered combination treatment of human tumor cells with Hsp90 inhibitors and Interferons.(165.16)
  1011. 31 Structure-based drug design of Hsp90 inhibitors and their anti-proliferative effects against cancerous diseases
  1012. โ€ฆ 90 (Hsp90) inhibitor as a candidate treatment option for gastrointestinal stromal tumor with acquired resistance for conventional receptor tyrosine kinase inhibitors
  1013. Hsp90 inhibitors enhance the antitumoral effect of osimertinib in parental and osimertinib-resistant non-small cell lung cancer cell lines
  1014. 35P Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small cell cell lung cancer cell models
  1015. Discovery of 2-((4-resorcinolyl)-5-aryl-1, 2, 3-triazol-1-yl) acetates as potent Hsp90 inhibitors with selectivity over TRAP1
  1016. Molecular docking studies investigating the interaction of a series of benzoquinone ansamycin Hsp90 inhibitors with NAD (P) H: quinone oxidoreductase 1 (NQO1)
  1017. Proteomics Fingerprints of Auy922 and 17-dmag Indicate Common Mechanisms of Action for Hsp90 Inhibitors
  1018. Amide-tethered quinoline-resorcinol conjugates as a new class of Hsp90 inhibitors suppressing the growth of prostate cancer cells
  1019. Synthesis Of Substituted Pyrrolo [2, 3-D] Pyrimidines As Microtubule-Binding Agents and Hsp90 Inhibitors
  1020. The Pursuit of Unshocking Hsp90 Inhibitors: Development of Gedunin and Cruentaren A as Chemical Leads
  1021. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma
  1022. Hsp90 Inhibitors Prevent NF-ฮบB-Dependent Gene Activation In Human Lung Microvascular Endothelial Cells By Inducing MDM2-Dependent Sirt-2-Promoter Binding
  1023. โ€ฆ expression profiling highlights modulation of chromatin-related proteins and chromatin-modifying enzymes in response to Hsp90 inhibitors: Identification of PRMT5 โ€ฆ
  1024. Discovery of 2-isoxazol-3-yl-acetamide analogues as heat shock protein 90 (Hsp90) inhibitors with significant anti-HIV activity
  1025. Improving the Hsp90 Inhibitors Containing 4-(2, 4-Dihydroxyphenyl)-1, 2, 3-thiadiazole Scaffold: Synthesis, Affinity and Effect on Cancer Cells
  1026. โ€ฆ vitro study comparing the efficacy of the water-soluble Hsp90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non-water-soluble Hsp90 inhibitor, 17-AAG โ€ฆ
  1027. Hybrids of the Benzofuran Core from Natural Products and the 2, 4โ€Dihydroxyโ€5โ€isopropylbenzene Fragment as Potent Hsp90 Inhibitors: Design, Synthesis and โ€ฆ
  1028. High-throughput screens identify Hsp90 inhibitors as potent therapeutics that target inter-related growth and survival pathways in advanced prostate cancer
  1029. โ€ฆ : Validation of a multiplex method for detection of several oncosignaling proteins with potential utility for assessment of pharmacodynamic activity of Hsp90 inhibitors
  1030. โ€ฆ Ca2+-sensitivity from troponin I phosphorylation by hypertrophic and dilated cardiomyopathy mutations can be reversed by EGCG and related Hsp90 inhibitors
  1031. โ€ฆ of truncated tau protein in transgenic rat cortical neurons and human cellular model of tauopathy and Alzheimerโ€™s disease is enhanced by Hsp90 inhibitors
  1032. โ€ฆ Discovery and Optimization of 4, 5-Diarylisoxazoles as Potent Dual Inhibitors of Pyruvate Dehydrogenase Kinase (PDHK) and Heat Shock Protein 90 (Hsp90)
  1033. Design, synthesis and molecular mechanisms of novel dual inhibitors of heat shock protein 90/phosphoinositide 3-kinase alpha (Hsp90/PI3Kฮฑ) against cutaneous โ€ฆ
  1034. โ€ฆ abstract Synthesis of 5, 6-dihydro-4H-benzo [d] isoxazol-7-one and 5, 6-dihydro-4H-isoxazolo [5, 4-c] pyridin-7-one derivatives as potential Hsp90 inhibitors
  1035. โ€ฆ analogue (HA) histone deacetylase (HDAC) inhibitors (HDIs)-induced apoptosis: New role of HDAC6 inhibition, acetylation and inhibition of Hsp90 and depletion of โ€ฆ
  1036. Patent application title: USES OF LABELED Hsp90 INHIBITORS Inventors: Gabriela Chiosis (New York, NY, US) Gabriela Chiosis (New York, NY, US) Tony โ€ฆ
  1037. Proteasome Inhibitors Suppress ErbB Family Expression through Hsp90-Mediated Lysosomal Degradation
  1038. Targeting Hsp90 chaperone machinery with small molecule inhibitors
  1039. Targeting both ends of Hsp90: Chimeric N-terminal inhibitors and novobiocin-derivatized C-terminal inhibitors
  1040. The Development of Organelle-localized Hsp90 Isoform-selective Inhibitors
  1041. Design of potential Hsp90 and HDAC6 dual inhibitors: virtual screening on Hsp90.
  1042. Sensitization of cancer cells to inhibitors of heat shock protein 90 (Hsp90) and proteasome by abamectin
  1043. Synthetic and computational efforts toward the understanding and development of novobiocin-derived inhibitors of Hsp90
  1044. Design and prediction of new inhibitors of Hsp90 by Virtual Screening
  1045. Understanding conformational diversity of heat shock protein 90 (Hsp90) and binding features of inhibitors to Hsp90 via molecular dynamics simulations
  1046. Design, Synthesis and Biological Evaluation of Ring-constrained and Biphenyl Derivatives as Hsp90 C-terminal Inhibitors
  1047. Unfolding the Hsp90 Foldasome: Structure-Activity Relationship Studies on EGCG and Development of Isoform-Selective Inhibitors
  1048. In silico identification and analysis of the binding site for aminocoumarin type inhibitors in the C-terminal domain of Hsp90
  1049. Regulation of Calcineurin Signaling Through Blocking of the Chaperone Function of Hsp90 by HDAC Inhibitors
  1050. In silico analysis of human Hsp90 for the identification of novel anti-cancer drug target sites and natural compound inhibitors
  1051. Impressive Enrichment of Semiempirical Quantum Mechanicsโ€Based Scoring Function: Hsp90 Protein with 4541 Inhibitors and Decoys
  1052. Blocking the protein folding machinery. Rational design of inhibitors of the molecular chaperone Hsp90 as new anticancer agents
  1053. Hsp90 Binding Inhibitors Improve Survival and Attenuate the Inflammatory Insult in a Murine Model of Sepsis-Induced Acute Lung Injury.
  1054. โ€ฆ OF Hsp90 IMPAIRS DNA-DAMAGE RESPONSE PROTEINS AND INCREASES THE SENSITIVITY OF OVARIAN CARCINOMA CELLS TO PARP INHIBITORS
  1055. Direct and Indirect Modulation of EGFR-Mediated Growth Signaling by Hsp90 Inhibition in NSCLCs Resistant to EGFR Tyrosine Kinase Inhibitors in vitro and in vivo
  1056. In silico identification of potent inhibitors of heat shock protein 90 (Hsp90) from Indonesian natural product compounds as a novel approach to treat ebola virus โ€ฆ
  1057. Retraction notice toโ€โ€ A novel class of specific Hsp90 small molecule inhibitors demonstrate in vitro and in vivo anti-tumor activity in human melanoma cellsโ€โ€.
  1058. โ€ฆ Study of the Hsp90 Inhibitor SNX-5422 and Erlotinib in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
  1059. Synthesis of Truncated C8-Modified-4โ€ฒ-thionucleosides as Potential Hsp90 Inhibitors
  1060. Development of novel Hsp90 inhibitors as potential anticancer agents
  1061. HDAC and Hsp90 Inhibitors Down-Regulate PTTG1 / Securin But Do Not Induce Aneuploidy
  1062. Stereoselective C, C coupling reactions for the total synthesis of the Hsp90 inhibitor geldanamycin
  1063. Preclinical studies on the effectiveness of the new Hsp90 โ€“ inhibitor AUY922 alone and in combination with the BCR-ABL inhibitor imatinib for โ€ฆ
  1064. Hsp90 inhibitors potentiate PGF2ฮฑ-induced IL-6 synthesis via p38 MAP kinase in osteoblasts (้ชจ ่Šฝ ็ดฐ่ƒž ใซ ใŠ ใ„ ใฆHSP90้˜ป ๅฎณ ๅ‰ค ใฏ p38 MAP kinase ใ‚’ ไป‹ ใ— ใฆโ€ฆ
  1065. Combined Molecular Modeling Studies of Hsp90 Chaperone Inhibitors by Pharmacophore Model, Molecular Docking and 3D-QSAR
  1066. Synergistic therapeutic effect of the combination of the Hsp90 inhibitor AUY922 and the PI3K inhibitor BYL719 with everolimus in neuroendocrine tumors
  1067. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells
  1068. 17-AAG, an Hsp90 inhibitor, ameliorates polyglutamine-mediated motor neuron degeneration
  1069. RACK1 competes with Hsp90 for binding to HIF-1ฮฑ and is required for O2-independent and Hsp90 inhibitor-induced degradation of HIF-1ฮฑ
  1070. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models
  1071. A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitor induced apoptosis in HCT116 colon carcinoma cells
  1072. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis
  1073. The Hsp90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms
  1074. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer.
  1075. Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents
  1076. 4-Amino derivatives of the Hsp90 inhibitor CCT018159
  1077. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy
  1078. (โˆ’)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor
  1079. A non-toxic Hsp90 inhibitor protects neurons from Aฮฒ-induced toxicity
  1080. NVP-AUY922: a small molecule Hsp90 inhibitor with potent antitumor activity in preclinical breast cancer models
  1081. Silencing of Hsp90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the Hsp90 inhibitor 17-allylamino-17 โ€ฆ
  1082. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with Hsp90 inhibitor NVP-AUY922
  1083. Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy
  1084. The Hsp90 inhibitor IPI-504 rapidly lowers EML4โ€“ALK levels and induces tumor regression in ALK-driven NSCLC models
  1085. A rhizosphere fungus enhances Arabidopsis thermotolerance through production of an Hsp90 inhibitor
  1086. Gedunin, a novel Hsp90 inhibitor: semisynthesis of derivatives and preliminary structureโˆ’ activity relationships
  1087. Gambogic acid, a natural product inhibitor of Hsp90
  1088. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6โ€“dependent B cell lymphomas
  1089. Inhibition of homologous recombination repair in irradiated tumor cells pretreated with Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin
  1090. Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with Hsp90 inhibitor and glycolysis inhibitor
  1091. Total synthesis of the Hsp90 inhibitor geldanamycin
  1092. CUDC-305, a novel synthetic Hsp90 inhibitor with unique pharmacologic properties for cancer therapy
  1093. Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma
  1094. Combination mammalian target of rapamycin inhibitor rapamycin and Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple โ€ฆ
  1095. Targeting KRAS-mutant nonโ€“small cell lung cancer with the Hsp90 inhibitor ganetespib
  1096. First-in-human phase I dose-escalation study of the Hsp90 inhibitor AUY922 in patients with advanced solid tumors
  1097. Angiogenesis impairment in Id-deficient mice cooperates with an Hsp90 inhibitor to completely suppress HER2/neu-dependent breast tumors
  1098. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using 89Zr-DFO-trastuzumab
  1099. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
  1100. 89Zr-trastuzumab PET visualises HER2 downregulation by the Hsp90 inhibitor NVP-AUY922 in a human tumour xenograft
  1101. Derrubone, an inhibitor of the Hsp90 protein folding machinery
  1102. Phase II study of the Hsp90-inhibitor BIIB021 in gastrointestinal stromal tumors
  1103. Efficacy of the Hsp90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells
  1104. The novel Hsp90 inhibitor STA-9090 exhibits activity against Kit-dependent and-independent malignant mast cell tumors
  1105. Functional characterization of the biosynthesis of radicicol, an Hsp90 inhibitor resorcylic acid lactone from Chaetomium chiversii
  1106. Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
  1107. BIIB021, a novel Hsp90 inhibitor, sensitizes head and neck squamous cell carcinoma to radiotherapy
  1108. Mechanistic evaluation of the novel Hsp90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma
  1109. Concise synthesis of pochonin A, an Hsp90 inhibitor
  1110. Hsp90 chaperone inhibitor 17-AAG attenuates Aฮฒ-induced synaptic toxicity and memory impairment
  1111. Hsp90 inhibitor, celastrol, arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way
  1112. Analysis of expression of heat shock protein-90 (Hsp90) and the effects of Hsp90 inhibitor (17-AAG) in multiple myeloma
  1113. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17โ€AAG)
  1114. Identification and initial SAR of silybin: an Hsp90 inhibitor
  1115. Molecular characterization of macbecin as an Hsp90 inhibitor
  1116. BIIB021, a synthetic Hsp90 inhibitor, has broad application against tumors with acquired multidrug resistance
  1117. Potentiation of paclitaxel activity by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated โ€ฆ
  1118. The Hsp90 inhibitor, 17โ€AAG, prevents the ligandโ€independent nuclear localization of androgen receptor in refractory prostate cancer cells
  1119. โ€ฆ isoforms of human Hsp90 differ with regard to their capacities for activation of certain client proteins, whereas only Hsp90ฮฒ generates sensitivity to the Hsp90 inhibitor โ€ฆ
  1120. The Hsp90 inhibitor NVP-AUY922 potently inhibits nonโ€“small cell lung cancer growth
  1121. Hsp90 inhibitor 17-AAG selectively eradicates lymphoma stem cells
  1122. Ganetespib (STA-9090), a nongeldanamycin Hsp90 inhibitor, has potent antitumor activity in in vitro and in vivo models of nonโ€“small cell lung cancer
  1123. Clusterin inhibition using OGX-011 synergistically enhances Hsp90 inhibitor activity by suppressing the heat shock response in castrate-resistant prostate cancer
  1124. The novel Hsp90 inhibitor STAโ€1474 exhibits biologic activity against osteosarcoma cell lines
  1125. Celastrol, a novel Hsp90 inhibitor, depletes Bcrโ€“Abl and induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation
  1126. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models
  1127. Hsp90 inhibitorโ€“mediated disruption of chaperone association of atr with Hsp90 sensitizes cancer cells to DNA damage
  1128. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1
  1129. Hsp90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair
  1130. Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling
  1131. 17-AAG, an Hsp90 inhibitor, causes kinetochore defects: a novel mechanism by which 17-AAG inhibits cell proliferation
  1132. Chemical proteomics-driven discovery of oleocanthal as an Hsp90 inhibitor
  1133. Discovery of a novel Hsp90 inhibitor by fragment linking
  1134. 89Zr-trastuzumab and 89Zr-bevacizumab PET to evaluate the effect of the Hsp90 inhibitor NVP-AUY922 in metastatic breast cancer patients
  1135. Antitumor activity of the combination of an Hsp90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
  1136. Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs
  1137. ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the Hsp90 inhibitor geldanamycin.
  1138. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model
  1139. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).
  1140. Hsp90 inhibitor induces autophagy and apoptosis in osteosarcoma cells
  1141. Lipophilic prodrugs of Hsp90 inhibitor geldanamycin for nanoencapsulation in poly (ethylene glycol)-b-poly (ฮต-caprolactone) micelles
  1142. BIIB021, an oral, synthetic non-ansamycin Hsp90 inhibitor: Phase I experience
  1143. Phase II trial of the Hsp90 inhibitor tanespimycin (Tan)+ trastuzumab (T) in patients (pts) with HER2-positive metastatic breast cancer (MBC)
  1144. A novel Hsp90 inhibitor delays castrate-resistant prostate cancer without altering serum PSA levels and inhibits osteoclastogenesis
  1145. The Hsp90 inhibitor radicicol interacts with the ATP-binding pocket of bacterial sensor kinase PhoQ
  1146. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells
  1147. Nano self-assembly of recombinant human gelatin conjugated with ฮฑ-tocopheryl succinate for Hsp90 inhibitor, 17-AAG, delivery
  1148. mTOR inhibition potentiates Hsp90 inhibitor activity via cessation of HSP synthesis
  1149. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models
  1150. The Hsp90 inhibitor ganetespib has chemosensitizer and radiosensitizer activity in colorectal cancer
  1151. Mechanisms of resistance to Hsp90 inhibitor drugs: a complex mosaic emerges
  1152. Opposite effects of the Hsp90 inhibitor Geldanamycin: induction of apoptosis in PC12, and differentiation in N2A cells
  1153. Development of a mitochondria-targeted Hsp90 inhibitor based on the crystal structures of human TRAP1
  1154. The Hsp90 inhibitor, AT13387, is effective against imatinib-sensitive and-resistant gastrointestinal stromal tumor models
  1155. Second-generation Hsp90 inhibitor onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate cancer cells
  1156. The novel oral Hsp90 inhibitor NVP-HSP990 exhibits potent and broad-spectrum antitumor activities in vitro and in vivo
  1157. The Hsp90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and-resistant MET-driven tumor models
  1158. Remarkable stereospecific conjugate additions to the Hsp90 inhibitor celastrol
  1159. A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in โ€ฆ
  1160. AUY922, a novel Hsp90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies.
  1161. Hsp90 inhibitor partially corrects nephrogenic diabetes insipidus in a conditional knock-in mouse model of aquaporin-2 mutation
  1162. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer
  1163. A C-terminal Hsp90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease
  1164. SNX-2112, an Hsp90 inhibitor, induces apoptosis and autophagy via degradation of Hsp90 client proteins in human melanoma A-375 cells
  1165. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression
  1166. Non-invasive MRI tumor imaging and synergistic anticancer effect of Hsp90 inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic pancreatic tumor model
  1167. The Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin modulates radiosensitivity by downregulating serine/threonine kinase 38 via Sp1 inhibition
  1168. Preclinical activity profile and therapeutic efficacy of the Hsp90 inhibitor ganetespib in triple-negative breast cancer
  1169. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies
  1170. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer
  1171. Phase I/II study of Hsp90 inhibitor AUY922 and erlotinib for EGFR-mutant lung cancer with acquired resistance to epidermal growth factor receptor tyrosine โ€ฆ
  1172. Phase II study of the Hsp90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).
  1173. Chemically accessible Hsp90 inhibitor that does not induce a heat shock response
  1174. Proteomeโ€wide changes induced by the Hsp90 inhibitor, geldanamycin in anaplastic large cell lymphoma cells
  1175. The Hsp90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage
  1176. A novel C-terminal Hsp90 inhibitor KU135 induces apoptosis and cell cycle arrest in melanoma cells
  1177. Hsp90 inhibitor encapsulated photo-theranostic nanoparticles for synergistic combination cancer therapy
  1178. Inhibition of gastric tumor growth by a novel Hsp90 inhibitor
  1179. The Hsp90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression
  1180. Targeting Hsp90 by the novel inhibitor NVP-AUY922 reduces growth and angiogenesis of pancreatic cancer
  1181. The Hsp90 inhibitor geldanamycin abrogates colocalization of eIF4E and eIF4E-transporter into stress granules and association of eIF4E with eIF4G
  1182. Natural product Kongensin A is a non-canonical Hsp90 inhibitor that blocks RIP3-dependent necroptosis
  1183. Phase I evaluation of STA-1474, a prodrug of the novel Hsp90 inhibitor ganetespib, in dogs with spontaneous cancer
  1184. An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) in patients (pts) with metastatic and/or unresectable GIST.
  1185. Why is this effective Hsp90 inhibitor not being developed in HER2+ breast cancer?
  1186. The anti-myeloma activity of a novel purine scaffold Hsp90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1
  1187. Antitumor effect of novel Hsp90 inhibitor NVP-AUY922 against oral squamous cell carcinoma
  1188. Synergistic action of the novel Hsp90 inhibitor NVPโ€AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma
  1189. The effects of an Hsp90 inhibitor on the paradoxical effect
  1190. A phase I study of the Hsp90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas
  1191. Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the Hsp90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma
  1192. Intelligent biosynthetic nanobiomaterials for hyperthermic combination chemotherapy and thermal drug targeting of Hsp90 inhibitor geldanamycin
  1193. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation
  1194. First-in-human phase I dose escalation study of a second-generation non-ansamycin Hsp90 inhibitor, AT13387, in patients with advanced solid tumors
  1195. P53-dependent radiosensitizing effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human oral squamous cell carcinoma cell lines
  1196. Anti-tumor activity against multiple myeloma by combination of KW-2478, an Hsp90 inhibitor, with bortezomib
  1197. Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context
  1198. Hsp90 inhibitor 17โ€AAG inhibits progression of LuCaP35 xenograft prostate tumors to castration resistance
  1199. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-ฮบB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in โ€ฆ
  1200. Targeting focal adhesion kinase with dominant-negative FRNK or Hsp90 inhibitor 17-DMAG suppresses tumor growth and metastasis of SiHa cervical xenografts
  1201. High-content, high-throughput analysis of cell cycle perturbations induced by the Hsp90 inhibitor XL888
  1202. Geldanamycin, a Hsp90 inhibitor, attenuates the hypoxia-induced vascular endothelial growth factor expression in retinal pigment epithelium cells in vitro
  1203. The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme
  1204. Combination therapy with Hsp90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells
  1205. Apoptosis caused by Hsp90 inhibitor geldanamycin in Leishmania donovani during promastigote-to-amastigote transformation stage
  1206. Identification of the plant compound geraniin as a novel Hsp90 inhibitor
  1207. The Novel Hsp90 inhibitor, IPI-493, is highly effective in human gastrostrointestinal stromal tumor xenografts carrying heterogeneous KIT mutations
  1208. Inhibition of archaeal growth and DNA topoisomerase VI activities by the Hsp90 inhibitor radicicol
  1209. Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1
  1210. Synthesis and in vitro anti-HSV-1 activity of a novel Hsp90 inhibitor BJ-B11
  1211. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin inhibits the proliferation of ARPE-19 cells
  1212. Synthesis and structureโ€“activity relationships of EGCG analogues, a recently identified Hsp90 inhibitor
  1213. Stage 1 testing and pharmacodynamic evaluation of the Hsp90 inhibitor alvespimycin (17โ€DMAG, KOSโ€1022) by the pediatric preclinical testing program
  1214. Mode of cell death induced by the Hsp90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX
  1215. ITZ-1, a client-selective Hsp90 inhibitor, efficiently induces heat shock factor 1 activation
  1216. The Hsp90 inhibitor geldanamycin perturbs endosomal structure and drives recycling ErbB2 and transferrin to modified MVBs/lysosomal compartments
  1217. Hsp90 inhibitor NVP-AUY922 enhances TRAIL-induced apoptosis by suppressing the JAK2-STAT3-Mcl-1 signal transduction pathway in colorectal cancer cells
  1218. Phase I trial of the Hsp90 inhibitor PF-04929113 (SNX5422) in adult patients with recurrent, refractory hematologic malignancies
  1219. Ganetespib, a novel Hsp90 inhibitor in patients with KRAS mutated and wild type, refractory metastatic colorectal cancer
  1220. The co-chaperone Hch1 regulates Hsp90 function differently than its homologue Aha1 and confers sensitivity to yeast to the Hsp90 inhibitor NVP-AUY922
  1221. Targeting GRP75 improves Hsp90 inhibitor efficacy by enhancing p53-mediated apoptosis in hepatocellular carcinoma
  1222. Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells
  1223. Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS)
  1224. Recent updates on the development of ganetespib as a Hsp90 inhibitor
  1225. SNX-2112, a novel Hsp90 inhibitor, induces G2/M cell cycle arrest and apoptosis in MCF-7 cells
  1226. Total synthesis of resorcinol amide Hsp90 inhibitor AT13387
  1227. A novel pulse-chase SILAC strategy measures changes in protein decay and synthesis rates induced by perturbation of proteostasis with an Hsp90 inhibitor
  1228. Topically applied Hsp90 inhibitor 17AAG inhibits UVR-induced cutaneous squamous cell carcinomas
  1229. Hsp90 inhibitor celastrol reinstates growth plate angiogenesis in thiram-induced tibial dyschondroplasia
  1230. Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90
  1231. Novel Hsp90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig2-Positive Glioma Tumorโ€“Initiating Cells
  1232. A Phase 1 dose-escalation study of the safety and pharmacokinetics (PK) of the oral Hsp90 inhibitor SNX-5422
  1233. Use of biomarkers and imaging to evaluate the treatment effect of AUY922, an Hsp90 inhibitor, in patients with HER2+ or ER+ metastatic breast cancer.
  1234. The Hsp90 inhibitor ganetespib radiosensitizes human lung adenocarcinoma cells
  1235. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in nonโ€“small cell lung cancer
  1236. Antiโ€myeloma activity of the novel 2โ€aminothienopyrimidine Hsp90 inhibitor NVPโ€BEP800
  1237. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer
  1238. A phase I dose-escalation study of the Hsp90 inhibitor STA-9090 administered twice weekly in patients with solid tumors.
  1239. Discovery of a stable macrocyclic o-aminobenzamide Hsp90 inhibitor which significantly decreases tumor volume in a mouse xenograft model
  1240. Molecular signature of response and potential pathways related to resistance to the Hsp90 inhibitor, 17AAG, in breast cancer
  1241. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down โ€ฆ
  1242. Effectively delivering a unique Hsp90 inhibitor using star polymers
  1243. Synthesis of Hsp90 inhibitor dimers as potential antitumor agents
  1244. Hsp90 inhibitor NVP-AUY922 enhances radiation sensitivity of tumor cell lines under hypoxia
  1245. Hsp90 inhibitor 17-AAG sensitizes Bcl-2 inhibitor (-)-gossypol by suppressing ERK-mediated protective autophagy and Mcl-1 accumulation in hepatocellular โ€ฆ
  1246. The Hsp90 inhibitor ganetespib potentiates the antitumor activity of EGFR tyrosine kinase inhibition in mutant and wild-type non-small cell lung cancer
  1247. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance
  1248. A purine scaffold Hsp90 inhibitor BIIB021 has selective activity against KSHV-associated primary effusion lymphoma and blocks vFLIP K13-induced NF-ฮบB
  1249. Targeting of multiple oncogenic signaling pathways by Hsp90 inhibitor alone or in combination with berberine for treatment of colorectal cancer
  1250. Pre-clinical efficacy of PU-H71, a novel Hsp90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma
  1251. Presence of MLH1 protein aggravates the potential of the Hsp90 inhibitor radicicol to sensitize tumor cells to cisplatin
  1252. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib
  1253. BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90
  1254. Targeting the Janus-activated kinase-2-STAT3 signalling pathway in pancreatic cancer using the Hsp90 inhibitor ganetespib
  1255. The Hsp90 inhibitor SNX-2112 induces apoptosis of human hepatocellular carcinoma cells: the role of ER stress
  1256. Evaluation of the Hsp90 inhibitor NVP-AUY922 in multicellular tumour spheroids with respect to effects on growth and PET tracer uptake
  1257. Phase I dose-escalation study of the Hsp90 inhibitor AUY922 in Japanese patients with advanced solid tumors
  1258. Structure-activity relationships in purine-based inhibitor binding to Hsp90 isoforms
  1259. Sensitization of chemo-resistant human chronic myeloid leukemia stem-like cells to Hsp90 inhibitor by SIRT1 inhibition
  1260. Hsp90 inhibitor geldanamycin increases hsp70 mRNA stabilisation but fails to activate HSF1 in cells exposed to hydrostatic pressure
  1261. Modeling spheroid growth, PET tracer uptake, and treatment effects of the Hsp90 inhibitor NVP-AUY922
  1262. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90
  1263. Hsp90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and Hsp90 signaling network complex in leukemia cells
  1264. BJ-B11, a novel Hsp90 inhibitor, induces apoptosis in human chronic myeloid leukemia K562 cells through the mitochondria-dependent pathway
  1265. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and-resistant chronic myeloid leukemia โ€ฆ
  1266. Targeting of multiple signaling pathways by the Hsp90 inhibitor SNX-2112 in EGFR resistance models as a single agent or in combination with erlotinib
  1267. Radicicol, an Hsp90 inhibitor, inhibits intestinal inflammation and leakage in abdominal sepsis
  1268. Hsp90 Inhibitorโ€“SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors
  1269. Combining an Hsp70 inhibitor with either an N-or C-terminal Hsp90 inhibitor produces mechanistically distinct phenotypes
  1270. Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation
  1271. The novel Hsp90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells
  1272. Protection of murine neural progenitor cells by the Hsp90 inhibitor 17โ€allylaminoโ€17โ€demethoxygeldanamycin in the low nanomolar concentration range
  1273. Phase II trial of tanespimycin (KOS-953), a heat shock protein-90 (Hsp90) inhibitor in patients with metastatic melanoma
  1274. The apoptotic effect and associated signalling of Hsp90 inhibitor 17โ€DMAG in hepatocellular carcinoma cells
  1275. Cellular growth kinetics distinguish a cyclophilin inhibitor from an Hsp90 inhibitor as a selective inhibitor of hepatitis C virus
  1276. Hsp90 inhibitor 17AAG causes apoptosis in ATRA-resistant acute promyelocytic leukemia cells
  1277. The Hsp90 inhibitor ganetespib: A potential effective agent for Acute Myeloid Leukemia in combination with cytarabine
  1278. Antiโ€tumor activity of the Hsp90 inhibitor SNXโ€2112 in pediatric cancer cell lines
  1279. Radiosensitization of human lung cancer cells by the novel purine-scaffold Hsp90 inhibitor, PU-H71
  1280. Hsp90 inhibitor SNX5422/2112 targets the dysregulated signal and transcription factor network and malignant phenotype of head and neck squamous cell โ€ฆ
  1281. IPI-493, a potent, orally bioavailable Hsp90 inhibitor of the ansamycin class
  1282. Hsp90 inhibitor AUY922 abrogates upโ€regulation of RTKs by mTOR inhibitor AZD8055 and potentiates its antiproliferative activity in human breast cancer
  1283. A phase II trial of ganetespib, a heat shock protein 90 Hsp90) inhibitor, in patients with docetaxel-pretreated metastatic castrate-resistant prostate cancer (CRPC)-a โ€ฆ
  1284. Hsp90 inhibitor antagonizing MIF: the specifics of pleiotropic cancer drug candidates
  1285. A CNS-permeable Hsp90 inhibitor rescues synaptic dysfunction and memory loss in APP-overexpressing Alzheimerโ€™s mouse model via an HSF1-mediated โ€ฆ
  1286. Elucidation of the Hsp90 C-terminal inhibitor binding site
  1287. Identifying a C-terminal ATP binding sites-based novel Hsp90-Inhibitor in silico: A plausible therapeutic approach in Alzheimerโ€™s disease
  1288. โ€ฆ 1-[4-(2-{6-amino-8-[(6-bromo-1, 3-benzodioxol-5-yl) sulfanyl]-9 H-purin-9-yl} ethyl) piperidin-1-yl]-2-hydroxypropan-1-one (MPC-3100), a purine-based Hsp90 inhibitor
  1289. The Hsp90 inhibitor SNX-2112, induces apoptosis in multidrug resistant K562/ADR cells through suppression of Akt/NF-ฮบB and disruption of mitochondria-dependent โ€ฆ
  1290. A Novel Hsp90 Inhibitorโ€“Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer
  1291. Profiling Hsp90 differential expression and the molecular effects of the Hsp90 inhibitor IPI-504 in high-grade glioma models
  1292. 17-AAG, a Hsp90 inhibitor, attenuates the hypoxia-induced expression of SDF-1ฮฑ and ILK in mouse RPE cells
  1293. The Hsp90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG) synergizes with cisplatin and induces apoptosis in cisplatin-resistant esophageal โ€ฆ
  1294. A phase I dose escalation study of AUY922, a novel Hsp90 inhibitor, in patients with advanced solid malignancies
  1295. Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies
  1296. An Hsp90 inhibitor, geldanamycin, as a brassinosteroid antagonist: evidence from salt-exposed roots of Vigna radiata
  1297. Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metalโ€catalyzed oxidation
  1298. โ€ฆ profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the Hsp90 โ€ฆ
  1299. Radiosynthesis of the iodineโ€124 labeled Hsp90 inhibitor PUโ€H71
  1300. Effects of treatment with an Hsp90 inhibitor in tumors based on 15 phase II clinical trials
  1301. Combination therapy of NSCLC using Hsp90 inhibitor and doxorubicin carrying functional nanoceria
  1302. MEK inhibition potentiates the activity of Hsp90 inhibitor 17-AAG against pancreatic cancer cells
  1303. Oral administration of an Hsp90 inhibitor, 17-DMAG, intervenes tumor-cell infiltration into multiple organs and improves survival period for ATL model mice
  1304. Radester, a novel inhibitor of the Hsp90 protein folding machinery
  1305. The combination of Hsp90 inhibitor 17 AAG and heavyโ€ion irradiation provides effective tumor control in human lung cancer cells
  1306. The novel, orally bioavailable Hsp90 inhibitor NVPโ€HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan โ€ฆ
  1307. Anti-tumor activity of a novel, water soluble Hsp90 inhibitor IPI-504 in multiple myeloma
  1308. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib
  1309. Hsp90 Inhibitor Ganetespib Sensitizes Nonโ€“Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation
  1310. Development of synthetic routes to macrocyclic compounds based on the Hsp90 inhibitor radicicol
  1311. Inhibition of RPE cell sterile inflammatory responses and endotoxin-induced uveitis by a cell-impermeable Hsp90 inhibitor
  1312. Antiproliferative effect of the Hsp90 inhibitor NVP-AUY922 is determined by the expression of PTEN in esophageal cancer
  1313. A phase I dose-escalation study of the Hsp90 inhibitor ganetespib (STA-9090) administered twice weekly in patients with solid tumors: Updated report.
  1314. Discovery of a novel fluorescent Hsp90 inhibitor and its anti-lung cancer effect
  1315. Novel C-terminal Hsp90 inhibitor for head and neck squamous cell cancer (HNSCC) with in vivo efficacy and improved toxicity profiles compared with standard agents
  1316. 17-DMAG, an Hsp90 inhibitor, ameliorates multiple organ dysfunction syndrome via induction of HSP70 in endotoxemic rats
  1317. A phase II study of Hsp90 inhibitor AUY922 and erlotinib (E) for patients (pts) with EGFR-mutant lung cancer and acquired resistance (AR) to EGFR tyrosine kinase โ€ฆ
  1318. Acquired Resistance to the Hsp90 Inhibitor, Ganetespib, in KRAS-Mutant NSCLC Is Mediated via Reactivation of the ERKโ€“p90RSKโ€“mTOR Signaling Network
  1319. Elevated expression of Hsp90 and the antitumor effect of an Hsp90 inhibitor via inactivation of the Akt/mTOR pathway in undifferentiated pleomorphic โ€ฆ
  1320. Effects of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) on NEU/HER2 overexpressing mammary tumours in MMTV-NEU-NT mice โ€ฆ
  1321. Preclinical pharmacokinetic analysis of SNX-2112, a novel Hsp90 inhibitor, in rats
  1322. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells
  1323. The Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases cisplatin antitumor activity by inducing p53-mediated apoptosis in head and neck โ€ฆ
  1324. First-in-human phase I study: Results of a second-generation non-ansamycin heat shock protein 90 (Hsp90) inhibitor AT13387 in refractory solid tumors.
  1325. A novel small molecule Hsp90 inhibitor, NXD30001, differentially induces heat shock proteins in nervous tissue in culture and in vivo
  1326. โ€ฆ protozoan infections biochemical characterization of Hsp90 from Plasmodium falciparum and trypanosoma evansi and evaluation of its inhibitor as a candidate drug
  1327. p53 independent radio-sensitization of human lymphoblastoid cell lines by Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin
  1328. Debio 0932, a new oral Hsp90 inhibitor, alleviates psoriasis in a xenograft transplantation model
  1329. Formulation and in vitro efficacy of liposomes containing the Hsp90 inhibitor 6BrCaQ in prostate cancer cells
  1330. Transformation of the non-selective aminocyclohexanol-based Hsp90 inhibitor into a Grp94-seletive scaffold
  1331. The Hsp90 inhibitor, 17AAG, protects the intestinal stem cell niche and inhibits graft versus host disease development
  1332. Sti1 is a non-competitive inhibitor of the Hsp90 Atpase binding prevents the N-terminal dimerization reaction during the Atpase cycle
  1333. Initial testing (Stage 1) of AT13387, an Hsp90 inhibitor, by the pediatric preclinical testing program
  1334. Novel Hsp90 inhibitor platycodin D disrupts Hsp90/Cdc37 complex and enhances the anticancer effect of mTOR inhibitor
  1335. Dual mode of cancer cell destruction for pancreatic cancer therapy using Hsp90 inhibitor loaded polymeric nano magnetic formulation
  1336. Preclinical activity of the Hsp90 inhibitor, ganetespib, in ALK-and ROS1-driven cancers.
  1337. Process development and scale-up of an Hsp90 inhibitor
  1338. โ€ฆ )-[5-(4-methylpiperazin-1-ylmethyl)-1, 3-dihydroisoindol-2-yl] methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug โ€ฆ
  1339. Phase I/II trial of the novel Hsp90 inhibitor, IPI-504, in patients with relapsed and/or refractory stage IIIB or stage IV non-small cell lung cancer stratified by EGFR โ€ฆ
  1340. Inhibition of constitutive and cxc-chemokine-induced NF-ฮบB activity potentiates ansamycin-based Hsp90-inhibitor cytotoxicity in castrate-resistant prostate โ€ฆ
  1341. Combined Hsp90 and kinase inhibitor therapy: insights from the cancer genome Atlas
  1342. Inhibition of thymidine phosphorylase expression by using an Hsp90 inhibitor potentiates the cytotoxic effect of cisplatin in non-small-cell lung cancer cells
  1343. Dose-escalation study of a second-generation non-ansamycin Hsp90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic โ€ฆ
  1344. Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art
  1345. Divergent synthesis of a pochonin library targeting Hsp90 and in vivo efficacy of an identified inhibitor
  1346. The Hsp90 inhibitor 17-AAG potentiates the antileishmanial activity of the ether lipid edelfosine
  1347. Phase IB/II study of the Hsp90 inhibitor AUY922, in combination with trastuzumab, in patients with HER2+ advanced breast cancer.
  1348. Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development
  1349. KU675, a concomitant heat-shock protein inhibitor of Hsp90 and Hsc70 that manifests isoform selectivity for Hsp90ฮฑ in prostate cancer cells
  1350. Low dose Hsp90 inhibitor 17AAG protects neural progenitor cells from ischemia induced death
  1351. Phase I study of the heat shock protein 90 (Hsp90) inhibitor onalespib (AT13387) administered on a daily for 2 consecutive days per week dosing schedule in patients โ€ฆ
  1352. A phase II trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with relapsed and/or refractory stage IIIb or stage IV non-small cell lung โ€ฆ
  1353. The Hsp90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer
  1354. TAS-116, a novel Hsp90 inhibitor, selectively enhances radiosensitivity of human cancer cells to X-rays and carbon ion radiation
  1355. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to fludarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a โ€ฆ
  1356. Hsp90 inhibitor BIIB021 enhances triptolide-induced apoptosis of human T-cell acute lymphoblastic leukemia cells in vitro mainly by disrupting p53-MDM2 โ€ฆ
  1357. First use of an oral Hsp90 inhibitor in patients (Pts) with solid tumors: Alvespimycin (A) administered QOD or Q
  1358. The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia โ€ฆ
  1359. A novel Hsp90 inhibitor activates compensatory heat shock protein responses and autophagy and alleviates mutant A53T ฮฑ-synuclein toxicity
  1360. A phase I trial of the Hsp90 inhibitor, alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours
  1361. A phase Ib trial of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in combination with docetaxel
  1362. โ€ฆ -stabilized mesoporous carbon nanospheres as versatile carriers for systemic delivery of amphiphobic SNX-2112 (a Hsp90 inhibitor) with enhanced antitumor effect
  1363. Leishmania donovani P23 protects parasites against Hsp90 inhibitor-mediated growth arrest
  1364. Effect of Hsp90 inhibitor in pheochromocytoma PC12 cells: an experimental investigation
  1365. A phase 2 study of the Hsp90 inhibitor AUY922 as treatment for patients with refractory gastrointestinal stromal tumors
  1366. Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors
  1367. Antiproliferative effect of Hsp90 inhibitor Y306zh against pancreatic cancer is mediated by interruption of AKT and MAPK signaling pathways
  1368. Effect of the Hsp90 inhibitor geldanamycin on androgen response of prostate cancer under hypoxic conditions
  1369. Expression of the protein chaperone, clusterin, in spinal cord cells constitutively and following cellular stress, and upregulation by treatment with Hsp90 inhibitor
  1370. Discovery of a macrocyclic o-aminobenzamide Hsp90 inhibitor with heterocyclic tether that shows extended biomarker activity and in vivo efficacy in a mouse โ€ฆ
  1371. Preclinical activity of the novel orally bioavailable Hsp90 inhibitor NVP-HSP990 against multiple myeloma cells
  1372. 5โ€ฒโ€Nโ€ethylcarboxamidoadenosine is not a paralogโ€specific Hsp90 inhibitor
  1373. A novel Hsp90 inhibitor with reduced hepatotoxicity synergizes with radiotherapy to induce apoptosis, abrogate clonogenic survival, and improve tumor โ€ฆ
  1374. Geldanamycin, an inhibitor of the chaperone activity of HSP90, induces MAPKโ€independent cell cycle arrest
  1375. Phase 1B/2 study of the Hsp90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab โ€ฆ
  1376. In silico design of small peptide-based Hsp90 inhibitor: a novel anticancer agent
  1377. Determination of SNX-2112, a selective Hsp90 inhibitor, in plasma samples by high-performance liquid chromatography and its application to pharmacokinetics in rats
  1378. Efficacy of onalespib, a long-acting second-generation Hsp90 inhibitor, as a single agent and in combination with temozolomide against malignant gliomas
  1379. โ€ฆ of Heat Shock Protein 90 (Hsp90) chaperone function in patienets with metastatic GIST: results of a Phase I Trial of IPI-504, a water-soluble Hsp90 inhibitor
  1380. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin
  1381. The Hsp90 inhibitor 17-AAG exhibits potent antitumor activity for pheochromocytoma in a xenograft model
  1382. NAD (P) H: Quinone oxidoreductase-1 expression sensitizes malignant melanoma cells to the Hsp90 inhibitor 17-AAG
  1383. Experience with Hsp90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma
  1384. Hypoxia attenuates Hsp90 inhibitor 17-DMAG-induced cyclin B1 accumulation in hepatocellular carcinoma cells
  1385. Novel Hsp90 inhibitor NVP-AUY922 enhances the anti-tumor effect of temsirolimus against oral squamous cell carcinoma
  1386. Down-regulation of MSH2 expression by an Hsp90 inhibitor enhances pemetrexed-induced cytotoxicity in human non-small-cell lung cancer cells
  1387. Hsp70 silencing with siRNA in nanocarriers enhances cancer cell death induced by the inhibitor of Hsp90
  1388. Hsp90 inhibitor SNX-7081 dysregulates proteins involved with DNA repair and replication and the cell cycle in human chronic lymphocytic leukemia (CLL) cells
  1389. Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design
  1390. Mitochondrial targeted Hsp90 inhibitor Gamitrinib-TPP (G-TPP) induces PINK1/Parkin-dependent mitophagy
  1391. STA-8666, a novel Hsp90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma
  1392. BIIB021, a novel Hsp90 inhibitor, sensitizes esophageal squamous cell carcinoma to radiation
  1393. Efficient synthesis of Hsp90 inhibitor dimers as potential antitumor agents
  1394. Hsp90 (heat shock protein 90) inhibitor occupancy is a direct determinant of client protein degradation and tumor growth arrest in vivo
  1395. Selective KIT inhibitor KI-328 and Hsp90 inhibitor show different potency against the type of KIT mutations recurrently identified in acute myeloid leukemia
  1396. 17-Demethoxy-reblastatin, an Hsp90 inhibitor, induces mitochondria-mediated apoptosis through downregulation of Mcl-1 in human hepatocellular carcinoma cells
  1397. The complementation of yeast with human or Plasmodium falciparum Hsp90 confers differential inhibitor sensitivities
  1398. Hsp90 inhibitor enhances anti-proliferative and apoptotic effects of celecoxib on HT-29 colorectal cancer cells via increasing BAX/BCL-2 ratio
  1399. Convergent synthesis and discovery of a natural product-inspired paralog-selective Hsp90 inhibitor
  1400. Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the pediatric preclinical testing program
  1401. Dual PI3K-and mTOR-inhibitor PI-103 can either enhance or reduce the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922 in tumor cells: the role of โ€ฆ
  1402. Gyrase B inhibitor impairs HIV-1 replication by targeting Hsp90 and the capsid protein
  1403. Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the Hsp90 inhibitor โ€ฆ
  1404. Preclinical study of AUY922, a novel Hsp90 inhibitor, in the treatment of esophageal adenocarcinoma
  1405. Reactivation of ERK and Akt confers resistance of mutant BRAF colon cancer cells to the Hsp90 inhibitor AUY922
  1406. Hsp90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2
  1407. Small molecule inhibitor screening identifified Hsp90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer
  1408. The Hsp90 inhibitor alvespimycin enhances the potency of telomerase inhibition by imetelstat in human osteosarcoma
  1409. Efficacy of an Hsp90 inhibitor, ganetespib, in preclinical thyroid cancer models
  1410. The Hsp90-specific inhibitor geldanamycin selectively disrupts kinase-mediated signaling events of T-lymphocyte activation
  1411. Geldanamycin, an inhibitor of heat shock protein 90 (Hsp90) mediated signal transduction has antiโ€inflammatory effects and interacts with glucocorticoid receptor in โ€ฆ
  1412. Role of the novel Hsp90 inhibitor AUY922 in hepatocellular carcinoma: Potential for therapy
  1413. Anticancer effects of the Hsp90 inhibitor 17-demethoxy-reblastatin in human breast cancer MDA-MB-231 cells
  1414. BIIB021, an Hsp90 inhibitor, effectively kills a myelodysplastic syndrome cell line via the activation of caspases and inhibition of PI3K/Akt and NFโ€‘ฮบB pathway โ€ฆ
  1415. The decline of porcine sperm motility by geldanamycin, a specific inhibitor of heat-shock protein 90 (Hsp90)
  1416. The purine scaffold Hsp90 inhibitor PU-H71 sensitizes cancer cells to heavy ion radiation by inhibiting DNA repair by homologous recombination and non โ€ฆ
  1417. Assessment of the heat shock protein 90 (Hsp90) inhibitor IPI504 alone or in combination with the tyrosine kinase inhibitor (TKI) imatinib in mice carrying xenografts of โ€ฆ
  1418. Discovery of XL888: a novel tropane-derived small molecule inhibitor of HSP90
  1419. SNX-25a, a novel Hsp90 inhibitor, inhibited human cancer growth more potently than 17-AAG
  1420. The Hsp90 inhibitor ganetespib alleviates disease progression and augments intermittent cyclophosphamide therapy in the MRL/lpr mouse model of โ€ฆ
  1421. Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery
  1422. VEGF downregulation by Hsp90 inhibitor NVP-AUY922 visualized with 89Zr-bevacizumab PET in triple negative breast cancer (TNBC)
  1423. In vivo synergism between PARP-inhibitor olaparib and Hsp90-inhibitor AT13387 in high grade serous ovarian cancer patient derived xenografts.
  1424. Acquired resistance to Hsp90 inhibitor 17-AAG and increased metastatic potential are associated with MUC1 expression in colon carcinoma cells
  1425. โ€ฆ anaplastic lymphoma kinase rearrangements (rALK) and the clinical activity of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor, in patients with โ€ฆ
  1426. MPC-3100, a fully synthetic, orally bioavailable Hsp90 inhibitor, in cancer patients.
  1427. Targeted delivery of chemotherapy using Hsp90 inhibitor drug conjugates is highly active against pancreatic cancer models
  1428. The mechanisms of apoptosis in HL-60 cells induced by Hsp90 inhibitor novobiocin
  1429. Hsp90 inhibitor SYโ€‘016 induces G2/M arrest and apoptosis in paclitaxel-resistant human ovarian cancer cells
  1430. P-glycoprotein (P-gp)-mediated efflux limits intestinal absorption of the Hsp90 inhibitor SNX-2112 in rats
  1431. The selective Hsp90 inhibitor BJ-B11 exhibits potent antitumor activity via induction of cell cycle arrest, apoptosis and autophagy in Eca-109 human โ€ฆ
  1432. Radiosensitizing effect of the novel Hsp90 inhibitor NVP-AUY922 in human tumour cell lines silenced for Hsp90ฮฑ
  1433. P-glycoprotein-evading anti-tumor activity of a novel tubulin and Hsp90 dual inhibitor in a non-small-cell lung cancer model
  1434. โ€ฆ protein 90 (Hsp90) inhibitor IPI-504 visualized by FDG-PET in patients (pts) with advanced gastrointestinal stromal tumors (GIST) resistant to tyrosine kinase inhibitor โ€ฆ
  1435. Radicicol, an inhibitor of Hsp90, enhances TRAIL-induced apoptosis in human epithelial ovarian carcinoma cells by promoting activation of apoptosis-related proteins
  1436. Discovery and pre-clinical profile of SNX-5422: an orally active Hsp90 inhibitor in phase 1 trials for solid and hematological tumors
  1437. Hsp90 inhibitor geldanamycin attenuates the cytotoxicity of sunitinib in cardiomyocytes via inhibition of the autophagy pathway
  1438. Hsp90 inhibitor 17-DMAG exerts anticancer effects against gastric cancer cells principally by altering oxidant-antioxidant balance
  1439. Phase II trial of single-agent ganetespib (STA-9090), a heat shock protein 90 (Hsp90) inhibitor in heavily pretreated patients with metastatic castration-resistant โ€ฆ
  1440. FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells
  1441. Geldanamycin, an inhibitor of Hsp90, potentiates cytochrome P4502E1-mediated toxicity in HepG2 cells
  1442. The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human, p53-negative chronic โ€ฆ
  1443. A phase II study of the Hsp90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer
  1444. The Hsp90-specific inhibitor, geldanamycin, blocks CD28-mediated activation of human T lymphocytes
  1445. Dynamic proteomics reveals bimodal protein dynamics of cancer cells in response to Hsp90 inhibitor
  1446. Geldanamycin, a potent and specific inhibitor of Hsp90, inhibits gene expression and replication of human cytomegalovirus
  1447. A phase I study of Debio 0932, an oral Hsp90 inhibitor, in patients with solid tumors.
  1448. Panaxynol, a natural Hsp90 inhibitor, effectively targets both lung cancer stem and non-stem cells
  1449. BIIB021 is a small molecule inhibitor of the heat shock protein, Hsp90, that shows potent anti-tumor activity in preclinical models
  1450. The Hsp90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells
  1451. The Hsp90 inhibitor 17-AAG represses calcium-induced cytokeratin 1 and 10 expression in HaCaT keratinocytes
  1452. PU-H71, a novel Hsp90 inhibitor, as a potential cancer-specific sensitizer to carbon-ion beam therapy
  1453. HPLC method development, validation and impurity characterization for an antitumor Hsp90 inhibitorโ€”PU-H71 (NSC 750424)
  1454. Proliferation and apoptosis of leukemia cell line K562 treated with Hsp90 inhibitor 17-DMAG
  1455. Heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line โ€ฆ
  1456. Abstract# 4679: The novel Hsp90 inhibitor STA-9090 has potent anticancer activity in in vitro and in vivo models of lung cancer
  1457. A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma
  1458. The novel Hsp90 inhibitor, PU-H71, suppresses glial cell activation but weakly affects clinical signs of EAE
  1459. A phase I trial of the heat shock protein 90 (Hsp90) inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, alvespimycin) administered โ€ฆ
  1460. The Hsp90 and DNA topoisomerase VI inhibitor radicicol also inhibits human type II DNA topoisomerase
  1461. Phase l study assessing a two-consecutive-day (QDร— 2) dosing schedule of the Hsp90 inhibitor, AT13387, in patients with advanced solid tumors
  1462. Geldanamycin, an inhibitor of Hsp90 increases cytochrome P450 2E1 mediated toxicity in HepG2 cells through sustained activation of the p38MAPK pathway
  1463. A phase I trial of the heat shock protein 90 (Hsp90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly โ€ฆ
  1464. Alternate Synthesis of Hsp90 Inhibitor AT13387
  1465. A phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma
  1466. Structural and computational biology of the molecular chaperone Hsp90: from understanding molecular mechanisms to computer-based inhibitor design
  1467. A facile and efficient synthesis of d6โ€labeled PUโ€H71, a purineโ€scaffold Hsp90 inhibitor
  1468. Discovery of 2โ€ฒ, 4โ€ฒ-dimethoxychalcone as a Hsp90 inhibitor and its effect on iressa-resistant non-small cell lung cancer (NSCLC)
  1469. Geldanamycin, an inhibitor of Hsp90, blocks cytoplasmic retention of progesterone receptors and glucocorticoid receptors via their respective ligand binding domains
  1470. NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases
  1471. Geldanamycin, an inhibitor of Hsp90, increases paclitaxel-mediated toxicity in ovarian cancer cells through sustained activation of the p38/H2AX axis
  1472. Significance of long term pharmacodynamic actions of the Hsp90 inhibitor AT13387
  1473. ATP acyl phosphate reactivity reveals native conformations of Hsp90 paralogs and inhibitor target engagement
  1474. Activity of the proprietary Hsp90 inhibitor IPI-493 in models of colorectal cancer correlates with RAS pathway activation
  1475. IPI-504, a novel orally administered Hsp90 inhibitor, demonstrates anti-tumor effects in EGFR mutant, kinase inhibitor resistant NSCLC
  1476. Anti-tumor selectivity of a novel Tubulin and Hsp90 dual-targeting inhibitor in non-small cell lung cancer models
  1477. Antiangiogenic activity of the Hsp90 inhibitor ganetespib in pancreatic cancer models
  1478. NVP-AUY922, a novel Hsp90 inhibitor, inhibits the progression of malignant pheochromocytoma in vitro and in vivo
  1479. Hsp90 inhibitor NVP-AUY922 induces cell apoptosis by disruption of the survivin in papillary thyroid carcinoma cells
  1480. Effects of Hsp90 inhibitor 17-AAG on cell cycle and apoptosis of human gastric cancer cell lines SGC-7901
  1481. In vitro and in vivo antitumor activity of the next generation Hsp90 inhibitor, AT13387, in both hormone-sensitive and castration-resistant prostate cancer models.
  1482. The Hsp90 inhibitor 17-PAG effectively inhibits the proliferation and migration of androgen-independent prostate cancer cells
  1483. Radioiodination, biodistribution and PET imaging studies of Hsp90 inhibitor [124I]-PU-H71
  1484. Comparative in vitro and in vivo metabolism of MPC-3100, an oral Hsp90 inhibitor, in rat, dog, monkey and human
  1485. A combination of histone deacetylase inhibitor LBH589 and the Hsp90 inhibitor 17-AAG is highly active against human CML-BC and AML cells with constitutively โ€ฆ
  1486. Preparation of the three C1-C7, C8-C15, and C16-N22 fragments of the Hsp90 inhibitor herbimycin A
  1487. A phase I dose-escalation study of the Hsp90 inhibitor AUY922 and erlotinib for patients with EGFR-mutant lung cancer with acquired resistance (AR) to EGFR โ€ฆ
  1488. RETRACTED ARTICLE: Potent antitumor activity of Hsp90 inhibitor AUY922 in adrenocortical carcinoma
  1489. Hsp90 inhibitor AT-533 blocks HSV-1 nuclear egress and assembly
  1490. Prediction of dual agents as an activator of mutant p53 and inhibitor of Hsp90 by docking, molecular dynamic simulation and virtual screening
  1491. Combination of the mTOR inhibitor Rapamycin and Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17AAG) inhibits proliferation and induces apoptosis โ€ฆ
  1492. Hsp90 inhibitor reduces porcine circovirus 2 replication in the porcine monocytic line 3D4/31
  1493. CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells
  1494. Hsp90 inhibitor sensitizes TRAIL-mediated apoptosis via chop-dependent DR5 upregulation in colon cancer cells
  1495. Inhibitor binding to Hsp90: a review of thermodynamic, kinetic, enzymatic, and cellular assays
  1496. Comparison of long-term pharmacodynamic actions of the synthetic small molecule Hsp90 inhibitor AT13387 in multiple xenograft models
  1497. Results of two phase 1 dose escalation studies of the oral heat shock protein 90 (Hsp90) inhibitor SNX-5422
  1498. Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90)
  1499. Image-guided photo-therapeutic nanoporphyrin synergized Hsp90 inhibitor in patient-derived xenograft bladder cancer model
  1500. Targeting Hsp90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma
  1501. Hsp90 inhibitor STA-9090 potently suppresses secondary KIT kinase-domain mutations responsible for gastrointestinal stromal tumor (GIST) progression โ€ฆ
  1502. Pharmaceutical development of IPIโ€504, an Hsp90 inhibitor and clinical candidate for the treatment of cancer
  1503. Activity of the Hsp90 inhibitor luminespib among non-small-cell lung cancers harboring EGFR exon 20 insertions
  1504. Hsp90 inhibitor drug conjugates (HDCs): Construct design and preliminary evaluation
  1505. BIIB021, a synthetic Hsp90 inhibitor, induces mutant ataxin-1 degradation through the activation of heat shock factor 1
  1506. In vitro effect of AZD1208 (Pim Kinase Inhibitor) and 17-AAG (Hsp90 Inhibitor) combination in CLL.
  1507. Cardiovascular safety profile of IPI-504 (retaspimycin hydrochloride), a novel Hsp90 inhibitor: Results from two independent phase I trials in patients with advanced โ€ฆ
  1508. โ€ฆ by a ring-expanding Claisen rearrangement. Synthesis and biological evaluation of ring and conformational analogues of the Hsp90 molecular chaperone inhibitor โ€ฆ
  1509. Fragment-based drug discovery of the synthetic small molecule Hsp90 inhibitor AT13387
  1510. IDH1057, A novel, synthetic, small molecule inhibitor of heat shock protein 90 (Hsp90)
  1511. โ€ฆ Protein 90 (Hsp90) Chaperone Function in Patients with Metastatic GIST: Preliminary Results of a Phase I Trial of IPI-504, a Water-Soluble Hsp90 Inhibitor
  1512. FS23 binds to the N-terminal domain of human Hsp90: a novel small inhibitor for Hsp90
  1513. Ganetespib, an Hsp90 inhibitor, kills Epsteinโ€“Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood
  1514. Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer
  1515. Wee1-Hsp90 inhibitor combination treatment: molecular therapy with potentially broad applicability
  1516. Hsp90 inhibitor CH5164840 induces micronuclei in TK6 cells via an aneugenic mechanism
  1517. Dendritic hexadecapeptide as a cathepsin B degradable carrier for delivery of Hsp90 inhibitor
  1518. The Hsp90 inhibitor, AT13387, displays single agent activity in erlotinib-sensitive and-resistant models of EGFR activated NSCLC
  1519. Pan-HDAC inhibitor LBH589 depletes EZH2 and DNMT1 by inhibiting chaperone association of Hsp90 with EZH2 and DNMT1.
  1520. Clinical efficiency and safety of Hsp90 inhibitor Novobiocin in avian tibial dyschondroplasia
  1521. 17AEP-GA, an Hsp90 antagonist, is a potent inhibitor of glioblastoma cell proliferation, survival, migration and invasion
  1522. The Hsp90 inhibitor 17-DMAG decreases infection of porcine circovirus type 2 in mice
  1523. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction
  1524. Cancer cell responses to Hsp70 inhibitor JG-98: Comparison with Hsp90 inhibitors and finding synergistic drug combinations
  1525. Effect of anacardic acid, a Hsp90 inhibitor, on proliferation, invasion and migration of breast cancer MDA-MB-231 cells
  1526. Abstract A96: Phase 1 study of Hsp90 inhibitor MPC-3100 in subjects with refractory or recurrent cancer.
  1527. Results from phase II trial of Hsp90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma
  1528. The novel Hsp90 inhibitor NVP-AUY922 shows synergistic anti-leukemic activity with cytarabine in vivo
  1529. Synergistic interactions of the Hsp90 inhibitor 17AAG and the PI3K inhibitor LY294002 in non-small cell lung cancer (NSCLC) cell lines involve disruption of Akt and c โ€ฆ
  1530. Abstract# 1857: The novel Hsp90 inhibitor, PU-H71, synergizes with cisplatin and blocks invasion and migration of ovarian cell lines.
  1531. Chiral resolution and pharmacological characterization of the enantiomers of the Hsp90 inhibitor 2โ€aminoโ€7โ€[4โ€fluoroโ€2โ€(3โ€pyridyl) phenyl]โ€4โ€methylโ€7, 8โ€dihydro โ€ฆ
  1532. C05. THE NEXT GENERATION Hsp90 INHIBITOR STA-9090, CURRENTLY IN PHASE 2 TRIALS, DISPLAYS POTENT IN VITRO AND IN VIVO ACTIVITY
  1533. Phase I study of the Hsp90 inhibitor AUY922 in combination with capecitabine as treatment for patients with advanced solid tumors.
  1534. C-terminal Hsp90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition
  1535. Abstract B98: AUY922, a novel Hsp90 inhibitor: Final results of a phase I dose escalation study in Japanese patients with advanced solid malignancies.
  1536. Evaluation of the pharmacokinetics and efficacy of a novel pro-drug of the Hsp90 inhibitor, MPC-3100, designed with improved solubility
  1537. [2+ 2+ 2] Cyclotrimerization with Propargyl Halides as Copartners: Formal Total Synthesis of the Antitumor Hsp90 Inhibitor AT13387
  1538. Consecutive day Hsp90 inhibitor administration improves efficacy in murine models of KIT-driven malignancies and canine mast cell tumors
  1539. Study on a Screening Model for Inhibitor of Hsp90 ATPase Activity [J]
  1540. Addition of Hsp90 inhibitor onalespib to crizotinib prior to progression in patients with ALK-pos NSCLC; results of a randomized Phase 2 study
  1541. โ€ฆ study comparing the efficacy of the water-soluble Hsp90 inhibitors, 17-AEPGA and 17-DMAG, with that of the nonโ€‘water-soluble Hsp90 inhibitor, 17-AAG, in โ€ฆ
  1542. In vitro Cytotoxic Activities of the Oral Platinum (IV) Prodrug Oxoplatin and Hsp90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines
  1543. Proteasome inhibitor-induced cleavage of Hsp90 is mediated by ROS generation and caspase 10-activation in human leukemic cells
  1544. Hsp90 Inhibitor Can Inhibit UV Carcinogenesis
  1545. A novel, orally active, small molecule Hsp90 inhibitor.
  1546. โ€ฆ of two novel Hsp90 proteins in Babesia orientalis: molecular characterization, and computational analyses of their structure, function, antigenicity and inhibitor โ€ฆ
  1547. The Hsp90 inhibitor, 17-Allylamino-17-Demethoxygeldanamycin (17AAG) abrogates the G2/M DNA damage checkpoint and induces apoptosis selectively in p53 โ€ฆ
  1548. Design of novel Geldanamycin analogue Hsp90 alpha-inhibitor in silico for breast cancer therapy
  1549. CNF2024-The first clinical stage synthetic oral Hsp90 inhibitor
  1550. โ€ฆ into whether the rapamycin inhibition of heat shock transcription factor (Hsf1) can prevent the Hsf1 activation that results from treatment with an Hsp90 inhibitor
  1551. Discovery of the Serenex Hsp90 Inhibitor, SNX5422
  1552. The broad stroke of Hsp90 inhibitors: painting over the RAF inhibitor paradox
  1553. The Hsp90 inhibitor, radicicol, attenuates bacterial lipopolysaccharide-induced endothelial permeability.
  1554. Immunotherapeutic targeting of Hsp90 client proteins in BRAF-inhibitor resistant melanoma
  1555. Discovery of licochalcone a as a natural product inhibitor of Hsp90 and its effect on gefitinib resistance in non-small cell lung cancer (NSCLC)
  1556. Radicicol, a Hsp90 inhibitor, inhibits intestinal inflammation and leakage in abdominal sepsis
  1557. Inhibitor-ฮบB kinase attenuates Hsp90-dependent endothelial nitric oxide synthase function in vascular endothelial cells
  1558. Effect of Hsp90 inhibitor novobiocin on STI571 resistant K562/G01 cells
  1559. Antiviral evaluation of an Hsp90 inhibitor, gedunin, against dengue virus
  1560. Metabolism and excretion of 6-chloro-9-(4-methoxy-3, 5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine, an Hsp90 inhibitor, in rats and dogs and assessment of its โ€ฆ
  1561. Inhibition of thyroid cancer proliferation in vitro by a novel small molecule Hsp90 inhibitor.
  1562. Phase 1 experience with BIIB021, an oral, synthetic, non-ansamycin Hsp90 inhibitor
  1563. Favorable interactions between fenretinide and the Hsp90 inhibitor 17AAG in neuroblastoma
  1564. Hsp90 inhibitor is a good candidate for effective combination therapy with carbon ions
  1565. Polymer mediated transport of the Hsp90 inhibitor LB76, a polar cyclic peptide, produces an Hsp90 cellular phenotype
  1566. A purine scaffold Hsp90 inhibitor has antitumor activity in KSHV-associated malignancies by suppressing vFLIP
  1567. 17-DMAG, an Hsp90 inhibitor, ameliorates ovariectomy-induced obesity in rats
  1568. Expression of Hsp90 in a panel of human tumor explants and its relation to response to treatment with the Hsp90 inhibitor 17-AAG.
  1569. Hsp90 Inhibitor Geldanamycin as a Radiation Response Modificator in Human Blood Cells
  1570. Preclinical safety profile of tanespimycin (KOS-953)-a heat shock protein 90 (Hsp90) inhibitor
  1571. Discovery of an L-alanine ester prodrug of the Hsp90 inhibitor, MPC-3100
  1572. BIIB021, an Hsp90 inhibitor: A promising therapeutic strategy for blood malignancies
  1573. Pediatric preclinical testing program (PPTP) efficacy and pharmacodynamic evaluation of the Hsp90 inhibitor 17-DMAG
  1574. Potent anticancer actions of the Hsp90 inhibitor STA-9090 in wild-type EGFR models of lung cancer
  1575. The Hsp90 inhibitor, onalespib (AT13387), delays the emergence of resistance to erlotinib in an EGFR-driven xenograft model
  1576. NVP-AUY922, a novel diarylisoxazole resorcinol Hsp90 inhibitor, potently inhibits growth and metastasis of human tumor xenografts
  1577. Hsp90 inhibitor STA-9090 induces HIF-1ฮฑ degradation in the hypoxic regions of solid tumors
  1578. โ€ฆ POSTER Modulation of the Hsp90 co-chaperone AHA1 affects client protein activity and increases cellular sensitivity to the Hsp90 inhibitor 17-allylamino-17 โ€ฆ
  1579. Combination of the Hsp90 inhibitor, 17AAG, with taxol in human ovarian tumour cell lines
  1580. Effects of cotreatment or sequence treatment with Hsp90 C-terminal inhibitor NB and Hsp90 N-terminal inhibitor GA on leukemia cells
  1581. Hsp90 inhibitor induces KG-1a cell differentiation and apoptosis via Akt/NF-ฮบB signaling
  1582. Delivery of Hsp90 Inhibitor Using Water Soluble Polymeric Conjugates with High Drug Payload
  1583. Acquired resistance to Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in adult and pediatric glioblastoma cell lines
  1584. Simultaneously targeting hypoxic cancer cells by Hsp90 inhibitor and glycolysis inhibitor in pancreatic cancer therapy
  1585. ATPS-05CHARACTERIZATION OF THE ACTIVITY OF AT13387, A NOVEL SECOND GENERATION Hsp90 INHIBITOR AGAINST GLIOMAS
  1586. Blood-brain-barrierโ€“permeable Hsp90 inhibitor reduces soluble tau burden in a mouse model of Alzheimerโ€™s disease
  1587. Abstract B199: In vitro and in vivo efficacy of the novel Hsp90 inhibitor STAโ€9090 and its synergy with paclitaxel
  1588. The effect of EC78, a novel Hsp90 inhibitor alone and in combination with radiation in head and neck squamous cell carcinoma
  1589. Progesterone Receptor Chaperone Complexโ€“Based High-Throughput Screening Assay: Identification of Capsaicin as an Inhibitor of the Hsp90 Machine
  1590. Hsp90 inhibitor NMS-E973 exerts the anticancer effect against glioblastoma via induction of PUMA-mediated apoptosis
  1591. Model system identifies kinetic driver of Hsp90 inhibitor activity against African trypanosomes and Plasmodium falciparum
  1592. IPI-504, a novel Hsp90 inhibitor is effective in EGFR T790M and non-T790M gefitinib-resistant lung cancer cell lines.
  1593. Ribosome Profiling Reveals Hsp90 Inhibitor Effects on Stage-Specific Protein Synthesis in Leishmania donovani
  1594. Radiosensitization of HSF-1 Knockdown Lung Cancer Cells by Low Concentrations of Hsp90 Inhibitor NVP-AUY922
  1595. Phase I study of vemurafenib and heat shock protein 90 (Hsp90) inhibitor XL888 in metastatic BRAF V600 mutant melanoma.
  1596. Hsp90 inhibitor induces cell cycle arrest and apoptosis of early embryos and primary cells in pigs
  1597. Hsp90 inhibitor geldanamycin reverts IL-13โ€“and IL-17โ€“induced airway goblet cell metaplasia
  1598. Hsp90 inhibitor STA-9090 enhances the activity of standard of care therapies in erlotinib-sensitive and-resistant NSCLC models
  1599. Abrogation of hsp70 induction: A strategy to enhance the antileukemia effects of Hsp90 inhibitor 17-allylamino-demethoxy geldanamycin (17-AAG)
  1600. Hsp90 Inhibitor 17-AAG Inhibits Multiple Myeloma Cell Proliferation by Down-regulating Wnt/ฮฒ-Catenin Signaling Pathway
  1601. Hsp90 inhibitor 17-DMAG effectively alleviated the progress of thoracic aortic dissection by suppressing smooth muscle cell phenotypic switch
  1602. TM-03THE Hsp90 INHIBITOR GANETESPIB IS AN EFFECTIVE THERAPY FOR GLIOBLASTOMA THAT BLOCKS EGFR-DRIVEN TUMOR GROWTH
  1603. Inhibition of Hsp90 sensitizes a novel Raf/ERK dual inhibitor CY-9d in triple-negative breast cancer cells
  1604. Preclinical testing demonstrates strong activity of STA-12-8666, an Hsp90 inhibitor-SN-38 conjugate, in small cell lung cancer (SCLC)
  1605. OA 12.02 final results of a phase 2 study of the Hsp90 Inhibitor Luminespib (AUY922) in NSCLC patients harboring EGFR Exon 20 insertions
  1606. A phase I study of the Hsp90 inhibitor AUY922 plus capecitabine for the treatment of patients with advanced solid tumors
  1607. Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-ฮบB Pathway in Endometrial Cancer
  1608. Biological effects of the novel small molecule Hsp90 inhibitor SNX-2112 as a single agent and in combination with Erlotinib in non-small cell lung cancer models
  1609. P2. 13-39 a phase Ib trial of the Hsp90 inhibitor AUY922 in combination with Pemetrexed in metastatic non-squamous, non-small cell lung cancer patients
  1610. Mechanism of Inhibition of Hsp90 Dimerization by Gyrase B Inhibitor Coumermycin A1 (Cโ€“A1) Revealed by Molecular Dynamics Simulations and Thermodynamic โ€ฆ
  1611. A novel, selective, orally active, potent small molecule inhibitor of Hsp90
  1612. 2โ€phenylethynesulphonamide (PFTโ€ฮผ) enhances the anticancer effect of the novel Hsp90 inhibitor NVPโ€AUY922 in melanoma, by reducing GSH levels
  1613. The novel Hsp90 inhibitor IPI-504 synergizes with bortezomib in mantle cell lymphoma cells by targeting both NF-kappaB signaling and unfolded protein response โ€ฆ
  1614. Abstract A110: A phase 1 study of PFโ€04929113 (SNX5422), an orally bioavailable heat shock protein 90 (Hsp90) inhibitor administered twice weekly in patients with โ€ฆ
  1615. A novel Hsp90 inhibitor, 17-DMAG, induces Tax down-regulation and its oral administration to ATL-model mice intervenes against the infiltration property of the ATL โ€ฆ
  1616. 17-AAG (KOS-953), an inhibitor of Hsp90 function, significantly enhances the cytotoxicity of anticancer drugs: An effective approach for combination therapy
  1617. Part I of GANNET53: A European multicenter Phase I/II trial of the Hsp90 inhibitor Ganetespib combined with weekly Paclitaxel in women with high-grade, platinum โ€ฆ
  1618. Triptolide, a Hsp90 middle domain inhibitor, induces apoptosis in triple manner
  1619. Molecular dynamics simulations of Hsp90 with an eye to inhibitor design
  1620. 1479PDPhase II study of TAS-116, an oral inhibitor of heat shock protein 90 (Hsp90), in metastatic or unresectable gastrointestinal stromal tumor refractory to โ€ฆ
  1621. โ€ฆ (PD) study of 17-dimethylaminoethylamino-17-demethoxygeldanamycin,(17DMAG, NSC 707545), an inhibitor of heat shock protein 90 (Hsp90), in patients with โ€ฆ
  1622. Chetomin as a Potent Hsp90 Inhibitor
  1623. Thermodynamics of Natural and Synthetic Inhibitor Binding to Human Hsp90
  1624. Development of Polymeric-Drug Conjugates for Delivering the Hsp90 Inhibitor SNX5422
  1625. Hsp90 Inhibitor Treatment for Cushing Syndrome and Other Diseases
  1626. Analysis of Genes Regulated by Hsp90 Inhibitor Geldanamycin in Neurons
  1627. Repositioning Irsogladine to Hsp90 Inhibitor
  1628. A novel inhibitor to disrupt Hsp90-Cdc37 interaction against pancreatic cancer
  1629. Identification of Hsp90 inhibitor sensitizers through pooled RNA interference screen
  1630. Abstract B19: The Hsp90 inhibitor, AT13387, is effective against multiple mechanisms of kinase inhibitor resistance
  1631. Abstract B90: Hsp90 inhibitor NVP-AUY922 sensitizes intrinsic MEK inhibitor Trametinib-resistant NSCLC cells harboring KRAS mutation
  1632. Preclinical efficacy of PF-04942847, a novel Hsp90 inhibitor, in osteosarcoma
  1633. Hsp90 Inhibitor Enhances the Pgd2-stimulated Hsp27 Induction in Osteoblasts
  1634. Novel Hsp90 inhibitor, STA-9090, for combination with radiotherapy
  1635. A new Hsp90 inhibitor as therapeutic agent for bladder cancer.
  1636. Hypoxic Radiosensitization By DMAG, an Hsp90 Inhibitor
  1637. A novel small molecule inhibitor of heat shock protein 90 (Hsp90)
  1638. Preclinical evaluation of WXFL1024H251, a potent second-generation Hsp90 inhibitor
  1639. Synthesis of the secoโ€Limonoid BCD Ring System Identifies a Hsp90 Chaperon Machinery (p23) Inhibitor
  1640. Combinatorial targeting of oncogenesis via a novel rationally designed Hsp90 inhibitor
  1641. Development of the high-throughput screening fluorescence polarization assay for Hsp90 inhibitor
  1642. Small-molecule inhibitor targeting the Hsp90-Cdc37 protein-protein interaction in colorectal cancer
  1643. The Hsp90 inhibitor Ganetespib: A Potential Effective
  1644. Hsp90 inhibitor, 17-DMAG, enhances radiosensitivity of human cancer cells
  1645. Penicisulfuranol A, a novel C-terminal inhibitor disrupting molecular chaperone function of Hsp90 independent of ATP binding domain
  1646. Abstract B1: Targeting KRAS mutant NSCLC with the Hsp90 inhibitor ganetespib
  1647. FS-108, an Hsp90 inhibitor, impairs survival and motility of oncogene addicted cancer cells
  1648. Hsp90 Inhibitor Strengthens Atp-stimulated Interleukin-6 Synthesis in Osteoblasts
  1649. Hsp90 inhibitor drug conjugates (HDCs): Proof of concept in preclinical studies
  1650. The design and synthesis of a novel orally available Hsp90 inhibitor CH5164840
  1651. Phase 1 study of onalespib, Hsp90 inhibitor, and AT7519M, CDK9 inhibitor, in patients with advanced solid tumors.
  1652. โ€ฆ Inhibitor Enhances Hsp90 Inhibitor-mediated Abrogation of Hsp90 Chaperone Function and Potentiates the Cytotoxicity of Hsp90 Inhibitor in Chemo-resistant โ€ฆ
  1653. Hsp90 inhibitor has a possibility to overcome imatinib resistance in gastrointestinal stromal tumors
  1654. Effectiveness of the combined treatment with Hsp90 inhibitor and heavy ion irradiation
  1655. The novel Hsp90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma
  1656. Abstract A212: A novel, small molecule inhibitor of Hsc70/Hsp70 potentiates Hsp90 inhibitorโ€induced apoptosis in HCT116 colon carcinoma cells
  1657. Hsp90 and histone deactylase inhibitor have synergistic activity against synovial sarcoma.
  1658. Hsp90 inhibitor (NVP-AUY922) enhances anti-cancer effect of Bcl-2 inhibitor (ABT-737) in small cell lung cancer
  1659. Abstract# 4690: Preclinical characterization of the Hsp90 inhibitor XL888 in melanoma models
  1660. Moleculary Targeted Nanomedicine: Role of Hsp90 Inhibitor and Sophorolipids
  1661. Discovery of a novel small inhibitor RJ19 targeting to human Hsp90
  1662. Molecular profile and anti-myeloma activity of the novel Hsp90 inhibitor NVP-AUY922
  1663. Inhibition of signal transduction by the Hsp90 inhibitor sensitizes human tumor cells to radiation
  1664. Chemical approaches to development of mitochondrial-targeted Hsp90 inhibitor in anti-cancer therapeutics: Mechanism and structure change of mitochondrial Hsp90
  1665. Essential oil from Cymbopogon flexuosus as the potential inhibitor for HSP90
  1666. Stability of the Hsp90 inhibitor 17AAG hydroquinone and prevention of metal-catalyzed oxidation
  1667. Preclinical antitumor activity of SST0116CL1, a novel heat shock protein 90 (Hsp90) inhibitor
  1668. Radiosensitization induced by 17DMAG: An orally bioavailable inhibitor of HSP90
  1669. AT13387, an Hsp90 inhibitor, is effective in both vemurafenib-sensitive and-resistant melanoma models
  1670. Treatment of Arabidopsis thaliana seeds with an Hsp90 inhibitor increases plant resistance
  1671. Treatment of advanced bronchoalveolar carcinoma with the Hsp90 inhibitor STA-9090.
  1672. Abstract B100: Preclinical evaluation of a novel Hsp90 inhibitor HSP990 in glioblastoma multiforme.
  1673. The investigation of AT7519 (CDK inhibitor) and AT13387 (Hsp90 inhibitor) as novel therapies for the treatment of pancreatic ductal adenocarcinoma
  1674. Identification of vibsanin A analog as a novel Hsp90 inhibitor
  1675. Abstract# 4678: Preclinical anti-myeloma activity of the novel Hsp90 ATPase inhibitor NVP-BEP800
  1676. Overcoming acquired resistance to BRAF inhibitors in melanoma with the Hsp90 inhibitor ganetespib
  1677. Identification of the ellagitannin geraniin as a novel Hsp90 inhibitor
  1678. Effect of Hsp90 inhibitor ganetespib on stemness in small cell lung cancer
  1679. Chemotherapeutic potential of Hsp90 and biological evaluation of a novel Hsp90 inhibitor
  1680. Gene Expression Profile of Apoptosis in Leukemia Cells Induced by Hsp90 Selective inhibitor 17-AAG
  1681. NVP-AUY922: A novel small molecule Hsp90 inhibitor with potent in vivo antitumor efficacy
  1682. Hsp90 inhibitor AUY922 abrogates mTOR inhibitor AZD8055-induced up-regulation of HER2/HER3 and potentiates antiproliferative activity in human breast cancer โ€ฆ
  1683. The succinct synthesis of AT13387, a clinically relevant Hsp90 inhibitor
  1684. The Hsp90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and crizotinib-resistant MET-driven renal tumor models
  1685. The Hsp90 inhibitor ganetespib is a potent chemosensitizer in preclinical colorectal cancer models
  1686. Synthesis and evaluation of a ring-constrained Hsp90 C-terminal inhibitor that exhibits neuroprotective activity
  1687. Results of toxicology studies with MPC-3100, an oral Hsp90 inhibitor.
  1688. Identification and validation of serum biomarkers for clinical assessment of Hsp90 inhibitor therapy
  1689. AT-533, a Hsp90 inhibitor, attenuates HSV-1-induced inflammation
  1690. Hsp90 Inhibitor, 17-AAG, Affects Meiotic Maturation and Preimplantation Embryos Development in Pigs.
  1691. Novel in vivo pan-Hsp90 family protein inhibitor, Panvotinib-401, showed potent anticancer activities without HSF1 activation
  1692. The novel Hsp90 inhibitor STA-12-1474 exhibits biologic activity against canine osteosarcoma cell lines
  1693. Abstract B88: Mechanisms of resistance to the Hsp90 inhibitor ganetespib in triple negative breast cancer
  1694. Proteasome inhibitorโ€induced protein aggregation is regulated via HSP90, HDACs and microtubulus stability in ARPEโ€19 cells
  1695. Hsp90-inhibitor drug conjugates (HDC): Novel tumor-selective drug delivery platform with unprecedented anticancer activity
  1696. NVP-AUY922/VER-52296: A novel 3, 4 diarylisoxazole Hsp90 chaperone inhibitor discovered via structure-based drug design
  1697. Hsp90-inhibitor Ganetesbip potentiates radiosensitizing and chemosensitizing effects of hyperthermia
  1698. Development of a noninvasive assay to determine drug concentration in tumor during Hsp90 inhibitor therapy
  1699. (-)-Epigallocatechin-3-gallate, Found in the Green Tea Extract, is a Novel Hsp90 Inhibitor
  1700. Molecular detection of Hsp90 inhibitor suppressing PCV2 replication in host cells
  1701. Antitumor activity of MPC-3100, a synthetic, orally bioavailable Hsp90 inhibitor, in animal models
  1702. The effects of Hsp90 inhibitor DMAG on the leukemia cell line HL-60
  1703. The Hsp90 inhibitor 17-AAG improves chemoresistance of cisplatin-resistant esophageal squamous cell carcinoma cell lines
  1704. Synthesis of isotopeโ€labeled Hsp90 inhibitor: [13CD3] and [14C]โ€TAKโ€459
  1705. Hsp90 inhibitor, 17-allylaminogeldanamycin, inhibits cell growth of lung cancer cell lines associated with overexpression of Hsp90 on lung cancer tissues.
  1706. The Hsp90 inhibitor ganetespib potentiates effect of ionizing radiation in human non-small cell lung cancer
  1707. DEBIO0932, an Hsp90 inhibitor downregulates key signaling pathways and sensitizes glioma cells to temozolomide
  1708. The Research and Analysis of Global Market about Hsp90 Inhibitor from Microbiology
  1709. Hsp90 inhibitor 17-DMAG enhances EphA2+ tumor cell recognition by specific CD8+ T cells (40.27)
  1710. Novel inhibitor of Hsp90-PU-H71 exhibits significant activity in Ewing sarcoma pre-clinical models.
  1711. Synthesis of an 18F labeled pyrazole-based Hsp90 inhibitor for PET imaging of cancers
  1712. 601 The Antimyeloma Activity of PU-H71, a Novel Purine Scaffold Hsp90 Inhibitor, is via Inhibition of Both HSP90A and HSP90B1
  1713. The Hsp90 inhibitor, AT13387, combined with erlotinib improves response in EGFR-driven xenograft models of NSCLC
  1714. Efficacy of the Hsp90 inhibitor NVP-AUY922 correlates with decreased vessel permeability and reduced interstitial fluid pressure
  1715. Abstract# LB-86: Probing cancer-specific activating signaling pathways through a tumor-specific Hsp90 inhibitor
  1716. Ganetespib, an Hsp90 Inhibitor, Sensitizes Colorectal Cancers to the Effects of Ionizing Radiation
  1717. MPC-3100, a synthetic Hsp90 inhibitor, induces biomarker changes in vitro and in vivo
  1718. ET-14. PRECLINICAL EVALUATION OF NXD30001, A NOVEL Hsp90 INHIBITOR, FOR EFFICACY IN GLIOMA
  1719. Identification and development of NVP-HSP990, a potent and orally active Hsp90 inhibitor for cancer treatment
  1720. Potent antitumor activity of the Hsp90 inhibitor SNX-2112 in type 1 papillary renal cell carcinoma
  1721. The Hsp90 Inhibitor 17-AAG Prevents Aberrant Endocytosis Mediated By The Rhodopsin Retinitis Pigmentosa R135L Mutation
  1722. Abstract LB-140: The Hsp90 inhibitor ganetespib overcomes EGFR-based intratumoral heterogeneity to block glioma proliferation
  1723. Determining the Effect of Hsp90 Inhibitor Geldanamycin on Herpes Simplex Virus Type-1 Production in Infected Vero Cells
  1724. Effect of the Hsp90 Inhibitor KW-2478 on HepG2 Cells.
  1725. Abstract LB-187: Hsp90 inhibitor SNX-2112 enhances neoantigen presentation on the surface of tumor cells
  1726. Signaling Profile and Anti-Tumor Activity of the Novel Hsp90 Inhibitor NVP-AUY922 in Multiple Myeloma.
  1727. The Hsp90 inhibitor onalespib potentiates 177Luโ€‘DOTATATE therapy in neuroendocrine tumor cells
  1728. Preclinical evaluation of the novel, potent diarylisoxazole resorcinol Hsp90 inhibitor NVP-AUY922 in adult and pediatric glioblastomas
  1729. Activity of PU-H71, a novel Hsp90 inhibitor, and bortezomib in Ewing sarcoma preclinical models.
  1730. The Hsp90 Inhibitor, AUY-922 Reduces Pulmonary Fibrosis and Airway Dysfunction in Mice Exposed to HCl
  1731. Abstract# 5632: NVP-BEP800: an orally bioavailable small molecule Hsp90 inhibitor with potent in vivo antitumor activity
  1732. 52. A Novel Small Molecule Hsp90 Inhibitor With Antiproliferative Effects in Differentiated and Anaplastic Thyroid Cancers
  1733. Targeting Hsp90 using EC154, a novel synthetic Hsp90 inhibitor, impairs multiple signaling pathways in human gastric and pancreatic cancer cells and reduces tumor โ€ฆ
  1734. Preclinical evaluation of the Hsp90 inhibitor KW-2478 in combination with bortezomib as a treatment for multiple myeloma
  1735. Mechanism of the antimyeloma activity of PU-H71, a novel purine scaffold Hsp90 inhibitor.
  1736. Clinical and biological significances of heat shock protein 90 (Hsp90) in human nasopharyngeal carcinoma cells and anti-cancer effects of Hsp90 inhibitor
  1737. Antitumor activity of MPC-3100, a synthetic Hsp90 inhibitor, in combination with erlotinib and sorafenib
  1738. Biological Evaluation of Natural Product as a Potent Hsp90 Inhibitor.
  1739. Design, synthesis, and biological evaluation of small molecule as Hsp90 inhibitor
  1740. 26 BC265: A Nonquinone Ansamycin Hsp90 Inhibitor Developed Using Biosynthetic Medicinal Chemistry
  1741. Experimental study on mouse bone marrow micronucleus of a novel Hsp90 inhibitor-SNX-2112
  1742. Abstract B101: Safety, tolerability, and pharmacokinetics of IPI-493, an oral Hsp90 inhibitor, in patients with advanced cancers.
  1743. Abstract A213: Potent anticancer activity in vitro and in vivo by NMSโ€E973, a novel synthetic inhibitor of HSP90
  1744. The Hsp90 inhibitor PU-H71 is a potent suppressor of metastasis in triple-negative breast cancer models
  1745. Abstract A218: Pharmacokinetic (PK) and pharmacodynamic (PD) data for MPCโ€3100, a fully synthetic Hsp90 inhibitor, in cancer patients
  1746. BJ-B11, an Hsp90 Inhibitor, Constrains the Proliferation and Invasion of Breast Cancer Cells
  1747. Antitumor activity of heat shock protein 90 (Hsp90) inhibitor AT13387 in head and neck squamous cell carcinoma
  1748. Preclinical efficacy of the Hsp90 inhibitor SNX-5422 in targeting C481S mutant BTK and ibrutinib resistant CLL
  1749. Hsp90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells
  1750. The Hsp90 Inhibitor Radicicol As A Bioinformatically-Derived Drug For M2 Macrophage Phenotype Inhibition
  1751. Multimodal action of the Hsp90 inhibitor STA-9090 in treating cancer cells with activated JAK/STAT signaling
  1752. A specific Hsp90 small molecular inhibitor demonstrates anti-tumor activity in melanoma cells through V600E B-Raf protein degradation
  1753. Abstract# 1853: Cancer cells harboring MET gene amplification are sensitive to Hsp90 inhibitor 17-AAG
  1754. STA-12-8666: a first-in-class Hsp90 inhibitor drug conjugate (HDC) designed to selectively deliver chemotherapy to tumors
  1755. A Novel Hsp90 Inhibitor to Disrupt HSP90/p50CDC37 Complex for Pancreatic Cancer Therapy.
  1756. Activity of the heat shock protein 90 (Hsp90) inhibitor, SNX-2112, in pediatric cancer cell lines.
  1757. Abstract# 4682: BIIB021, a fully synthetic oral small molecule inhibitor of Hsp90, shows anti-tumor activity in multiple xenograft models.
  1758. Activity of Hsp90-inhibitor drug conjugate (HDC) STA-12-8666 in preclinical models of pediatric sarcoma.
  1759. The advances of the Hsp90 inhibitor NVP-AUY922: applied alone or in combination with anti-tumor treatment
  1760. The Hsp90 inhibitor, 17-AAG, reduces pulmonary arterial calcineurin activity in monocrotaline-induced pulmonary arterial hypertension (PAH)
  1761. Targeting Hsp90 using EC154, a novel synthetic Hsp90 inhibitor, impairs multiple oncogenic signaling pathways in human gastric and pancreatic cancer cells and โ€ฆ
  1762. Pre-clinical and clinical evaluation of the heat shock protein 90 (Hsp90) inhibitor 17-allylamino, 17-demethoxygeldanamycin.
  1763. Human cytochrome P450 and UDP-glucuronosyltransferase reaction phenotyping of MPC-3100, an oral Hsp90 inhibitor.
  1764. Hsp90 Inhibitor-Based Strategies for Cancer Therapy: Advancing Toward Clinical Impact
  1765. Proteinโ€“protein inhibitor designed de novo to target the MEEVD region on the C-terminus of Hsp90 and block co-chaperone activity
  1766. Activity of IPI-504, a water-soluble Hsp90 inhibitor, combined with bortezomib in a human multiple myeloma xenograft model
  1767. Abstract B105: Ganetespib, a unique resorcinolic Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile in preclinical models.
  1768. Hsp90 inhibitor SY-016 induces G2/M arrest and apoptosis in paclitaxel-resistant human ovarian
  1769. Topically applied Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin inhibits ultraviolet radiation-induced development of cutaneous squamous cell โ€ฆ
  1770. Hsp90 inhibitor induces nuclear translocation of HSF1 predominantly in hippocampal CA1 region
  1771. Post-treatment with the heat shock protein 90 (Hsp90) inhibitor, AUY-922, reduces lung Hsp90 tyrosine (Y) phosphorylation and pulmonary inflammation in LPS โ€ฆ
  1772. The Hsp90 Inhibitor, 17-AAG Prevents The Progression Of Monocrotaline-Induced Right Ventricular Hypertrophy And Pulmonary Arterial Hypertension
  1773. Abstract B105: Hsp90 inhibitor, ganetespib, enhances responses to cancer immunotherapy through increased expression of interferon response genes
  1774. Combined treatment wth Hsp90 inhibitor and TRAIL down-regulated NFฮบB activity through their effects on the death receptor complex.
  1775. Proteomic analysis of Hsp90 inhibitor effects on human leukemia cells
  1776. Abstract# 1922: Antitumor activity of CUDC-305, a novel oral Hsp90 inhibitor, in solid and hematological tumor xenograft models
  1777. Synthesis and biological evaluation of geldanamycinโ€“ferulic acid conjugate as a potent Hsp90 inhibitor
  1778. Hsp90 inhibitor NVP-AUY922 exhibits the potent antiproliferative effect in gastrointestinal cancer cells with a lack of PTEN expression
  1779. Hsp90 inhibitor DPB induces autophagy and more effectively apoptosis in A549 cells combined with autophagy inhibitors
  1780. A Hsp90 inhibitor, AUY922, is effective to overcome the MET-and AXL-mediated resistance to EGFR-TKI in lung cancer
  1781. Abstract# 5649: Pharmakokinetic/phamacodynamic relationship of the Hsp90 inhibitor NVP-AUY922 in human xenografts and patients in a clinical Phase I trial
  1782. MEK-inhibitor PD184352 enhances the radiosensitizing effect of the Hsp90 inhibitor NVP-AUY922: the role of cell type and drug-irradiation schedule
  1783. Discovery of a novel butein derivative as a promising Hsp90 inhibitor
  1784. Cassette dosing in tumor bearing animals for the discovery of NVP-AUY922, a novel Hsp90 inhibitor.
  1785. Antiproliferative effects and signaling profiles of the novel Hsp90 inhibitor NVP-AUY922 in non-small cell lung cancer
  1786. Pharmacokinetics (PK) and toxicology of KOS-1022, an orally administered heat shock protein 90 (Hsp90) Inhibitor
  1787. The novel Hsp90 inhibitor, PF-04929113, inhibits AR activity and osteoclastogenesis and delays castrate-resistant LNCaP prostate cancer tumor growth
  1788. Effect of Hsp90 inhibitor NVP-AUY922 with radiation on lung adenocarcinoma cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors
  1789. Evaluating the Hsp90 Inhibitor Ganetespib as a Radiosensitizing Agent in Breast Cancer Models In Vitro
  1790. Modulation of AHA1: A novel therapeutic strategy to increase cellular sensitivity to the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG)
  1791. Abstract B14: Hsp90-inhibitor drug conjugate STA-12-8666 demonstrates complete tumor regression in preclinical models of pediatric sarcoma
  1792. Development and validation of a highly sensitive ELISA method for the quantitation of Hsp70-a tumor biomarker associated with Hsp90 inhibitor therapy
  1793. Abstract# 3998: 89Zr-trastuzumab immunoPET visualizes HER2 downregulation induced by the Hsp90 inhibitor NVP-AUY922 in human tumor xenograft
  1794. Role of NAD (P) H: quinone oxidoreductase 1 (NQO1) in the cytotoxicity of the Hsp90 inhibitor 17AAG in human pancreatic cancer cells
  1795. Abstract B184: Hsp90 inhibitor STAโ€9090 potently suppresses heterogeneous KIT kinaseโ€domain mutations responsible for gastrointestinal stromal tumor โ€ฆ
  1796. Spotlight on 17โ€AAG as an Hsp90 inhibitor for molecular targeted cancer treatment
  1797. A research of apoptosis-inducing effects of APL cells NB4 by an Hsp90 inhibitor HDN-1
  1798. Retraction: Novel Hsp90 Inhibitor NVP-HSP990 Targets Cell-Cycle Regulators to Ablate Olig 2-Positive Glioma Tumorโ€“Initiating Cells
  1799. Abstract A217: The Hsp90 inhibitor AT13387 demonstrates potent antitumor activity in both imatinib-sensitive and imatinib-resistant gastrointestinal stromal tumor โ€ฆ
  1800. Revisiting silibinin as a novobiocin-like Hsp90 C-terminal inhibitor: Computational modeling and experimental validation
  1801. Zr-bevacizumab PET imaging of early anti-angiogenic tumor response to treatment with Hsp90 inhibitor NVP-AUY922
  1802. Non-steroidal anti-inflammatory drugs sensitize CD44-overexpressing cancer cells to Hsp90 inhibitor through autophagy activation
  1803. Abstract C130: The Hsp90 inhibitor ganetespib promotes the degradation of FGFR3 in bladder cancer models and induces regression in tumors harboring oncogenic โ€ฆ
  1804. Hs-27, a Novel Hsp90 Inhibitor, Exhibits Diagnostic and Therapeutic Potential in Triple Negative Breast Cancer
  1805. Abstract A214: A novobiocin analogue Hsp90 inhibitor induces apoptosis and has potent antitumor effects in head and neck squamous cell cancer in vivo
  1806. The Hsp90 inhibitor FW-04-806 suppresses Bcr/Abl-mediated growth of leukemia cells by inhibiting proliferation and inducing apoptosis
  1807. PO-440 Targeting of triple negative breast tumours using liposomes as drug delivery systems for sirna and Hsp90 inhibitor
  1808. Abstract A215: Hsp90 inhibitor IPIโ€504 demonstrates antitumor activity against a panel of neuroendocrine/carcinoid cell lines in vitro and in vivo
  1809. Hsp90 inhibitor 17โ€AAG prevents apoptosis of cardiomyocytes via miRโ€93โ€“dependent mitigation of endoplasmic reticulum stress
  1810. Clinical Development of Gamitrinib, a Novel Mitochondrial-Targeted Small Molecule Hsp90 Inhibitor
  1811. โ€ฆ protozoan infections: biochemical characterization of Hsp90 from Plasmodium falciparum and Trypanosoma evansi and evaluation of its inhibitor as a candidate drug
  1812. Differing mechanisms of synergistic interaction of the Hsp90 inhibitor 17-AAG and TRAIL in resistant colon cancer cell lines
  1813. Preclinical evidence of synergism between DNA damaging agents and the Hsp90 Inhibitor, 17-DMAG, in tumors with mutant p53
  1814. Abstract# LB-7: Targeting triple-negative breast cancer via PU-H71, a purine-scaffold heat shock protein 90 (Hsp90) inhibitor
  1815. C76 HEAT SHOCK PROTEIN: The Hsp90 Inhibitor Radicicol As A Bioinformatically-Derived Drug For M2 Macrophage Phenotype Inhibition
  1816. Hsp90 inhibitor 17-allylamino-geldanamycin enhances sensitivity to double-strand DNA break-inducing agents (platinum and PARP inhibitors) in epithelial ovarian โ€ฆ
  1817. Combining the Hsp90 inhibitor, AT13387, with vemurafenib delays the emergence of resistance in a preclinical model of BRAF V600E mutant melanoma.
  1818. Mechanism of resistance to 17-DMAG, an Hsp90 inhibitor, in lung cancer cell lines with ALK rearrangement
  1819. Identification of synergistic drug combinations with the oral Hsp90 inhibitor Debio 0932 in non-small cell lung cancer and renal cell cancer
  1820. Radiosensitization by post-irradiation treatment with an Hsp90 inhibitor, 17-DMAG, in the p53 mutant pancreatic cancer cell line, MiaPaca2
  1821. Expedient Access to 2โ€Benzazepines by Palladiumโ€Catalyzed Cโˆ’ H Activation: Identification of a Unique Hsp90 Inhibitor Scaffold
  1822. Potent activity of the heat shock protein 90 (Hsp90) inhibitor, 17AAG in head and neck squamous cell carcinoma (HNSCC) lines
  1823. Phase I evaluation of STA-1474, a pro-drug of the novel Hsp90 inhibitor STA-9090, in dogs with spontaneous cancer
  1824. Blood-brain barrier permeable Hsp90 inhibitor reduces soluble tau burden and rescues tau-dependent phenotype in a mouse model of tau accumulation
  1825. The effects of a novel Hsp90 inhibitorโ€”โ€”SNX-2112 on hepatis metablic enzymes in rats
  1826. Demonstrating preclinical efficacy of AUY922, a novel Hsp90 inhibitor, alone and in combination with standard chemotherapy or radiation in esophageal โ€ฆ
  1827. Cover Picture: Discovery and Biological Activity of 6BrCaQ as an Inhibitor of the Hsp90 Protein Folding Machinery (ChemMedChem 5/2011)
  1828. Preclinical investigation of the Hsp90 inhibitor, ganetespib, in combination with FDA-approved cytotoxic agents for their potential anti-tumor effects on human โ€ฆ
  1829. 4-Amino-substituted 5-resorcinol-isoxazole derivatives, a novel class of Hsp90 inhibitor: Synthesis and evaluation of in vitro activity
  1830. Abstract# 4712: The Hsp90 inhibitor IPI-504 inhibits proliferation and tumor growth of HER2 overexpressing breast cancer cells with acquired trastuzumab resistance
  1831. Abstract C91: Pharmacodynamic analysis of the Hsp90 inhibitor STAโ€9090 in a lung cancer xenograft model supports an infrequent dosing schedule in the clinic
  1832. Targeting angiogenesis and tumor growth with the Hsp90 inhibitor NVP-AUY922 in a model of pancreatic cancer: impact on cMet, VEGFR2 and PDGFR signaling
  1833. IPI-504, a selective Hsp90 inhibitor is biologically active and tolerated in combination with trastuzumab in preclinical models of HER2 positive tumor xenografts
  1834. Enhancement by Hsp90 inhibitor of PGD2-stimulated HSP27 induction in osteoblasts: suppression of SAPK/JNK and p38 MAP kinase
  1835. Hsp90 inhibitor SNX-2112 inhibits cell growth by regulating Bcl-2 family proteins and cyclin proteins in MCF-7 cells
  1836. Identification of the circRNA-miRNA-mRNA regulatory network of Hsp90 inhibitor-induced cell death in colorectal cancer by integrated analysis
  1837. Preclinical efficacy of STA-12-8666, an Hsp90 inhibitor-targeted SN-38 conjugate, in small cell lung cancer (SCLC).
  1838. BAG3โ€dependent expression of Mclโ€1 confers resistance of mutant KRAS colon cancer cells to the Hsp90 inhibitor AUY922
  1839. First-in-human phase I study of an oral Hsp90 inhibitor, TAS-116, in patients with advanced solid tumors
  1840. P03. 09 AUY922, A NOVEL Hsp90 INHIBITOR EFFECTIVE AGAINST ABC-DLBCL AND MALT LYMPHOMA CELLS HARBORING GENETIC ALTERATION โ€ฆ
  1841. Abstract# 4686: The molecular and biological effects of KW\# 8722; 2478, a novel non-ansamycin Hsp90 inhibitor, on multiple myeloma cells having various IgH โ€ฆ
  1842. C1-07: IPI-504, a novel Hsp90 inhibitor is effective in EGFR T790M and Non-T790M Gefitinib-resistant Lung Cancer Cell Lines.
  1843. First-in-human phase I study of an oral Hsp90 inhibitor, TAS-116, in advanced solid tumors.
  1844. C-terminal Hsp90 inhibitor, L80, targets cancer stem cell (CSC)-like property and suppresses metastasis via JAK/STAT3 inactivation in triple-negative breast cancer
  1845. Abstract# 5650: The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma by downregulation of the prosurvival ER chaperone BiP โ€ฆ
  1846. Hsp90 inhibitor 17-AAG plays an important role in JAK3/STAT5 signaling pathways in HTLV-1 infection cell line HUT-102
  1847. Evaluating the Therapeutic Effect of an Hsp90 Inhibitor in Mouse Models of Alzheimerโ€™s Disease
  1848. 5.26 Hsp90 Inhibitor Restores P53-Mutated MEC1 Chronic Lymphocytic Leukemia Cell Sensitivity to Fludarabine by Downregulating DNA Repair and Endoplasmic โ€ฆ
  1849. Novel Hsp90 Inhibitor C086 Potently Inhibits Non-Small Cell Lung Cancer Cells As A Single Agent Or In Combination With Gefitinib
  1850. Combination immunotherapy integrating Hsp90 inhibitor 17-DMAG reconditions the tumor microenvironment for improved T cell recruitment and anti-tumor efficacy โ€ฆ
  1851. 1622P Heat shock protein 90 (Hsp90) inhibitor as a candidate treatment option for gastrointestinal stromal tumor with acquired resistance for conventional receptor โ€ฆ
  1852. Hsp90 inhibitor, NVP-AUY922, improves myelination in vitro and supports the maintenance of myelinated axons in neuropathic mice
  1853. Phase I study of vemurafenib (VEM) and cobimetinib (COB) with heat shock protein 90 (Hsp90) inhibitor XL888 in advanced BRAFV600 mutant melanoma.
  1854. ET-41. A NOVEL Hsp90 INHIBITOR, NVP-HSP990, TARGETS CELL CYCLE REGULATORS TO PRODUCE AN ANTI-GLIOMA EFFECT IN OLIG2-EXPRESSING โ€ฆ
  1855. Abstract# 1855: The novel Hsp90 inhibitor NVP-AUY922 reduces insulin-like growth factor receptor type 1 expression and lowers migration rate in triple-negative โ€ฆ
  1856. Hsp90 inhibitor PU-H71 increases radiosensitivity of breast cancer cells metastasized to visceral organs and alters the levels of inflammatory mediators
  1857. โ€ฆ # 4687: OSU-HDAC42, a novel HDAC inhibitor, exhibits biologic activity against human and canine malignant mast cells through both histone dependent and Hsp90 โ€ฆ
  1858. Erratum to: A novel small molecule Hsp90 inhibitor, NXD30001, differentially induces heat shock proteins in nervous tissue in culture and in vivo
  1859. Abstract# 2937: A purine scaffold heat shock protein 90 (Hsp90) inhibitor destabilizes BCL6 and has specific anti-tumor activity in BCL6 dependent lymphomas in vitro โ€ฆ
  1860. Abstract B80: Hsp90 inhibitor SNXโ€2112 and prodrug SNXโ€5422 (PFโ€04929113) inhibit key signal pathways Akt, Src and STAT3 and reactivate tumor suppressor โ€ฆ
  1861. Abstract P6-11-02: Efficacy of Hsp90 inhibitor ganetespib plus standard neoadjuvant therapy in high-risk breast cancer: Results from the I-SPY 2 trial
  1862. โ€ฆ study comparing the efficacy of the water-soluble Hsp90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non-water-soluble Hsp90 inhibitor, 17-AAG, in โ€ฆ
  1863. Abstract LB-289: Synthetic Hsp90 inhibitor, PF-04928473 and prodrug PF-04929113, demonstrates potent antitumor activity in head and neck cancer by inhibiting โ€ฆ
  1864. Assessing the Impact of HER2 Status on the Antitumor Activity of an Hsp90 Inhibitor in Human Tumor Xenograft Mice using Pharmacokinetics-Pharmacodynamic โ€ฆ
  1865. Preclinical Testing Demonstrates Striking Efficacy of STA-12-8666, an Hsp90 Inhibitorโ€“Targeted SN-38 Conjugate, in Small Cell Lung Cancer: Small Cell Lung โ€ฆ
  1866. Re: First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin Hsp90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors
  1867. Inhibition of thymidine phosphorylase expression by Hsp90 inhibitor potentiates the cytotoxic effect of salinomycin in human non-small-cell lung cancer cells
  1868. A novel Hsp90 inhibitor induces metabolic oxidative stress in head and neck squamous cancers and prevents migration and stem cell EMT even under hypoxic โ€ฆ
  1869. Novel mechanism of attenuation of LPS-induced NF-ฮบB activation by the Hsp90 inhibitor, 17-AAG, in human lung microvascular endothelial cells
  1870. Supplemental Data Functional Characterization of the Biosynthesis of Radicicol, an Hsp90 Inhibitor Resorcylic Acid Lactone from Chaetomium chiversii
  1871. The HALO study: A phase I-II of the oral Hsp90 inhibitor Debio0932 in combination with SOC in first-and second-line therapy of advanced NSCLC.
  1872. Pharmacodynamic and clinical results from a phase 1/2 study of the Hsp90 inhibitor onalespib in combination with abiraterone acetate in prostate cancer.
  1873. AT-533, a novel Hsp90 inhibitor, inhibits breast cancer growth and HIF-1ฮฑ/VEGF/VEGFR-2-mediated angiogenesis in vitro and in vivo
  1874. Abstract# 5443: Pharmacokinetics (PK) of PF-04929113 (SNX5422), an orally bioavailable heat shock protein 90 (Hsp90) inhibitor after single and multiple dose โ€ฆ
  1875. Hsp90 Inhibitor SNX-2112 Enhances TRAIL-Induced Apoptosis of Human Cervical Cancer Cells via the ROS-Mediated JNK-p53-Autophagy-DR5 Pathway
  1876. A Phase IB Dose-Escalation Study of the Hsp90 Inhibitor SNX-5422 and Erlotinib in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to โ€ฆ
  1877. Therapeutic Effects and Related Molecular Mechanisms of Celastrol, a Triterpenoid Natural Compound and Novel Hsp90 Inhibitor Extracted from Plants of the โ€ฆ
  1878. Oral targeted delivery by nanoparticles enhances efficacy of an Hsp90 inhibitor by reducing systemic exposure in murine models of colitis and colitis-associated โ€ฆ
  1879. Corrigendum toโ€โ€ Panaxynol, a natural Hsp90 inhibitor, effectively targets both lung cancer stem and non-stem cellsโ€โ€[Canc. Lett. 412 (2018) 297-307].
  1880. Post-treatment with the heat shock protein 90 (Hsp90) inhibitor, 17-AAG, reduces pulmonary inflammation, hyper-permeability and airway dysfunction associated with โ€ฆ
  1881. โ€ฆ Grevel A physiology-based model predicts pharmacokinetics, target occupancy in the tumour, and HSP70 biomarker response in serum for the Hsp90 inhibitor, 17 โ€ฆ
  1882. An in vitro and in vivo evaluation of the combination of the heat shock protein 90 (Hsp90) inhibitor 17-allylamino, 17-demethoxygeldanamycin (17-AAG) and โ€ฆ
  1883. Part I of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous, high โ€ฆ
  1884. EUDARIO/ENGOTov-48: A European multicenter randomised phase II trial on the combination of the Hsp90 inhibitor ganetespib with carboplatin followed by โ€ฆ
  1885. Phase I results of GANNET53: A multicenter phase I/II trial of the Hsp90 inhibitor ganetespib (G) combined with weekly paclitaxel (P) in women with high-grade serous โ€ฆ
  1886. Phase II results of GANNET53: A European multicenter phase I/randomized II trial of the Hsp90 inhibitor Ganetespib (G) combined with weekly Paclitaxel (P) in women โ€ฆ
  1887. โ€ฆ 4-(4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl)-1H-pyrazolo[3,4-b]pyridin-1-yl)benzamide (TAS-116) as a Potent, Selective, and Orally Available Hsp90 Inhibitor
  1888. ET-44. HSP990-AN INHIBITOR OF Hsp90 CHAPERON PROTEIN TARGETS OLIG2-EXPRESSING GLIOMA STEM CELLS
  1889. Targeting Hsp90 with the inhibitor AT13387 in tumour cells
  1890. A novel Hsp90 machine inhibitor combining chemotherapy and immunotherapy
  1891. Structural comparison of inhibitor binding to Hsp90 isoforms.
  1892. TAS-116. Second-generation Hsp90-alpha/beta inhibitor, Cancer therapy
  1893. A docking-based structural analysis of geldanamycin-derived inhibitor binding to human or Leishmania Hsp90
  1894. Combination of Hsp90 and proteasome inhibitor is effective in pancreatic cancer
  1895. Discovery of a synthetic small molecule inhibitor of Hsp90 for cancer therapy
  1896. Study of the Binding Peptide-Derivatives on Hsp90 Protein which have Anti-Cancer and Autoimmune Inhibitor Effects
  1897. Small Molecule Inhibitor for the Protein-Protein (Cdc37-Hsp90) Complex Studied by NMR
  1898. Abstract# 4685: Identification of a potent and specific inhibitor of Hsp90 showing in vivo efficacy.
  1899. Supplemental Data Structure-Activity Relationships in Purine-Based Inhibitor Binding to Hsp90 Isoforms
  1900. Abstract# 5117: KU135, a novobiocin-derived C-terminal inhibitor of Hsp90, exerts potent antiproliferative effects in human leukemic Jurkat T cells
  1901. Abstract# 2753: Biologic effects of NVP-AUY922, a novel small molecule inhibitor of Hsp90 in human colon and gastric cancer cell lines
  1902. Glutaminyl cyclase inhibitor contributes to the regulation of HSP70, HSP90, actin, and ribosome on gene and protein levels in vitro
  1903. Author Correction: Cancer cell responses to Hsp70 inhibitor JG-98: Comparison with Hsp90 inhibitors and finding synergistic drug combinations
  1904. Abstract# LB-207: The antitumor effects of OSU-HDAC42, a histone deacetylase inhibitor, in HER2-positive breast cancer are mediated partly through Hsp90 โ€ฆ
  1905. Abstract# 4684: NVP-BEP800/VER-82576: A potent orally active Hsp90 chaperone inhibitor evolved by SBDD from Vernalis fragment (\# 8220; SeeDs\# 8221;) hits โ€ฆ
  1906. IPI-504, a selective inhibitor of Hsp90, exhibits potent anti-tumor activity against metastatic melanoma cell lines that harbor B-Raf or N-Ras mutations
  1907. In Vitro Metabolism of 6-Chloro-9-(4-methoxy-3, 5-dimethylpyridin-2-ylmethyl)-9H-purin-2-ylamine (BIIB021), an Inhibitor of HSP90, in Liver Microsomes and โ€ฆ
  1908. SIRT1 inhibitor ์— ์˜ํ•œ Hsp90 inhibitor ์˜ Hsp90 ์ƒคํŽ˜๋ก  ๊ธฐ๋Šฅ ์–ต์ œ ๋ฐ ํ•ญ์•”์ œ ๋‚ด์„ฑ์„ธํฌ์˜ Hsp90 inhibitor ์— ๋Œ€ํ•œ ์„ธํฌ๋…์„ฑ ์ฆ๊ฐ•
  1909. Radiosensitization of Hsp90 inhibitor Geldanamycin in normal and tumor cells.
  1910. Hsp90 Inhibitor, 17-AAG, Affects Early Embryonic Development and Apoptosis of Bovine Embryos
  1911. Discovery of FS36 as a novel Human Hsp90 inhibitor
  1912. Novel Hsp90 Inhibitor Identified by Ligand-based Pharmacophore Modelx
  1913. โ€ฆ of Hsp90 inhibitor in enhancing the anti-cancer effects of BCL-2 inhibitor in small cell lung cancer= ์†Œ์„ธํฌํ์•”์—์„œ BCL-2 ์–ต์ œ์ œ ํ•ญ์•”ํšจ๊ณผ๋ฅผ ํ–ฅ์ƒ์‹œํ‚ค๋Š” Hsp90 โ€ฆ
  1914. FW-04-806, a novel Hsp90 inhibitor, disrupt Hsp90/Cdc37 complex against human breast cancer cells
  1915. The Hsp90 Inhibitor SY-J-55, Induces G2/M Arrest and Apoptosis in Paclitaxel-resistant Human Ovarian Cancer Cells
  1916. Altered Cross Linking of HSP27 Sensitizes Breast Cancer Cells to Doxorubicin or Hsp90 inhibitor, 17-AAG
  1917. GO-21: The Hsp90 Inhibitor SY-016, Induces G2/M Arrest and Apoptosis in Paclitaxel-resistant Human Ovarian Cancer Cells
  1918. Hsp90 inhibitor, 17-AAG, abrogates breast cancer cells growth through EGFR and IGFR-1 pathway
  1919. Novel Hsp90 inhibitor NVP-AUY922 downregulates mutant c-Kit protein through transcription and enhancing protein degradation via both proteasome and autophagy โ€ฆ
  1920. Synergistic antitumor effect of Hsp90 inhibitor P7 combined with docetaxel in triple-negative breast cancer
  1921. Synergistische Therapiewirkung der Kombination des Hsp90 Inhibitor AUY922 und des PI3K Inhibitors BYL719 mit Everolimus bei neuroendokrinen Tumoren
  1922. Auy922, a novel Hsp90 inhibitor effective against ABC-dlbcl and malt lymphoma cells harboring genetic alteration-associated NF-kappa B activation
  1923. 2-phenylethynesulphonamide (PFT-ฮผ) enhances the anticancer effect of the novel Hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels
  1924. Die Wirkung von Fumarsรคure, intravenรถsen Immunglobulinen und dem Hsp90-Inhibitor 17-DMAG auf die Antikรถrper induzierte Leukozytenaktivierung im โ€ฆ
  1925. โ€ฆ Untersuchungen zur Wirksamkeit des neuen Hsp90-Inhibitors AUY922 allein und in Kombination mit dem BCR-ABL-Inhibitor Imatinib zur Therapieoptimierung der โ€ฆ
  1926. A heat shock protein 90 (Hsp90) chaperone complex inhibitor, radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate canser cell line โ€ฆ
  1927. PP-646 ้žๆตธๆฝคๆ€ง่†€่ƒฑ็™Œใซๅฏพใ™ใ‚‹ survivin-Hsp90 complex inhibitor ่†€่ƒฑๅ†…ๆณจๅ…ฅ็™‚ๆณ•ใƒขใƒ‡ใƒซใฎ็ขบ็ซ‹ (็™บ่กจใƒป่จŽ่ซ–, ไธ€่ˆฌๆผ”้กŒใƒใ‚นใ‚ฟใƒผ, ็ฌฌ 98 ๅ›žๆ—ฅๆœฌๆณŒๅฐฟๅ™จ็ง‘ๅญฆ็ทไผš)
Related Posts

Altered Intercellular Communication

Fasting & The Brain

Hair Growth

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

Mandatory FDA Disclaimer: Not intended to diagnose, treat, cure or prevent any disease.

0
    0
    Your Cart
    Your cart is emptyReturn to Shop
    Continue Shopping